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Abstract 
 
The asperparalines belong to a large family of prenylated indole alkaloids possessing a 
characteristic bicyclo[2.2.2]diazaoctane core structure. More than 70 examples are known to 
have been isolated from various diverse sources. Chapter 1 discusses the isolation and 
structure of these compounds along with an introduction to their biosynthesis and biological 
activities. 
 
A combination of unique structural features and intriguing biological profiles has inspired a 
large body of work regarding the chemical synthesis of this alkaloid family. Chapter 2 gives 
an overview of the most important strategies for the construction of the central 
bicyclo[2.2.2]diazaoctane and presents these in the context of several total syntheses. 
 
Chapter 3 details an approach to the bicyclo[2.2.2]diazaoctane core using a free radical 
cascade comprised of a 1,6-hydrogen atom translocation followed by 6-exo-trig and 5-exo-
trig cyclisations. An initial model system is presented consisting of a series of DKPs 
synthesised from a propargylated proline derived from a modification of Seebach’s procedure 
for the self-reproduction of chirality. Addition of a sulfur radical to the acetylene triggers the 
desired reaction in good to excellent yield and favours the asperparaline stereochemistry. 
 
In Chapter 4 the application of this strategy to the synthesis of an advanced asperparaline core 
structure is presented. While construction of the key cyclisation intermediate proved difficult, 
the radical cascade proceeds in modest yield to furnish a bicyclo[2.2.2]diazaoctane possessing 
the key structural features of the asperparalines. 
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Glossary of Abbreviations 
1,2-DCE 1,2-dichloroethane 
1D  one dimensional 
2D  two dimensional 
4-DMAP 4-dimethylaminopyridine 
9-BBN 9-borabicyclo[3.3.1]nonane 
AIBN  azobisisobutyronitrile 
Boc  tert-butoxycarbonyl 
BOP  benzotriazole-1-yl-oxy-tris(dimethylamino)-phosphonium 
hexafluorophosphate 
Bz benzoyl 
CaM  calmodulin 
Cbz  carboxybenzyl 
COSY  correlation spectroscopy 
DABCO 1,4-diazabicyclo[2.2.2]octane 
DBU  1,8-diazabicycloundec-7-ene 
DCB  ortho-dichlorobenzene 
DCC  N,N'-dicyclohexylcarbodiimide 
DDQ  2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DIBAL diisobutylaluminium hydride 
DIPEA diisopropylethylamine (Hünig’s base) 
DKP  diketopiperazine 
DMF  dimethylformamide 
DMP  Dess-Martin periodinane 
 
 
DMSO dimethylsulfoxide 
ESI  electrospray ionization mass spectrometry 
ESR  electron spin resonance spectroscopy 
FAB  fast atom bombardment 
Fm  fluorenylmethyl 
Fmoc  fluorenylmethyloxycarbonyl 
FT  Fourier transform 
GI50  concentration of compound required for 50% growth inhibition 
GOESY gradient enhanced nuclear Overhauser effect spectroscopy 
HATU  O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 
HMBC heteronuclear multiple-bond correlation spectroscopy 
HMDS hexamethyldisilazane/bis(trimethylsilyl)amine 
HOAt  1-hydroxy-7-azabenzotriazole 
HOMO highest occupied molecular orbital 
HPLC  high pressure (or performance) liquid chromatography 
HSQC  heteronuclear single-quantum correlation spectroscopy 
IC50  concentration of compound required for 50% inhibition of activity 
IMDA  intramolecular Diels-Alder reaction 
IR  infrared spectroscopy 
J  coupling constant (in nuclear magnetic resonance spectroscopy) 
kcal  kilocalorie 
LC-MS liquid chromatography-mass spectrometry 
LD50  dose of compound required to kill 50% of subjects 
LDA  lithium diisopropylamide 
 
 
LUMO lowest unoccupied molecular orbital 
mCPBA meta-chloroperoxybenzoic acid 
MIC  minimum inhibitory concentration 
MKP  monoketopiperazine 
MOM  methoxymethyl 
Ms  methylsulfonyl 
MS  mass spectrometry 
MTM  methylthiomethyl 
nOe  nuclear Overhauser effect 
NOESY nuclear Overhauser effect spectroscopy 
NMM  N-methylmorpholine 
NMR  nuclear magnetic resonance spectroscopy 
OTf  trifluoromethanesulfonate (triflate) 
Piv  pivaloyl 
PMB  para-methoxybenzyl 
ppm  parts per million 
PTLC  preparative thin layer chromatography 
Rose Bengal 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt 
RNA  ribonucleic acid 
RSE  radical stabilisation enthalpy 
SAR  structure-activity relationship 
SEM  2-(trimethylsilyl)ethoxymethyl 
SOMO singly occupied molecular orbital 
TBAF  tetra-n-butylammonium fluoride 
 
 
TBAI  tetra-n-butylammonium iodide 
TBAT  tetra-n-butylammonium difluorotriphenylsilicate 
TBDPS tert-butyldiphenylsilyl 
TBS  tert-butyldimethylsilyl 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
TKP  triketopiperazine 
TLC  thin layer chromatography 
TMM  trimethylenemethane 
TMP  2,2,6,6-tetramethylpiperidine 
TMS  trimethylsilyl 
UV  ultraviolet spectroscopy 
  
Chapter 1   Introduction 
     
 
1 
 
Chapter 1 
Introduction 
 
1.1 The Prenylated Indole Alkaloid Family 
A large and diverse family of natural products classified as prenylated indole alkaloids are 
characterised by a central 2,5-diketopiperazine (DKP) core structure or a partially reduced 
derivative (monoketopiperazine, MKP). This heterocycle is often present as part of a bridged 
bicyclo[2.2.2]diazaoctane motif and may possess various substituents as outlined in  
Figure 1.1. 
 
Figure 1.1 
 
In total, the structures of more than 70 members of this family have been reported leading to a 
number of total syntheses and some detailed investigations of their biological activities. 
 
1.2 Isolation and Structure Elucidation 
The first report detailing members of this family dates from an initial communication in 1969 
when Birch and Wright reported the isolation of brevianamides A-E as a mixture of pigments 
from Penicillium brevi-compactum (Figure 1.2).[1] Elemental analysis of brevianamide A (1) 
revealed an empirical formula of C21H23N3O3. An indoxyl chromophore along with two 
adjacent but non-equivalent methyl groups suggested a spiro fused ring junction. No double 
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bonds were observed apart from those in the indoxyl portion of the molecule.  Two peaks in 
the infrared (IR) spectrum at 1670 cm-1 and 1690 cm-1 along with further studies of 1 
suggested the presence of a DKP. However, no evidence was found for a proton alpha to a 
carbonyl and amide nitrogen suggesting a bridged bicyclo[2.2.2]diazaoctane structure. Further 
spectroscopic evidence along with proposed biosynthetic routes led the authors to propose the 
presence of a pyrrolidine ring derived from proline. This was confirmed by feeding 
experiments incorporating 14C labelled proline. 
 
Figure 1.2 
 
A second paper in 1970 provided a more complete analysis of both brevianamides A (1) and 
E (5) along with further speculation of their biosynthesis (vide infra).[2] Further proof of the 
spiro-indoxyl moiety was obtained by reduction of 1 with sodium borohydride followed by 
treatment with acid to give the 2,3-disubstituted indole deoxybrevianamide A (8) in an 
analogous manner to a previously reported transformation (Scheme 1.1).[3] This presumably 
proceeds through the hydroxyindoline 7, although this compound was never isolated. 
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Scheme 1.1 
 
The structures of brevianamides B (2), C (3), D (4) and F (6) were reported in 1972 using 
broadly similar analytical techniques.[4] Brevianamide B possesses the same spiro-indoxyl 
motif as brevianamide A and can be converted into the latter by a sequence involving 
reduction, dehydration, re-oxidation and rearrangement. This suggested brevianamides A and 
B are stereoisomers differing only by the configuration of the spiro-centre. However, more 
detailed analysis showed that the absolute configuration of the spiro centres are the same (R) 
and brevianamides A and B are, in fact, enantiomorphic with respect to the DKP core (Figure 
1.3). 
 
Figure 1.3 
 
In a similar way, brevianamides C and D differ only by their configuration around the double 
bond connecting the DKP to the indole. Interestingly, brevianamides C and D were not 
isolated when Penicillium brevi-compactum was grown in the dark, suggesting that they are 
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actually photochemical artefacts of isolation.[4] More recently a number of other 
brevianamides have been described, although none possessing the bridged DKP core.[5] 
 
In 1981, a similar but more structurally complex compound was isolated from Penicillium 
paraherquei by the group of Yamazaki and named paraherquamide (now known as 
paraherquamide A, 9, Table 1.1).[6] The IR spectrum for this compound indicated two 
carbonyl groups, but only one of them was characteristic of a DKP amide implying a different 
core structure. The 1H NMR spectrum showed doublets at δ 4.87 and 6.30 corresponding to 
an enol ether functional group. These signals were replaced by two upfield doubled doublets 
at δ 2.10 and 4.28 after catalytic hydrogenation using palladium on carbon, presumably 
corresponding to a saturated ether motif. 
 
To determine the structure, paraherquamide A was recrystallised from ethyl acetate. Solving 
the crystal structure revealed a spiro-oxindole ring system in contrast to the spiro-indoxyl 
found in the brevianamides along with a partially reduced central DKP. The proton NMR 
signals that had shifted after hydrogenation turned out to be a double bond in a dioxygenated 
seven-membered ring. Another marked contrast to the brevianamides is the presence of 
substitution on the pyrrolidine ring – in this case a methyl and hydroxyl group. It is also 
important to note the syn relationship between the proline residue and the carbon possessing 
the gem dimethyl at the ring junction of the reduced DKP. This is in contrast to the anti 
configuration of the brevianamides. 
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paraherquamide R1 R2  paraherquamide R1 R2 R3 
 9, A (VM29919) OH Me   12, F (VM55594) H Me Me 
 10, B H H   13, G (VM54158) OH Me Me 
 11, E (VM54159) H Me   14, VM55595 H Me H 
 
Table 1.1 
 
More recently, a number of other members of this family have been reported.[7] 
Paraherquamide B (10) possesses the same basic structure as A but without decoration on the 
proline residue while paraherquamide E (11) lacks the hydroxyl group of 9. Other examples 
incorporate a pyran ring in place of the unusual seven-membered heterocycle (e.g. 
paraherquamides F and G, 12 and 13 along with VM55595, 14). As well as those shown 
above, a number of other members of the paraherquamide family have been isolated from 
various sources, including Aspergillus japonicus and Penicillium fellutanum.[8]  
 
At around the same time as the initial reports of the paraherquamides, three compounds 
named the marcfortines were isolated (Figure 1.4).[9] They were found in extracts from 
Penicillium roqueforti – a fungus used in the production of a number of blue cheeses. The 
structure of marcfortine A was determined both by NMR analysis and crystallography. This 
showed a structure very similar to the paraherquamides. In fact, the only structural difference 
between paraherquamide B (10) and marcfortine A (15) is a single CH2 moiety – the 
marcfortines all possess a piperidine ring in place of the proline-like pyrrolidine found in the 
paraherquamides. Further studies showed that marcfortine B (16) differs only by 
incorporating a secondary rather than tertiary amide in the monoketopiperazine ring while 
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marcfortine C (17) has a slightly simpler structure with a pyran in place of the seven-
membered ring.[10] 
 
Figure 1.4 
 
Interest in this family of compounds grew rapidly after a patent was filed in 2000 describing 
the isolation a novel compound named avrainvillamide or CJ-17,655 (18, Figure 1.5) from an 
Aspergillus species designated CNC358.[11] The following year the group of Sugie at the 
Pfizer laboratories reported the same compound, this time from fermentation of Aspergillus 
ochraceus CL41582.[12] 
 
Various 2D NMR techniques were employed to determine the empirical formula of 
avrainvillamide, but the proposed molecular structure differed from that expected from mass 
spectral analysis by one oxygen atom. Reasoning that the missing oxygen could be attached to 
one of the three nitrogens the authors carried out more detailed studies. Grigor’ev and 
colleagues have previously reported a method for the determination of the structure of cyclic 
nitrones by analysing the 13C NMR spectra in different solvents.[13] Solvents that are capable 
of forming hydrogen bonds with the N-oxide group cause the signal for the nitrone carbon to 
move downfield. This can be exploited by comparing the chemical shifts in chloroform-d and 
methanol-d4, expressed as δC (CD3OD) - δC (CDCl3). A difference of 3.5-7.5 ppm is 
considered enough to determine the position of the oxygen. Figure 1.5 shows that in the case 
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of avrainvillamide the difference for the nitrone carbon is 4.3 ppm, leading Sugie et al. to 
assign the missing oxygen as being on the indole nitrogen. 
 
Figure 1.5 
 
Soon after the isolation of avrainvillamide, the related compounds stephacidins A (19) and B 
(20) were discovered from fermentation of Aspergillus ochraceus WC76466 by researchers at 
Bristol-Myers Squibb (Figure 1.6).[14] 
 
The UV spectrum of stephacidin A (19) suggested the presence of a highly conjugated 
aromatic moiety, supported by FAB-MS (fast atom bombardment mass spectrometry) 
analysis (showing 14 degrees of unsaturation) as well as ten signals in the 13C NMR spectrum 
between δ 148.1 and 104.0 (showing five double bonds). A number of signals in the IR 
spectrum were characteristic of an amide or lactam, again supported by two carbonyl signals 
in the 13C NMR with shifts at δ 174.0 and 169.3. The connectivity of all of these functional 
groups and the overall structure of the molecule was determined by detailed analysis using a 
variety of 2D-NMR studies. The molecular mass of stephacidin B (20) indicated it was 
approximately a dimer of stephacidin A (19). After some difficulties with solvent selection, 
the authors were able to obtain well resolved NMR spectra by using a 1:1 mixture of DMSO-
d6 and acetonitrile-d3 but were still unable to determine the nature of the connectivity between 
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the two monomers. In the end the structure was solved unambiguously by X-ray analysis of 
crystals grown from acetonitrile. 
 
Figure 1.6 
 
Avrainvillamide and both stephacidins can all be isolated from the same fungal species and 
are closely related to one another. Stephacidin A can be oxidised to form avrainvillamide 
which, in turn, dimerises to form stephacidin B. Stephacidin B is of particular interest as one 
of the most structurally complex alkaloids known – possessing 15 rings and 9 asymmetric 
centres.[15] 
 
In total, more than 70 members of this family are known, with reports of related compounds 
appearing frequently. Table 1.2 shows another two classes, the malbrancheamides and 
notoamides. Malbrancheamide (21) was first reported in 2006 with malbrancheamide B (22) 
isolated two years later.[16] They are unique in incorporating either one or two chlorine atoms 
on the indole part of the molecule, along with a partially reduced DKP core. Notoamides A 
and B (23 and 24) are a good example of the close relationship between various family 
members. They possess similar structural features to some of the paraherquamides but with a 
DKP core.[17] 
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 malbrancheamide R    notoamide R  
 21,  ̶ Cl    23, A OH  
  22, B H    24, B H  
 
Table 1.2 
 
The asperparalines are a sub-family of natural products related to those described above. 
While they have the same bridged core structure (present as a MKP) they differ significantly 
by incorporating a spiro-succinimide in place of the more common indole derivatives. Despite 
the apparent differences, the asperparalines share a common biological precursor with the 
paraherquamides (vide infra). 
 
The first compound isolated was asperparaline A (25) in two reports published in 1997. The 
group of Hayashi identified the fungal strain Aspergillus japonicus JV-23 as a potential 
source of paralytic compounds using a bioassay with silkworm (Bombyx mori).[18]  At the 
same time, scientists based at the Pfizer laboratories in Sandwich, England, noted the 
anthelmintic activity of an aspergillus strain named IMI 337664.[19]  After culture and 
purification, both groups were able to identify fractions of extract that exhibited the desired 
biological activities. 
 
Analysis of the relevant fractions by mass spectrometry revealed a compound with mass 359, 
indicating a molecular formula of C20H29N3O3. The 
13C NMR spectra had resonances for three 
carbonyl groups along with four additional quaternary centres, five methyl groups, six CH2 
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and two CH carbons. The similarity of the data with those from another alkaloid – 
paraherquamide F (VM55594)[20] and further analysis by 1H NMR, HMBC and COSY 
experiments suggested the structure shown in Figure 1.7. 
 
Figure 1.7 
 
As shown, HMBC correlations from H-30 to C-2 and C-8 demonstrated that C-30 is an N-
methyl in a succinimide motif. The presence of this structural feature was confirmed by the 
HMBC data around C-9 and C-21, and the spiro fused nature of the ring shown by 
correlations around C-3. Additionally, Hayashi reasoned that IR signals at 1773 and  
1698 cm-1 corresponded with two imide carbonyls in a five membered ring. The amide 
portion of the bicyclo[2.2.2]diazaoctane motif was shown by connections from H-29 to C-18, 
while interactions around C-11, C-12, C-13 and C-19 confirmed the remainder of the core 
structure. The make-up of the pyrrolidine moiety was elucidated by a combination of both 
HMBC and 1H-1H COSY interactions. The relative stereochemistry was assigned by nOe 
experiments by irradiation of the protons at the gem dimethyl group (C-22/C-23) and 
comparison with the known paraherquamide F. The proposed structure was finally secured by 
X-Ray crystallography. It should be noted that this compound has also been known as 
aspergillimide and VM55598 but will hereon be referred to as asperparaline A. 
 
Chapter 1   Introduction 
     
 
11 
 
In addition to asperparaline A, one of the 1997 reports detailed a related compound known as 
16-keto aspergillimide or SB202327 (26, Figure 1.8). The structure was determined using 
similar methods to those discussed above. In 2000, another paper appeared in the literature by 
Hayashi and co-workers reporting two more alkaloids named asperparalines B (27) and C 
(28).[21] 
 
Figure 1.8 
 
Analysis by mass spectrometry showed that both of these compounds had the molecular 
formula C19H27N3O3 suggesting structures similar to 25 but each lacking one methyl group. 
Further analysis by 1H and 13C NMR experiments showed that asperparaline B (27) possesses 
an N-H succinimide, while asperparaline C (28) lacks the methyl decoration on the 
pyrrolidine ring. The structure of the asperparalines are unique as no other natural products 
have been reported to incorporate a spiro-succinimide motif, leading to some interesting 
biosynthetic suggestions (vide infra).[22] 
 
1.3  Biosynthesis 
1.3.1  Origin of the bicyclo[2.2.2]diazaoctane motif 
Soon after the isolation of the brevianamides, a short communication by Porter and Sammes 
reported a novel Diels-Alder reaction “of possible biosynthetic importance.”[23] They 
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postulated that the bridged bicyclic core could arise from a [4+2] cycloaddition of an isoprene 
unit to a DKP (Scheme 1.2). 
 
Scheme 1.2 
 
To test this hypothesis, they treated substituted pyrazine 31 with dimethyl 
acetylenedicarboxylate in DMF at room temperature and successfully isolated bicyclic DKP 
32 (Scheme 1.3).[24] 
 
Scheme 1.3 
 
In 1974, Birch and co-workers showed that labelled brevianamide F (cyclo-L-tryptophyl-L-
proline, 6) was incorporated into brevianamide A when fed to Penicillium 
brevicompactum,[25] an organism it had previously been isolated from.[4] This led to the 
suggestion that brevianamides A and B could arise from isoprene addition to 6 followed by 
oxidation to form brevianamide E (5) as a precursor for the Diels-Alder cyclisation (Scheme 
1.4). 
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Scheme 1.4 
 
However, 5 has never been isolated from Penicillium brevicompactum and more recently it 
was demonstrated that synthetic brevianamide E was not incorporated into brevianamides A 
and B.[26] Instead, Williams and co-workers suggested that brevianamide E could arise from a 
‘shunt’ pathway involving nucleophilic addition (Scheme 1.5, pathway A) whereas spiro 
rearrangement via pathway B would lead to 35. Further oxidation and enol formation to give 
36 would precede intramolecular Diels-Alder (IMDA) cycloaddition to give brevianamides A 
and B. 
 
Using a 3H labelled precursor, Williams observed incorporation of deoxybrevianamide E 33 
into 1 and 2, lending strong support to this proposed pathway. Interestingly only (+)-1 and 
(+)-2 have been isolated, presumably showing that the key IMDA proceeds with total facial 
selectivity. It has been proposed that this is the result of the involvement of an (R)-selective 
oxidase in the conversion of 33 to 34 giving rise to a single enantiomer of the IMDA 
precursor 36.[27] 
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Scheme 1.5 
 
Brevianamide A is produced in much larger quantities than brevianamide B. Calculations of 
the relative energies of the four possible transition states suggest that cyclisation from the two 
lowest energy transition states (A and B, Scheme 1.6) would lead to the naturally occurring 
alkaloids while cycloaddition proceeding through A' or B' would result in the unobserved C-
19 epimers.[28] The lowest energy transition state could plausibly be stabilised by hydrogen 
bonding between the DKP and indole portions of the molecule helping to explain why 
brevianamide A is the more abundant natural product. However, as similar reactions in the 
laboratory do not show a significant bias for the syn or anti relationship it is not clear if the 
energy differences in these transition states have a strong effect.[28b] 
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Scheme 1.6 
 
The apparent stereoselectivity of this reaction raises the intriguing prospect of the 
involvement of an enzyme or other biomolecule.[29] Some evidence of this type of 
transformation exists, although not for the specific case of bridged DKPs. For example, 
Hilvert and co-workers have reported the catalysis of a Diels-Alder reaction by an 
antibody.[30] Ribonucleic acid (RNA) has also been shown to catalyse [4+2] cycloadditions[31] 
and some proteins have been isolated and identified as potential Diels-Alderases.[32] 
 
1.3.2 Biosynthesis of the asperparalines and paraherquamides 
The biosynthetic origins of the asperparalines are particularly interesting due to the presence 
of the unique spiro-succinimide motif and are thought to be linked to that of the 
paraherquamides.[8c] 
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Early work on this combined pathway focused on the precursor for the β-methyl proline 
residue common to some members of the two families of natural products. The 
stereochemistry of the β-methyl group led to the theory that an oxidative cyclisation of 
isoleucine could be involved (Scheme 1.7). Feeding experiments with 13C labelled isoleucine 
(37) suggest that this is indeed the case.[33] 
 
Scheme 1.7 
 
Coupling of β-methyl proline with L-tryptophan followed by prenylation and Diels-Alder 
cyclisation (as outlined above) would lead to a common intermediate for both series of natural 
products (40, Scheme 1.8). 
 
Scheme 1.8 
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Williams has shown in feeding experiments that the diketopiperazine version of 40 is not a 
viable intermediate for the synthesis of paraherquamide, so reduction to the 
monoketopiperazine must occur at a relatively early stage. In paraherquamide synthesis, 
oxidation to dihydroxyindole 41 would be followed by prenylation and cyclisation to afford 
the dioxepin ring as shown in Scheme 1.8. Alternatively, cleavage of four carbons from the 
indole moiety would be followed by rearrangement to form the spiro-succinimide found in 
the asperparalines (Scheme 1.9). 
 
Scheme 1.9 
 
A number of further feeding experiments have been carried out to determine the amino acids 
incorporated into the asperparalines (Scheme 1.10). It appears that the β-methyl proline 
residue is derived from isoleucine (as above); the succinimide motif arises from tryptophan; 
and the amide and imide methyl groups come from methionine.[22]  
 
Scheme 1.10 
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It is also worth noting that the stereochemistry of the spiro-oxindole ring in the 
paraherquamides is the same as the spiro-succinimide in the asperparalines, lending weight to 
the idea of a common biosynthetic pathway. 
 
1.4 Biological Activity 
Much of the interest around this family of alkaloids has been driven by the potent biological 
activities of some of the compounds.[34] 
 
1.4.1 The paraherquamides and marcfortines 
The paraherquamides and marcfortines have been investigated as antiparasitic agents. 
Paraherquamide A (7) was shown to be effective in sheep against a number of infections 
including H. contortus, T. colubriformis and C. curticei. A single oral dose was enough to 
remove the adult parasites. The research also demonstrated similar efficacy against nine 
nematodes in cattle with no side effects reported in either animal.[35] However, the same 
compound was found to be toxic in much lower doses in canine models.[36] Interestingly, there 
is no decrease in activity against strains resistant to other agents and no cross-resistance has 
been reported; this has led to speculation of a novel mode of action.[37] 
 
The reported activity has led to a number of groups modifying the paraherquamides and 
marcfortines to probe their structure-activity relationship (SAR). Some examples of this are 
shown in Table 1.3. 
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compound R1 R2  compound R X Y 
15 H H  9 Me O N 
43 OH H  45 Et O N 
44 OH Me  46 Me O +N–O− 
    47 Me H2 N 
 
Table 1.3 
 
The initial results of these experiments were disappointing. For example, modification of 
marcfortine A (15) by adding a hydroxyl group to the piperidine ring to give 43 (Table 1.3) 
led to no improvement in efficacy.[38] Methylation adjacent to this position also had no effect 
(44).[39] More success was had through modifications to paraherquamide A (9). For example, 
replacing the pyrrolidine methyl group with an ethyl function (45) led to a 3-fold in vitro 
increase in activity against C. elegans.[40] Oxidising the tertiary amine in the 
monoketopiperazine gave 46 which was found to be equipotent to 9,[7d] but reduction of the 
oxindole motif provided compound 47 with a 2-4 fold increase in efficacy.[41] Perhaps most 
interesting was the toxicity data for this compound. Whereas paraherquamide A has an LD50 
in a mouse model of < 15 mg/kg, 47 showed no significant side effects at doses of 200 mg/kg. 
The same was seen in dogs where 9 was lethal at 0.5 mg/kg while a 25 mg/kg dose of 47 
caused only mild side effects. 
 
1.4.2 Avrainvillamide and the stephacidins 
When avrainvillamide was first isolated, it was reported to have anti-proliferative activity 
against the breast cancer cell lines βT-549 and T-47D as well as the lung cancer line 
MALME-3M.[11-12] Interesting antibacterical effects were also reported with minimum 
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inhibitory concentrations (MICs) against resistant strains considerably lower than some 
established antibiotics  (Table 1.4). 
 MIC (µg/mL) 
microorganism avrainvillamide (18) erythromycin azithromycin vancomycin 
S. aureus 01A1105 12.5 >100 >100 1.56 
S. pyogenes 02C1068 12.5 >100 >100 0.39 
E. faecalis 03A1069 25 >100 >100 12.5 
E. coli 51A0266 >100 100 1.56 >100 
 
Table 1.4 
 
Two years later, Qian-Cutrone reported that the stephacidins have potent cytotoxic effects 
against a number of cancer cell lines including a Taxol resistant line.[14] Stephacidin B (20) 
seems to be the more potent of the two compounds (Table 1.5) and the authors noted that the 
effects are not mediated by p53, mdr, bcl2, tubulin or topoisomerase II suggesting an unusual 
mode of action. 
   IC50 (µM) 
cell line histotype characteristic 19 20 
PC3 prostate testosterone-independent 2.10 0.37 
LNCaP prostate testosterone-sensitive 1.00 0.06 
A2780 ovarian parental 4.00 0.33 
A2780/DDP ovarian mutp53/bcl2+ 6.80 0.43 
A2780/Tax ovarian Taxol-resistant 3.60 0.26 
HCT116 colon parental 2.10 0.46 
HCT116/mdr+ colon overexpress mdr+ 6.70 0.46 
HCT116/topo colon etoposide-resistant 13.10 0.42 
MCF-7 beast estradiol-sensitive 4.20 0.27 
SKBR3 breast estradiol-independent 2.15 0.32 
LX-1 lung sensitive 4.22 0.38 
 
Table 1.5 
 
As stephacidin B is the dimer of avrainvillamide, Myers and co-workers carried out a side-by-
side analysis of the cytotoxicity of these two compounds as well as their unnatural 
enantiomers.[42] Interestingly, the unnatural enantiomers of the two compounds (i.e. ent-18 
and ent-20) also have reasonably low GI50 values (concentration at which cancer cell growth 
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is inhibited by 50%). This is especially apparent in the case of the βT-549 cell line where the 
unnatural compounds are only about 2-fold less potent than their natural counterparts (Table 
1.6). 
 GI50 (nM) 
cell line 18 20 ent-18 ent-20 
LNCaP 135 241 952 1514 
βT-549 346 621 550 786 
T-47D 91 205 942 1485 
MALME-3M 289 406 987 1854 
 
Table 1.6 
 
It is also worth noting that, correcting for stoichiometry, it seems the two compounds have 
almost the same activity (i.e. for equimolar solutions, stephacidin B is twice as active as 
avrainvillamide). This raises the question of which compound is actually responsible for the 
observed cytotoxic effects. To answer this, Myers followed the conversion of 20 (the dimer) 
into 18 (the monomer) by HPLC analysis of solutions of the compounds in cell culture 
medium. The half-life of stephacidin B was found to be about 50 minutes at 23 °C and only 
10 minutes at 37 °C. As Myers reports it takes around 3 hours to prepare the solutions for cell 
culture assays, these data suggest that only negligible amounts of stephacidin B would be 
present. This indicates that avrainvillamide is probably responsible for the majority of the 
biological effects observed. 
 
1.4.3 The malbrancheamides 
Malbrancheamide has been reported to inhibit calcium modulated protein (calmodulin, 
CaM).[16a] Williams has synthesised a number of analogues of the malbrancheamides to 
further investigate this effect (Table 1.7).[43] 
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 entry R1 R2 X Y Z IC50 (µM) 
N
N
R1H
H
N
H
X
Y
Z
R2  
1 O O Cl Cl H 33.92 ± 4.64 
2 O O H Cl Cl 45.41 ± 2.39 
3 O H2 Cl Cl H 134.47 ± 
4 H2 O Cl Cl H 11.95 ± 1.05 
5 O H2 H Cl Cl 81.24 ± 4.46 
6 H2 O H Cl Cl 27.51 ± 3.13 
7 O O Cl H H 62.34 ± 4.58 
8 O O H Cl H 42.77 ± 1.66 
9 O O H H H 23.61 ± 4.21 
 
 entry R X Y IC50 (µM) 
 
10 O Cl Cl 18.57 ± 2.87 
11 O H Cl 31.49 ± 2.52 
12 O Cl H 61.79 ± 5.48 
13 O H H 150.66 ± 
14 (±)-21 H2 Cl Cl 15.99 ± 0.87 
15 (+)-21 H2 Cl Cl 19.33 ± 1.40 
16 H2 H Cl 60.33 ± 6.84 
17 (±)-22 H2 Cl H 42.85 ± 4.22 
18 (+)-22 H2 Cl H 183.28 ± 
19 H2 H H 35.73 ± 3.01 
 
Table 1.7 
 
Whilst it is difficult to draw firm conclusions from these data, it appears possible that the 
unnatural enantiomers of malbrancheamide (21) and malbrancheamide B (22) may be more 
active than their natural counterparts as the racemic mixtures have lower IC50 values than the 
corresponding genuine samples (entries 14/17 vs. 15/18). The chlorine present on the indole 
ring seems to improve potency in some cases, for example a dichlorinated compound (entry 
10) is more active than the equivalent monochlorinated derivatives (entries 11 and 12) which 
in turn have lower IC50 values than the non-halogenated indole (entry 13). However, in other 
series the opposite appears to be true, for example entry 9 shows a higher activity than the 
chlorinated compounds in entries 7 and 8. 
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1.4.4 The asperparalines 
Whilst both of the initial isolation papers contained preliminary biological testing data, little 
else is known about the activity of these compounds. Hayashi reported that asperparalines A, 
B and C all showed similar paralytic effects in silkworms.[18] A dose of 10 µg/g of diet was 
sufficient to cause paralysis for 7 to 10 hours within 1 hour of oral administration. A lower 
dose of 3 µg/g of body weight led to paralysis for 4 to 5 hours within 20 minutes of 
administration via syringe. The group at Pfizer carried out experiments using gerbils infected 
with the parasite Trichostrongylus colubriformis, measuring a reduction in faecal egg count 
after oral administration. A dose of 20 mg/kg of asperparaline A led to a 98% reduction while 
16-keto aspergillimide had no effect.[19] 
 
1.5 Summary 
A wide variety of alkaloids possessing a characteristic bicyclo[2.2.2]diazaoctane core have 
been isolated. Numerous studies have investigated the biosynthesis of these molecules and 
probed their biological effects. Of particular interest are the various anti-cancer properties that 
have been reported. 
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Chapter 2 
Previous Synthetic Work 
 
2.1 Introduction 
Since their isolation in the late 1960’s, the family of alkaloids possessing a 
bicyclo[2.2.2]diazaoctane core has inspired numerous total syntheses. Driven by an interest in 
their biological profiles and intriguing biosynthesis, several groups have reported work in this 
area. Most notable is the group of Williams who have published in excess of twenty syntheses 
since completing brevianamide B in 1988.[44] This Chapter presents some of the most 
significant work in this field and is broadly arranged by the strategy employed for 
construction of the bridged core structure. 
 
2.2 SN2' Cyclisations 
The Williams group’s first synthesis of brevianamide B relied on an SN2' reaction for the 
formation of the bridged core.[45] They began by using Seebach’s method for the self-
reproduction of chirality to synthesise pyrrolidine 50 (Scheme 2.1). This powerful sequence 
of reactions allows L-proline to be substituted with retention of the original stereochemistry. 
First, condensation of L-proline with pivalaldehyde affords oxazolidinone 48 as a single 
diastereomer in 92% yield. This compound is extremely sensitive to hydrolysis but can be 
purified by distillation and substituted with a variety of electrophiles. In this case 
deprotonation with LDA was followed by external quench with allyl bromide to afford 
oxazolidinone 49 in 87% yield. Next, treatment with lithiated para-methoxybenzylamine 
(PMB) led to clean conversion to amide 50. 
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Scheme 2.1 
 
Conversion of 50 into DKP 51 was achieved by acylation of the proline nitrogen with 
bromoacetyl bromide followed by treatment with sodium hydroxide in DCM (Scheme 2.2). 
From this intermediate a four-step procedure consisting of oxidative cleavage of the double 
bond, Wittig olefination, reduction, and protection with tert-butyldimethylsilyl chloride (TBS-
Cl) gave 52 in 86% yield. The lithium enolate of 52 was then quenched with methyl 
chloroformate to afford ester 53 as a mixture of diastereomers. 
 
Scheme 2.2 
 
To install the indole moiety, Williams used a method described by Kametani for the 
tributylphosphine catalysed coupling of gramine with 1,3-dicarbonyl 53 (Scheme 2.3).[46] This 
was followed by decarboxylation, indole protection, desilylation, and conversion to chloride 
55 in 85% yield over the four steps. 
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Scheme 2.3 
 
Next, exposure to sodium hydride in benzene promoted the key SN2' reaction to afford 
bridged DKP 57 in 92% yield (Scheme 2.4). However, analysis of the stereochemistry at the 
C-6 position showed that the undesired epimer had been formed. The authors postulated that 
this would arise from a “closed” transition state such as 56 where the chloride ion is in close 
proximity to the sodium enolate. Repeating the reaction with the addition of 18-crown-6 
resulted in formation of the desired epimer (59). The authors suggest this is a result of 
solvation of the enolate to form the sterically crowded intermediate 58 and favour the desired 
stereochemistry. 
 
Scheme 2.4 
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To complete the synthesis 59 was exposed to concentrated HCl causing Boc cleavage and 
cyclisation to form hexacycle 60. Oxidation with mCPBA gave 61 as a single isomer which 
rearranged on treatment with sodium methoxide to give indoxyl 62. Removal of the PMB 
protecting group proved difficult but was eventually achieved by deprotonation of the 
benzylic position with tert-butyllithium followed by quenching with oxygen to give  
(−)-brevianamide B (2) in 20 steps and 4% overall yield. 
 
Scheme 2.5 
 
The oxidation of 60 is interesting in that the epimer produced leads to brevianamide B rather 
than brevianamide A – the more abundant natural product. This suggests that if the 
biosynthesis follows a similar sequence, enzyme control is necessary for the oxidation to give 
the precursor to brevianamide A. 
 
Following this work, the Williams group applied the same methodology to the synthesis of 
paraherquamides A[47] and B[48] as well as stephacidins A and B.[49] 
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2.3 Intramolecular Diels-Alder Cyclisations 
It has been proposed that in Nature the bicyclo[2.2.2]diazaoctane core arises through an 
intramolecular Diels-Alder (IMDA) cyclisation (vide supra). Testing this using a biomimetic 
approach to the synthesis of these compounds has always been an attractive proposition. The 
first demonstration of this strategy in the laboratory was Williams’ synthesis of brevianamide 
B.[50] They began with brevianamide E (5) which had previously been synthesised by 
Kametani.[51] Protection of the DKP as the lactim ether was accomplished by treatment with 
trimethyloxonium tetrafluoroborate to furnish 63 in 69% yield. Next, oxidation with DDQ 
gave the unsaturated Diels-Alder precursor 64 (Scheme 2.6). 
N
NH
O
O
H
N
H
Me3OBF4
(69%)
N
N
O
OMe
H
N
H
(40%)
N
N
O
OMe
N
H
DDQ
5 63 64  
Scheme 2.6 
 
Treatment of 64 with potassium hydroxide afforded azadiene 65 which spontaneously 
cyclised to give bridged DKP 66 as a 2:1 mixture of epimers (Scheme 2.7). In this case, the 
minor epimer was converted to brevianamide B (2) in a sequence similar to that shown above 
in Section 2.2. 
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Scheme 2.7 
 
Unfortunately, as the proposed intermediate 65 is prochiral the products are necessarily 
racemic. Nevertheless, the extremely rapid access to the bicyclo[2.2.2]diazaoctane core 
results in a very brief access to these natural products. 
 
Independently of Williams, Liebscher and co-workers reported a similar Diels-Alder reaction 
for the construction of a model system (Scheme 2.8).[52] 
 
Scheme 2.8 
 
The cyclisation precursor 69 was synthesised from DKP 67 and substituted indole 68. 
Exposure of this compound to neat acetyl chloride afforded the bridged core 70 as a single 
diastereomer in 48% yield after twenty days. 
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While Liebscher never applied this methodology to a total synthesis, Williams realised that 
the use of this method would allow the stereochemistry of a substituent on the pyrrolidine ring 
to be retained throughout the sequence. The alkaloid VM55599 provided a suitable target for 
this approach.[53] Starting from (S)-isoleucine, methylproline 71 was synthesised in an overall 
yield of 45% (Scheme 2.9). Hydrolysis of the methyl ester under standard conditions was 
followed by amide bond formation to furnish dipeptide 73. Treatment with trifluoroacetic acid 
resulted in Boc cleavage before heating in toluene to effect cyclisation. Protection of the 
amide as the methylthiomethyl (MTM) derivative was accomplished using sodium hydride as 
the base to give DKP 74 in 55% yield over four steps. 
 
Scheme 2.9 
 
Next, the enolate of 74 was generated with sodium bis(trimethylsilyl)amide and this was 
condensed with aldehyde 75 to afford DKP 76 as a mixture of diastereomers (Scheme 2.10). 
Treatment with methyl iodide in the presence of sodium hydrogen carbonate resulted in MTM 
cleavage and exposure of the resulting intermediate to formic acid led to dehydration and 
hydrolysis of the methoxymethyl (MOM) group to yield 77. 
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Scheme 2.10 
 
Using the conditions previously described by Liebscher, the Diels-Alder reaction proceeded 
through three of the four possible transition states to give 78, 80 and 81 – all with retention of 
the stereochemistry on the methylproline (Scheme 2.11). A DIBAL mediated reduction of the 
tertiary amide of the major component (78) furnished (−)-VM55599 (79) as a single 
enantiomer. 
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Scheme 2.11 
 
Although the selectivity of the penultimate step of this route is poor, this synthesis allowed 
the determination of the absolute configuration of VM55599. 
 
As well as the examples shown here, Williams has applied this IMDA strategy to the 
synthesis of stephacidin A,[54] marcfortine C[55] and the malbrancheamides.[56] 
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2.4 Oxidative Enolate Coupling 
Baran and co-workers devised an approach to avrainvillamide and the stephacidins using an 
oxidative enolate coupling to synthesise the core bridged DKP.[57] These natural products are 
somewhat complex as they incorporate an acid sensitive pyran ring. To synthesise this 
component, Baran began with hydroxypyrrolidine 82 and aniline 83 (Scheme 2.12). After 
extensive optimisation studies, they found that treatment with palladium acetate, 1,4-
diazabicyclo[2.2.2]octane (DABCO) and tetrabutylammonium iodide (TBAI) afforded the 
desired tryptophan 84 in good yield. The authors propose that this proceeds through 
condensation of the aniline with the aldehyde tautomer of 82 followed by a palladium 
catalysed cyclisation. Subsequent selective protection of the amine nitrogen was 
accomplished under standard conditions (Boc2O, 4-DMAP) to yield 85. 
 
Scheme 2.12 
 
To install the pyran ring, a magnesium promoted removal of the tosyl group was followed by 
a copper catalysed addition of acetylene 86 to give 87 in 75% yield over the two steps 
(Scheme 2.13). Heating this compound in ortho-dichlorobenzene caused cyclisation via an 
allenyl Claisen rearrangement, but this unfortunately also led to deprotection of the indole 
nitrogen. Reprotection with Boc anhydride was then followed by ester saponification using 
lithium hydroxide to afford the completed indole section as carboxylic acid 89. 
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Scheme 2.13 
 
In a similar way to previous syntheses by Williams (vide supra) pyrrolidine 90 was obtained 
using Seebach’s method for the self-reproduction of chirality. Hydroxylation of the olefin 
gave 91 which was oxidised to the corresponding acid and methylated with diazomethane to 
give ester 92 in good yield (Scheme 2.14). Removal of the Cbz protecting group afforded the 
free amine 93 ready for coupling with acid 89. 
 
Scheme 2.14 
 
Amide bond formation proceeded well under standard conditions (HATU, Hünig’s base) to 
yield dipeptide 94 (Scheme 2.15). To obtain the desired DKP, a palladium catalysed Cbz 
removal was followed by thermal cyclisation on heating in DMF. At this point the amide 
nitrogen was protected with a MOM group to afford 95 primed for the key oxidative 
cyclisation step. 
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Scheme 2.15 
 
Using conditions investigated on a simpler model system, deprotonation of 95 with LDA was 
followed by treatment of the resulting enolate with the oxidant Fe(acac)3 leading to bridged 
DKP 97 (Scheme 2.16). The authors propose that the reaction occurs through the chelated 
transition state 96 in an analogous manner to that described by the Williams group in their 
SN2' work. As well as the concerted process shown in Scheme 2.16 the reaction could proceed 
through a radical mechanism either by initial ester oxidation, or initial amide oxidation, or 
diradical formation. In any case, 97 was obtained as single diastereomer which was 
deprotected with B-bromocatecholborane to afford bridged DKP 98. 
 
Scheme 2.16 
 
To complete the synthesis the ester was converted into the corresponding olefin by treatment 
with methyl Grignard followed by dehydration using the Burgess reagent. The acid-sensitive 
nature of the pyran ring made Boc removal non-trivial, but Baran found that heating to 200 °C 
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effected deprotection, formal ene cyclisation, and 1,2-rearrangement to afford stephacidin A 
(19) as shown in Scheme 2.17. 
 
Scheme 2.17 
 
At the time of this work the absolute configuration of stephacidin A was not known. 
Comparison of a synthetic sample with a genuine isolation product showed that the authors 
had, in starting from L-proline, produced ent-19. To confirm this, Baran repeated the synthesis 
with D-proline and found that the resulting compound matched exactly with the natural 
sample. In addition, Baran carried this material forward to avrainvillamide (18) and 
stephacidin B (20) as outlined in Scheme 2.18. Reduction of the indole to the corresponding 
indoline proceeded in near-quantitative yield on treatment with sodium cyanoborohydride to 
afford intermediate 102. This was then oxidised by exposure to selenium oxide and hydrogen 
peroxide to yield avrainvillamide (18) in 27% yield. 
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Scheme 2.18 
 
The authors found that 18 dimerises to stephacidin B (20) under a variety of conditions such 
as purification by preparative TLC (PTLC; SiO2, EtOAc) or dissolution in DMSO followed 
by solvent removal in vacuo. 
 
2.5 Radical Cyclisations 
2.5.1 Work by Myers 
In 2005, Myers and co-workers published a synthesis of avrainvillamide and stephacidin B 
using a radical cyclisation to form the bicyclo[2.2.2]diazaoctane core.[58] Their synthesis 
began with the known cyclohexanone 103 (Scheme 2.19).[59] Alkylation of the corresponding 
enolate with dihydropyrrole sulfonate 104 proceeded with complete stereoselectivity to give 
the trans product 105 in 70% yield. Next, addition of hydrogen cyanide under Strecker 
conditions gave 65% of 106 along with 16% of the corresponding diastereomer (not shown). 
Epimerisation alpha to the carbonyl was accomplished by quenching of the potassium enolate 
with pivalic acid, before hydration of the nitrile using a platinum catalyst developed by 
Ghaffar and Parkins gave primary amide 107 in good yield. 
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Scheme 2.19 
 
Treatment of 107 with thiophenol in the presence of triethylamine led to Michael addition of 
sulfur along with hemiaminal formation to afford 108. Next, trimethylsilyl triflate (TMS-OTf) 
was used to cleave the Boc protecting group with simultaneous dehydration and the 
pyrrolidine nitrogen was acylated in the presence of Hünig’s base to give radical precursor 
109. 
 
Scheme 2.20 
 
To initiate the key cyclisation, 109 was heated with tert-amyl peroxybenzoate to form the 
bridged DKP 111 in 62% yield (Scheme 2.21). The authors postulate that this proceeds 
through formation of aminoacyl radical 110 followed by attack of the enamide at the more 
substituted carbon leading to migration of the double bond and expulsion of a sulfur radical. 
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Scheme 2.21 
 
With the central bicyclo[2.2.2]diazaoctane constructed, Myers used an Ullmann coupling to 
introduce the indole portion of the molecule.[60] Thus, desilylation using hydrogen fluoride 
followed by oxidation with Dess-Martin periodinane yielded an enone which was converted 
to the α-iodo derivative (112) with iodine and 4-DMAP (Scheme 2.22). Next, coupling with 
known aryl iodide 113[61] proceeded in good yield to afford 114 with all of the carbons 
required for the total synthesis in place. The synthesis was completed by reduction of the nitro 
group with zinc to afford (−)-avrainvillamide (18) in 49% yield. 
 
Scheme 2.22 
 
In a similar way to Baran (vide supra), Myers found that dimerisation of 18 to stephacidin B 
(20) occurred on exposure to triethylamine, again helping to confirm the biosynthetic 
relationship between these two components. 
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2.5.2 Work by Trost 
Trost and co-workers applied a radical cyclisation for the construction of the MKP ring found 
in marcfortine B.[62] Their synthesis relied on a trimethylenemethane (TMM) [3+2]-
cycloaddition between 117 (accessible from known oxindole 115)[63] and previously prepared 
118
[64] (Scheme 2.23). The cycloaddition proceeded well to afford tricycle 120 in 93% yield 
after methylation with dimethyl sulfate. 
 
Scheme 2.23 
 
Epoxidation of the exocyclic double bond was achieved with mCPBA before ring opening 
with DBU gave primary alcohol 121 in 64% yield (Scheme 2.24). Formation of the mesylate 
(122) was followed by substitution with piperidine 123 which, after elimination of the 
secondary alcohol, gave amide 124. At this stage, the authors found that subsequent steps led 
to degradation of the material, but this could be avoided by Boc removal using tin 
tetrachloride to afford 125. 
 
Scheme 2.24 
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Treatment of this compound with KHMDS promoted a Michael addition of the primary amide 
to generate the spiro ring junction of 127 as a single diastereomer (Scheme 2.25). Trost 
speculates that the stereocontrol in this step is a result of intramolecular protonation of the 
intermediate enolate by the amide N-H of 126. Replacing this with the corresponding N-
methyl amide results in a complete reversal to give exclusively the undesired isomer. 
 
Scheme 2.25 
 
To improve solubility, the oxindole of 127 was protected with PMB chloride before DIBAL 
mediated reduction of the methyl ester to the corresponding alcohol (128, Scheme 2.26). 
Substitution with carbon disulfide was followed by S-methylation to form xanthate 129 as the 
precursor for the radical cyclisation. 
 
Scheme 2.26 
 
Despite investigating numerous conditions, the authors were unable to isolate the desired 
saturated product 134 (Scheme 2.28). Instead, unsaturated compound 133 was isolated which 
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they speculate could arise from reaction of intermediate 130 with AIBN to give 131 (Scheme 
2.27). Subsequent 1,4-H abstraction to give 132 would then be followed by elimination to 
afford the observed product, 133. After optimisation studies, the best yield (61%) was 
achieved using 1.7 equivalents of AIBN along with sub-stoichiometric quantities of tin 
hydride. 
 
Scheme 2.27 
 
To obtain the desired saturated compound, reduction of the unwanted double bond in 133 was 
accomplished using Crabtree’s catalyst under a hydrogen atmosphere. Cleavage of the PMB 
protecting group failed under several standard conditions but proceeded cleanly on exposure 
to TFA in refluxing anisole to afford 135. 
 
Scheme 2.28 
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To complete the synthesis, the dioxepine ring was constructed in four steps following 
Williams’ procedure to furnish (±)-marcfortine B (16).[65] 
 
2.6 Cationic Cascade 
In 2009, our group published a concise synthesis of malbrancheamide B using a cationic 
cascade to construct the central bicyclo[2.2.2]diazaoctane.[66] The synthesis began with 
chloroindole 136, prepared using a method reported by Appella (Scheme 2.29).[67] 
Condensation with ester 137 proceeded in near-quantitative yield in the presence of LiHMDS 
to afford aldol product 138 as a 4:1 mixture of diastereomers. Elimination of the secondary 
alcohol was accomplished by mesylate formation followed by treatment with DBU to give 
139. Lithium hydroxide mediated ester cleavage gave the free acid 140, albeit in relatively 
modest yield due to partial cleavage of the Boc group before completion of the desired 
reaction. 
 
Scheme 2.29 
 
Prenylated proline 141 was synthesised using Seebach’s method for the self-reproduction of 
chirality (vide supra). The O-benzyl protecting group was selected to avoid the problems 
previously observed with PMB cleavage from bridged DKPs. Coupling of 141 with acid 140 
was accomplished using HATU and Hünig’s base to afford dipeptide 142 in 74% yield 
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(Scheme 2.30). Surprisingly, SEM ether 142 was stable to a variety of standard deprotection 
conditions such as TBAF, TBAT and HF. In the end, treatment with carbon tetrabromide in 
warm (50 °C) isopropanol led to SEM cleavage along with DKP formation to give the 
cyclisation precursor 143. 
 
Scheme 2.30 
 
To initiate the key cationic cascade, alcohol 143 was exposed to TMS triflate in 
dichloromethane (Scheme 2.31). This presumably leads to formation of 144 which undergoes 
prenyl trapping to give tertiary cation 145. Indole trapping of this intermediate then affords 
the malbrancheamide core 146 in 64% yield as a 4:1 mixture of diastereomers. At some point 
in this sequence Boc deprotection occurs to reveal the N-H indole.  
 
Scheme 2.31 
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To complete the synthesis, samarium iodide mediated O-benzyl removal was followed by 
reduction using Williams’ protocol to afford ent-malbrancheamide B (ent-22). While the 
overall yield of this sequence is lower than Williams’ corresponding IMDA approach, a single 
enantiomer of malbrancheamide B is delivered in only 10 steps from commercially available 
6-chloroindole. 
 
2.7 Work Towards the Asperparalines 
As outlined above, there have been numerous total syntheses of alkaloids possessing a 
bicyclo[2.2.2]diazaoctane core. However, no synthesis of the asperparalines has been 
forthcoming.  The synthetic challenges of these molecules include the unusual spiro-
succinimide motif; decoration on the proline ring; and the partially reduced nature of the 
central DKP. There have, however, been a number of reports detailing the synthesis of various 
components of the asperparalines. 
 
2.7.1 Work by Williams 
As with many other prenylated indole alkaloids, the first published work towards the 
asperparalines was by the Williams group in 1999.[68] This involves an approach to a spiro 
fused 5,5 ring system incorporating a succinimide and methylated cyclopentane (Scheme 
2.32). Commercially available cyclohexanone 148 was converted into oxime 149 by treatment 
with hydroxylamine hydrochloride. Pyrrole 151 was synthesised in good yield using the 
Trofimov reaction followed by methylation of the resulting amine. Oxidation was 
accomplished under photooxygenation conditions before the key spiro-rearrangment was 
carried out by heating 152 in DMSO in the presence of sodium hydride. 
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Scheme 2.32 
 
Since this paper, Williams has published no further work on the synthesis of the 
asperparalines. 
 
2.7.2 Work by Tanimori 
The Tanimori group has published several papers discussing the synthesis of the 
asperparalines. In 2000, they published an approach to the spiro-succinimide motif starting 
from cyclopentanone 154 (Scheme 2.33).[69] Treatment with malononitrile afforded dinitrile 
155 in reasonable yield and a third nitrile group was incorporated by Michael addition of 
sodium cyanide to give 156. Hydrolysis and decarboxylation then led to diacid 157 which, in 
turn, was transformed to anhydride 158. The synthesis was completed by conversion of the 
anhydride to succinimide 159 by treatment with methylamine. 
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Scheme 2.33 
 
Soon after this approach to the succinimide portion of the molecule, the same group published 
a synthesis of the core bicyclo[2.2.2]diazaoctane motif using a Pauson-Khand reaction 
(Scheme 2.34).[70] Allyl proline 160 was prepared using the Seebach protocol for the self-
reproduction of chirality. Formation of the methyl ester 161 and N-propargylation afforded 
enyne 162.  Treatment of 162 with Co2(CO)8 in a mixture of THF and DMSO triggered the 
desired Pauson-Khand [2+2+1] cycloaddition to form tricycle 163 in up to 94% yield and as a 
single diastereomer.  Finally, treatment with methylamine and exposure to silica gel furnished 
bridged tetracycle 165 in excellent yield. 
 
Scheme 2.34 
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In principle, combining these two approaches would lead to the asperparaline core structure 
but no further reports have been forthcoming. 
 
2.8 Summary 
Since their discovery, the family of prenylated indole alkaloids possessing a bridged 
bicyclo[2.2.2]diazaoctane core have provided inspiration for numerous total syntheses. A 
number of different methods have been used for the construction of key parts of these 
molecules driving the development of new chemistry and helping to further understand the 
biosynthetic origins of these molecules. The asperparalines are yet to succumb to total 
synthesis but their unique structure has inspired novel approaches to individual features. 
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Chapter 3 
Model System Studies 
 
3.1 Introduction 
As discussed in Chapter 2, previous work in our group has led to the total synthesis of both 
(+)-brevianamide B and (−)-malbrancheamide B using a cationic cascade.[66] We were 
interested in applying an analogous radical cyclisation cascade to the synthesis of the 
asperparaline C core structure (Scheme 3.1). Starting with a DKP such as 166 possessing a 
substituted proline along with a maleimide moiety, generation of a vinylic radical by scission 
of a suitable group (e.g. X = Br, I) would be followed by 1,6-hydrogen atom transfer to give 
radical 168. A 6-exo-trig cyclisation would then form a new carbon-carbon bond to afford 
intermediate 169. We hoped that this would then undergo a 5-exo-trig cyclisation onto the 
maleimide to afford the asperparaline core structure 170. 
 
Scheme 3.1 
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A number of potential problems are evident in this process. Firstly, the vital stereochemistry 
at C-6 needs to be controlled. Previous work in our group has shown that the analogous 
cationic cascade tends to favour the syn relationship between the pyrrolidine and DKP ring 
junction – the same configuration as the majority of the natural products. However, the extent 
of this bias depends on the protecting group on the amide nitrogen. As shown in Scheme 3.2, 
this is presumably due to steric constraints – the favoured transition state positions the bulky 
dimethyl group away from protecting group P leading to products such as 172. We hoped that 
similar interactions in our system would give the same stereochemical outcome. 
 
Scheme 3.2 
 
Secondly, as well as the 1,6-H abstraction there is a competing 1,5-H transfer alpha to the 
nitrogen in the pyrrolidine motif. We hope that a combination of conformational and 
stereoelectronic effects will promote the pathway we desire (vide infra). 
 
Finally, the cyclisation onto the maleimide might proceed in 6-endo-trig mode rather than the 
5-exo-trig attack that we desire. The stereocontrol at the spiro centre is also important. These 
issues are discussed further in Chapter 4. 
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3.2  Radical Translocations 
While there are numerous methods for the radical cleavage of various C-X bonds (e.g. with 
AIBN/tributyltin hydride) direct intermolecular radical scission of an unactivated C-H bond is 
typically significantly endothermic. Intramolecular abstraction of a hydrogen atom from a 
remote position has often been used as an elegant solution to this problem.[71] 
 
Parsons and co-workers published an early example where they showed that a radical 
generated from a vinyl iodide would abstract an allylic hydrogen in 1,5 mode (Scheme 
3.3).[72] This abstraction was followed by a 5-exo-trig cyclisation to afford the pyrrolizidine 
ring system of 174. As all of the mechanisms in this section are broadly similar to that shown 
above in Scheme 3.1, individual steps are not shown but an arrow ( ) is used to indicate 
the position from which the hydrogen atom is transferred. 
 
Scheme 3.3 
 
Seminal work by Curran demonstrated a more general method for hydrogen atom transfer. 
Radical scission of a vinyl bromide was again followed by cyclisation in 5-exo-trig mode 
(Scheme 3.4).[73] In this case, the site of abstraction on 175 is alpha to a functional group that 
weakens the C-H bond and stabilises the newly formed radical. This example uses a protected 
alcohol but acetals, esters and phenyl rings were also shown to be effective. 
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Scheme 3.4 
 
Other examples broadly similar to those shown above include Robertson’s synthesis of 
pyrrolizidines[74] and our group’s work on spiro acetals.[75] Chatgilialoglu reported a 
particularly elegant application of this methodology for the synthesis of spiro nucleosides 
(Scheme 3.5).[76] In this case 1,5-abstraction is followed by 5-endo-trig cyclisation and loss of 
a bromine radical to give 178 and 179 still possessing a double bond. 
 
Scheme 3.5 
 
In all of the examples shown above, the hydrogen atom is abstracted in 1,5 mode, but other 
transformations are also possible. The groups of Lendvay[77] and Dannenberg[78] have 
published theoretical studies on the activation energy required for 1,x-H abstractions over 
various different chain lengths (Table 3.1). These calculations are based on simple 
hydrocarbon chains and the situation is very different when bulky substituents are present. 
Nevertheless, it is interesting to note that in terms of activation energies 1,5-H abstraction is 
the most favourable, closely followed by 1,6-H. 
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 activation energy bond angle 
transformation kcal/mol
[77] kcal/mol[78] (C-H--C)[78] 
1,2- 41.1 - - 
1,3- 41.6 42.5 98.5 
1,4- 24.6 27.5 125.2 
1,5- 17.2 20.9 144.5 
1,6- - 21.0 158.0 
1,7- - 23.0 163.6 
1,8- - 24.9 178.1 
 
Table 3.1 
 
Table 3.1 also shows the effect of chain length on the C-H--C bond angle of the transition 
state. While the stereoelectronic preference is for an angle of as close to 180° as possible, 
Dannenberg calculated that a distortion of 35° has less than a 1 kcal/mol effect on the 
activation energy. As shown, the 6-membered transition state necessary for a 1,5-abstraction 
has a C-H--C bond angle of 145° so suffers no severe enthalpic penalty. Abstractions over 
shorter distances (1,2-H, 1,3-H, 1,4-H) result in an increase in ring strain and therefore higher 
activation energies. 
 
However, as well as enthalpic considerations, the conformation of the molecule can be very 
important in determining which hydrogen is transferred. An example of this is provided by 
Breslow’s classic work on the remote functionalisation of steroids. In the example shown in 
Scheme 3.6 a radical generated by complexation of a chlorine species with the aryl iodide 
abstracts a hydrogen in 1,11-mode from C-9 to give the haloalkane 181 in good yield.[79] This 
selectivity is entirely due to the shape of the molecule – extending the linker to the aryl iodide 
by one carbon completely changes the selectivity to C-14. 
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Scheme 3.6 
 
Another interesting example is Bosch and Bachi’s synthesis of bicyclic β-lactams where both 
1,5- and 1,6-abstraction are possible but the strained nature of the four membered ring helps 
favour the 1,6-H transfer. Cyclisation in 7-endo-trig mode is then followed by expulsion of a 
stannane radical, leaving a double bond in the product (183) and making the reaction catalytic 
in tributyltin hydride. (Scheme 3.7).[80] 
 
Scheme 3.7 
 
In this example it is also worth noting that the intermediate radical SOMO (singly occupied 
molecular orbital) is stabilised by a one-electron interaction with the carbonyl LUMO (lowest 
unoccupied molecular orbital) as well as a three-electron interaction with the nitrogen HOMO 
(highest occupied molecular orbital). This demonstrates an unusual property of radicals – they 
are stabilised by both electron-releasing and electron-withdrawing groups as shown in Figure 
3.1.[81]  Radicals positioned adjacent to one of each of these are known as capto-dative 
radicals and are highly stabilised. 
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Figure 3.1 
 
The extent of this stabilisation has been the subject of a number of investigations. For 
example, Rüchardt and co-workers used electron spin resonance (ESR) spectroscopy to 
analyse the energy differences for radicals next to various substituents and quantified these as 
radical stabilisation enthalpies (RSEs, Table 3.2).[82] Their work demonstrates that radicals 
flanked by both a carbonyl group and a nitrogen are considerably more stabilised than those 
by a carbonyl or nitrogen only (entry 10 vs. entries 5 and 3 respectively). Again, these are 
simple systems and the effect is likely to be less pronounced in the amide variations of these 
functionalities. 
entry X Y RSE (kcal mol
-1
) 
1 C C ≡ 0 
2 C COOR −2.8 
3 C NR2 −3.9 
4 C OR −5.9 
5 C CO −6.0 
6 CO CO −8.1 
7 C Ph −8.4 
8 Ph Ph −12.9 
9 COOR NR2 −14.4 
10 CO NR2 −20.7 
 
Table 3.2 
 
X
H
Y
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A number of other groups have published theoretical investigations into this effect with 
broadly the same conclusions.[83] 
 
To investigate the conformational and stereoelectronic effects in our proposed synthesis, we 
designed a model system comprised of a proline-fused DKP possessing a propargyl unit (184, 
Scheme 3.8). 
 
Scheme 3.8 
 
We hoped that radical addition to the triple bond would be followed by 1,6-H transfer and  
6-exo-trig cyclisation to afford the bridged bicyclic DKP 185. Importantly, the intermediate 
radical would be capto-dative; and molecular models suggest that the conformation should 
favour this process rather than the potential 1,5-H abstraction alpha to the pyrrolidine 
nitrogen. 
 
At this stage, it is important to note that we have used the cheaper L-proline for all of our 
work so the compounds in Scheme 3.8 are of the opposite enantiomeric series to the natural 
products shown in Chapter 1. Of course, all of the chemistry we have developed should be 
equally applicable to the D-proline series. 
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3.3 Mixed Proline-Glycine Model Systems 
To synthesise our model system as a single enantiomer, we opted to use Seebach’s method for 
the self-reproduction of chirality (Scheme 3.9).[84] The original sequence of reactions was 
discussed in Chapter 2 in the context of Williams’ synthetic studies. In 1999, Wang and 
Germanas reported a modification of this procedure employing chloral 
(trichloroacetaldehyde) in place of pivalaldehyde.[85] More recently, Amedjkouh and Ahlberg 
published an improvement to this method increasing the yield of 186 to 91% (Scheme 3.9).[86] 
This method is advantageous in that the resulting oxazolidinone is a stable crystalline solid 
that can be stored at room temperature without degradation; and chloral is considerably 
cheaper than pivalaldehyde. Cordero and co-workers used this methodology for the synthesis 
of propargylated oxazolidinone 187, albeit in poor yield (24% based on 63% conversion).[87] 
N
O
O
Cl
Cl
Cl
H
NH
OH
O
H
CHCl3, ref lux
(91%)
N
O
O
Cl
Cl
Cl
LDA, THF
(71%)
Br
186 187
O
H
Cl
Cl
Cl
 
Scheme 3.9 
 
Carrying out brief optimisation studies, we were able to improve this yield to 71% by using a 
large excess (five equivalents) of propargyl bromide and keeping the reaction at −78 °C until 
total comsumption of oxazolidinone 186. Opening of the oxazolidinone ring was achieved 
using acetyl chloride in refluxing methanol to afford substituted proline 188 in quantitative 
yield (Scheme 3.10).[88] 
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Scheme 3.10 
 
This hydrochloride salt was then treated with bromoacetyl bromide and triethylamine to 
afford the acylation product 189. Formation of the DKPs 190a-c was accomplished smoothly 
by treatment with ammonia, methylamine or para-methoxybenzylamine respectively. 
Exposure of 189 to the less nucleophilic tert-butyl carbamate failed to furnish the DKP, so the 
Boc group was instead introduced by treating 190a with Boc2O in the presence of 4-DMAP 
and triethylamine to yield 190d (Scheme 3.11). 
 
Scheme 3.11 
 
With DKPs 190a-d in hand, we were keen to test our key radical cyclisation. While a large 
body of work describes the use of tributyltin hydride in radical reactions, we were attracted to 
reports by Burke and co-workers describing the addition of sulfur to a triple bond (Scheme 
3.12).[89] The use of thiophenol avoids toxic tin derivatives and introduces the possibility of 
further functionalisation by oxidation of the sulfide.[90] In this example the first step is the 
addition of a sulfur centred radical to the triple bond of 191 followed by 1,5-H transfer and 5-
exo-trig cyclisation to give a 2:1 mixture of 192a and 192b. 
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Scheme 3.12 
 
Following a more general approach described by the group of Renaud,[91] a refluxing solution 
of the DKP 190b in tert-butanol was treated with solutions of thiophenol and AIBN, each in 
toluene. This addition took place over twenty hours via syringe pump and we were delighted 
to find that we obtained the desired compounds 193a and 193b in 62% yield as a 5:4 mixture 
of inseparable diastereoisomers (Scheme 3.13). 
 
Scheme 3.13 
 
Detailed NMR analysis allowed us to identify the signals corresponding to each diastereomer, 
but determining the stereochemistry was somewhat problematic. Figure 3.2 shows a section of 
a 1H NMR spectrum for the mixture of diastereomers along with two nOe experiments. As 
shown, the crucial H-6 is poorly resolved presenting a broad multiplet corresponding to both 
diastereomers. Selectively exciting the signal for the N-methyl group of the minor component 
shows no nOe correlation to H-6 suggesting a syn relationship between this proton and the 
pyrrolidine ring (blue spectrum). Carrying out the same experiment with the major 
diastereomer shows a good correlation between H-6 and the N-methyl (red spectrum). 
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However, in this case we were not able to selectively excite only the peak corresponding to  
H-10 leaving this assignment somewhat ambiguous. 
N N
O
OH8
H6
S
N N
O
OH8
H6
Ph
S
Ph
H10 H10
excitation
of H10
excitation
of H10
nOe to H6nOe to H8
nOe to H8 no nOe
to H6
193a
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193b
(minor)
 
Figure 3.2 
 
Although we were pleased with our success using thiophenol, we were also interested in other 
methods for the initiation of the radical process. While all of our attempts using Renaud’s 
dialkyl phosphite reagents failed,[92] we were able to effect cyclisation of 190b using the 
classic conditions of tributyltin hydride and AIBN.[80] This afforded the bridged bicycles 194a 
and 194b in 28% yield as a 5:3 mixture of diastereomers (Scheme 3.14). 
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Scheme 3.14 
 
In this case determination of the stereochemistry was more straightforward. While the signal 
corresponding to H-6 was still poorly resolved, we were easily able to selectively excite both 
N-methyl groups as shown in Figure 3.3. Excitation of H-10 of the major component showed 
a nOe correlation with H-6 (red spectrum) while excitation of H-10 of the minor component 
did not (blue spectrum). These experiments demonstrate that the major isomer (194a) has an 
anti relationship between H-6 and the pyrrolidine ring – the same as that found in the majority 
of natural products. 
 
Figure 3.3 
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As well as securing the configuration of these compounds, these experiments lend weight to 
our initial assignment of N-methyl compounds 193a and 193b by demonstrating that there is a 
strong nOe from the N-methyl to H-6 in only one of the diastereomers.  
 
Having successfully cyclised N-Me DKP 190b, we were interested in the effect the  
N-protecting group would have on the stereochemical outcome of the reaction. Thus N-PMB 
derivative 190c was treated with AIBN and thiophenol using the same conditions as described 
above to give the desired compounds 195a and 195b in 53% yield. We were pleased to find 
that in this case the bridged bicycle was isolated as a 2:1 mixture of diastereomers. Again, 
nOe experiments showed that the major diastereomer has an anti relationship between H-6 
(brevianamide numbering) and the pyrrolidine ring (Scheme 3.15). 
 
Scheme 3.15 
 
While the N-PMB derivative gave an improvement in the diastereomeric ratio, previous work 
both in our group[66b] and by Williams[45, 93] has identified difficulty in removing this group at 
the end of the synthesis. Therefore, we did not plan to use this protecting group in more 
complex systems, but we again attempted this cyclisation using a tin-centred radical. 
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However, in this case we isolated compound 198 possessing an exo-methylene motif in 20% 
yield (Scheme 3.16). Presumably this comes about from intermolecular hydrogen atom 
abstraction from the captodative position of DKP 190c followed by 6-exo-dig cyclisation and 
reaction with tributyltin hydride to give 198. We are unsure why this only happens when the 
PMB protecting group is present, but perhaps a steric or electronic interaction with the triple 
bond slows down the addition of a stannane radical enough to allow this alternative process. 
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Scheme 3.16 
 
This example along with the corresponding tin mediated reaction with N-methyl DKP 190b 
demonstrate that tributyltin hydride can be used for our cyclisation – albeit with somewhat 
unpredictable results. As the yields are disappointing and there is little change in the 
stereoselectivity, we have used thiophenol/AIBN in all subsequent work with acetylene units. 
 
The last of our simple model systems, 190d, has an N-Boc protecting group. We hoped that 
this would be much easier to remove than a PMB group but display some similar 
characteristics in terms of controlling the diastereoselectivity. As in the previous examples, 
treatment with AIBN and thiophenol furnished the desired bridged DKPs 199a and 199b in 
reasonable yield (Scheme 3.17). The diastereomeric ratio was again 5:4, but determining the 
configuration of each epimer proved more difficult. The only protons on the Boc group are 
positioned some distance from the DKP so no nOe was observed in either diastereomer. 
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Scheme 3.17 
 
After studying molecular models, we reasoned that the conversion to the corresponding N-H 
DKP might aid our assignment. Thus, 199a and 199b were treated with HCl in dioxane 
resulting in clean Boc removal to afford 200a and 200b (Scheme 3.18). While this served to 
demonstrate the ease of removal of the Boc group, unfortunately it was of no help in 
determining the stereochemistry at the vital C-6 position. 
 
 
Scheme 3.18 
 
Having had no success with nOe experiments, we turned our attention to the 1H NMR spectra 
of our previous examples. In all cases, the signals for H-8 in the major and minor epimers are 
well resolved doublets separated by between 0.01 and 0.16 ppm. As summarised in entries 1 
to 6 of Table 3.3, we found that the signal corresponding to a syn relationship between H-6 
and the pyrrolidine ring is slightly further downfield and has a smaller coupling constant (J = 
1.4 – 1.5 Hz) than the anti diastereomer (J = 3.1 – 3.5 Hz). Comparing this with the data for 
N-Boc compounds 199a and 199b (entries 7 and 8) we observed the same relationship so 
have tentatively assigned the 5:4 diastereomeric ratio as favouring the anti epimer. In an 
attempt to confirm this, we analysed the other protons close to the stereocentre. 
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Unfortunately, the signals for the H-6 and H-7 are generally poorly resolved so we found it 
difficult to reliably assign exact chemical shifts for each epimer. However, one of the H-5 
protons is a well resolved doubled doublet at around 2 ppm. We found that in all cases the 
anti proton was slightly downfield of the corresponding syn signal – and this relationship was 
maintained in the N-Boc series. 
 
     H-8 (d)  H-5 (dd) 
entry compound R X syn/anti ppm J (Hz)  ppm J (Hz) 
1 194a Me SnBu3 anti 3.58 3.5  2.18 12.8, 9.6 
2 194b Me SnBu3 syn 3.59 1.4  2.05 12.9, 9.5 
3 193a Me SPh anti 3.90 3.3  2.12 12.6, 9.1 
4 193b Me SPh syn 4.06 1.4  2.08 12.6, 8.9 
5 195a PMB SPh anti 4.04 3.1  2.15 12.7, 9.6 
6 195b PMB SPh syn 4.10 1.4  2.10 12.2, 8.4 
7 199a Boc SPh anti 5.03 3.3  2.21 13.8, 9.8 
8 199b Boc SPh syn 5.05 1.5  2.12 13.9, 10.3 
 
Table 3.3 
 
Taken together, these results show that our key cyclisation works for a simple model system 
in reasonable yield. While the stereocontrol is relatively poor, we hoped that the extra steric 
bulk present in more complex systems would lead to an improvement in this. 
 
3.4 Other Mixed DKPs 
Having demonstrated our key cyclisation on simple proline-glycine DKPs, we turned our 
attention to mixed DKPs made up of proline along with various other amino acids. We hoped 
that by incorporating an indole motif we would include a radical trap suitable for a second 
cyclisation to occur. Thus, substituted proline 188 was coupled with Boc-tryptophan using 
HATU in the presence of Hünig’s base to afford dipeptide 201 in 73% yield (Scheme 
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3.19).[94] Cleavage of the Boc group was accomplished using TFA and the resulting free 
amine underwent ring closure by heating with potassium carbonate to give DKP 202.[95] 
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Scheme 3.19 
 
Unfortunately the use of such harsh basic conditions resulted in epimerisation at the 
tryptophan moiety leading to a ca. 1:1 mixture of diastereomers. As we required a single 
diastereomer for our subsequent radical cyclisation to be successful, we needed to separate 
this mixture. Exposure of 202 to triethylamine and methyl iodide led to smooth methylation 
of both the DKP and the indole to afford 203. We were then able to separate the two 
diastereomers by preparative HPLC to afford the desired cyclisation precursor and confirm 
the structure by X-ray crystallography (Figure 3.4). 
 
Figure 3.4 
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With DKP 203 in hand, we turned to our established optimal conditions for the radical 
cyclisation (thiophenol/AIBN, syringe pump addition). This example is, of course, 
considerably more complicated that those discussed above and a number of products are 
possible. We presume that the first cyclisation (analogous to our earlier results) should lead to 
the formation of two diastereomers. These could each then generate two regioisomers by 
attack on the indole either in 5-exo-trig or 6-endo-trig mode. The regioisomeric products 
could occur as a mixture of diastereoisomers, potentially leading to a very complex mixture – 
which is what we in fact observed. While analysis by mass spectrometry showed the correct 
molecular weight, we were disappointed to find that despite our best efforts we were unable to 
isolate any pure compounds. 
 
Taking a step back, we turned our attention to slightly simpler mixed DKPs incorporating 
proline along with a substituted but non-participating amino acid. Again, HATU and Hünig’s 
base mediated coupling afforded dipeptides 204a-c in good yield incorporating an alanine, 
leucine or a protected aspartic acid residue (Scheme 3.20). To avoid the epimerisation we had 
witnessed with the Pro-Trp series, we adopted a different approach for the DKP formation.[96] 
Cleavage of the Boc group was accomplished with neat formic acid which was then removed 
in vacuo. For the alanine and leucine derived systems DKP formation was achieved by 
heating the primary amine in a mixture of 2-butanol and toluene. The dipeptide derived from 
aspartic acid (205c) would not react under these conditions, presumably as it is more sterically 
hindered. However, we found that using xylenes and employing a higher temperature led to 
formation of the desired DKP 206c. To avoid the use of strong base we decided to use a Boc 
protecting group that could be introduced under mild conditions. Thus treatment of DKPs 
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206a-c with Boc anhydride in the presence of 4-DMAP gave 207a-c ready for our cyclisation 
reactions. 
 
Scheme 3.20 
 
To initiate our radical cyclisation we again employed Renaud’s conditions using thiophenol 
and AIBN and were delighted to find that alanine derived DKP 207a formed the bridged 
bicycles 208a and 208b in near-quantitative yield as a 2:1 mixture of diastereomers (Table 
3.4). The proline-leucine DKP 207b gave 209a and 209b as a 4:1 mixture of epimers again in 
excellent yield. Finally, the aspartic acid derived system 207c cyclised to furnish 210a and 
210b in 73% yield and with a d.r. of 2:1. 
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entry compounds R % yield d.r. 
1 208a/208b Me 98 2:1 
2 209a/209b i-Bu 96 4:1 
3 210a/210b CH2CO2Bn 73 2:1 
 
Table 3.4 
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While we were delighted by the improved yields, we found it difficult to conclusively 
determine the stereochemistry of each epimer. As with the proline-glycine system we 
observed no nOe from the N-Boc group to H-6 in either diastereomer. Moreover, we were 
unable to use the chemical shift and coupling constant of the bridgehead proton as it has been 
replaced by a carbon in these examples. The only other proton for which we had previously 
observed a useful difference was H-5, where the signal corresponding to the anti epimer was 
always shifted slightly further downfield than the syn signal. In all of the examples in Table 
3.4 the H-5 signal of the major diastereomer is downfield of the minor component (Table 3.5). 
While this is consistent with the major epimer having the desired anti relationship between  
H-6 and the pyrrolidine, it should not be considered as conclusive proof. 
 
   H-5 (dd) 
compounds R  ppm J (Hz) 
208a/208b Me major 2.24 13.8, 9.6 
  minor 2.15 13.2, 9.8 
209a/209b i-Bu major 2.24 13.8, 9.4 
  minor 2.10 13.5, 8.8 
210a/210b CH2CO2Bn major 2.28 13.8, 9.7 
  minor 2.15 13.5, 9.9 
 
Table 3.5 
 
Nevertheless, as all of the examples of this bond formation using N-acyliminium  
chemistry,[66, 96] IMDA cycloaddition,[50, 53, 55-56, 97] SN2' reactions
[45, 47-49] and our earlier 
radical cyclisations (vide supra) have resulted in predominantly the anti isomer, we were 
reasonably confident that these systems would show the same bias. 
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We wondered if we could improve the ratio of epimers by carrying out the reaction at a lower 
temperature. In our first attempt, we used a 300 W sunlamp to irradiate a solution of DKP 
207b in toluene with the temperature maintained below 35 °C.[98] As before, thiophenol and 
AIBN were added via syringe pump over twenty hours. While we were able to isolate bridged 
bicycles 209a and 209b in 28% yield, the stereoselectivity was not improved from our 
previous attempts and some starting material remained. Using slightly different conditions we 
exposed a solution of DKP 207b and thiophenol to a 400 W mercury lamp.[99] Again, the 
temperature was maintained below 35 °C and again the reaction did not go to completion. 
This time though, the bridged DKP was not formed and instead we isolated 18% of vinyl 
sulfide 211 as a 6:1 E:Z mixture (Scheme 3.21). Presumably this compound arises from 
addition of a sulfur radical to the triple bond followed by either a failure of the 1,6-H 
abstraction step or the subsequent 6-exo-trig cyclisation. 
 
Scheme 3.21 
 
While we were somewhat disappointed at being unable to improve the diastereoselectivity of 
this reaction, further investigation on such a simple model system was considered a low 
priority. With this in mind we considered a more complex DKP (212) substituted with an allyl 
group to allow a second cyclisation to occur (Scheme 3.22). 
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Scheme 3.22 
 
We hoped that treatment of 212 with our established cyclisation conditions would, as before, 
afford radical intermediate 213. Instead of terminating the chain process by picking up a 
hydrogen, this radical would be able to cyclise in 5-exo-trig mode to give tetracycle 214 as a 
simplified model of our real system. 
 
To obtain allyl DKP 212 we first considered deprotonation of a simple Pro-Gly mixed DKP 
followed by electrophilic quench with allyl bromide (Scheme 3.23). Thus, DKP 190b was 
treated with LiHMDS followed by allyl bromide. Unfortunately we did not observe any of the 
desired product and instead isolated triketopiperazine (TKP) 215 in low yield along with 
starting material. We were able to confirm the structure unambiguously by X-ray 
crystallography. This presumably arises through either direct radical oxidation at the capto-
dative position of the DKP or oxidation of the intermediate enolate. The synthesis of TKPs is 
relatively unexplored[100] and oxidation of DKPs could provide a route to single enantiomers 
of these interesting compounds although we have not investigated this any further at present. 
 
Scheme 3.23 
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To circumvent this problem we set about the synthesis of an allyl glycine derivative suitable 
for coupling with a substituted proline residue. To do this we used Cinchona alkaloid 220 as a 
phase transfer catalyst in chemistry that has been developed by Lygo[101] and Corey.[102] 
Known glycine imine 217 was prepared by a simple procedure using benzophenone imine and 
tert-butyl bromoacetate (Scheme 3.24).[103] Treatment with allyl bromide in the presence of 
the Cinchona alkaloid 220, aqueous sodium hydroxide and toluene then afforded protected 
allylglycine 218 in 97% yield. While we did not determine the ee by chiral HPLC, we 
reasoned that once we had coupled this piece with another amino acid we would be able to 
indirectly determine the ee by analysis of the diastereomeric ratio. Continuing the synthesis, 
we were unable to selectively cleave the tert-butyl ester under a variety of conditions. Instead, 
imine hydrolysis was accomplished by treatment with citric acid in THF to afford amine 219 
which we were able to prepare on a multi-gram scale. 
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Scheme 3.24 
 
With amine 219 in hand we turned our attention to the synthesis of a suitably protected 
proline as a coupling partner. Thus, previously prepared substituted proline 188 was Boc 
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protected in the presence of Hünig’s base before ester hydrolysis under standard conditions 
afforded carboxylic acid 222 in good yield. 
 
Scheme 3.25 
 
Exposing a mixture of proline 222 and allylglycine 219 to the same peptide coupling 
conditions we had used previously, we were pleased to obtain dipeptide 223 in 89% yield 
(Scheme 3.26). This is somewhat more efficient than the couplings detailed above, possibly 
because in this example we have used a primary amine rather than a sterically hindered 
pyrrolidine.[104] 
 
Scheme 3.26 
 
At this stage, we hoped to effect DKP formation by Boc cleavage followed by thermal 
cyclisation as we had carried out before. Treatment of 223 with formic acid resulted in 
smooth Boc deprotection to give the corresponding secondary amine 224 with the tert-butyl 
ester remaining intact (Scheme 3.27). However, heating this compound either neat or in a 
range of solvents failed to provide any of the desired allyl DKP 225. Despite having concerns 
of causing epimerisation we also screened a number of both organic and inorganic bases, 
again without any useful reaction occurring. 
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Scheme 3.27 
 
Trying another approach, we treated dipeptide 223 with TFA in DCM to cause both Boc 
deprotection and hydrolysis of the ester. Hoping to effect DKP formation via a conventional 
peptide coupling reaction, we treated 226 with a number of common reagents such as DCC, 
HATU and 4-DMAP, but without any success. In the end we managed to obtain DKP 225, 
albeit in poor yield, by formation of a mixed anhydride followed by amide bond construction. 
Presumably the low yield is due to a fast attack on iso-butyl chloroformate by the pyrrolidine 
amine preventing DKP formation from occurring. We were surprised to find that 225 resisted 
all attempts of amide Boc protection with recovery of unreacted starting material in all cases. 
Although this was frustrating, we reasoned that the desired radical cyclisation should not be 
adversely affected by a free N-H. Thus, following our standard procedure, AIBN and 
thiophenol were slowly added to a solution of DKP 225 in tert-butanol. As this reaction 
constructs two carbon-carbon bonds along with three new stereocentres we anticipated a 
complex mixture of products. While this was indeed the case, we were able to isolate the 
desired tetracycle 227 in 27% yield (Scheme 3.28). 
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Scheme 3.28 
 
We were able to determine the stereochemistry of 227 using nOe experiments. A correlation 
between the N-H and one H-10 allowed us to differentiate between H-10a and H-10b. As 
shown in Figure 3.5 we were able to use this to establish the stereochemistry at C-6, C-11 and 
C-12. An nOe between H-10b and H-6 shows an anti relationship between the pyrrolidine 
nitrogen and the vital H-6. Another correlation demonstrates that H-6, H-10b and H-12 are all 
on the same side of the cyclopentane ring. Finally, an nOe between H-10a and H-11 shows 
these protons are on the same side as each other – i.e. the opposite side to H-6. 
 
Figure 3.5 
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While the yield of this reaction was somewhat disappointing, we were pleased that the major 
component had the desired stereochemistry at C-6. This was also the first demonstration of a 
complete radical cascade analogous to our proposed synthesis of asperparaline C. 
 
3.5 Summary 
In this Chapter we have shown that our key cyclisation proceeds in good to excellent yields 
using a range of simple model systems. Additionally, a more complex system incorporating 
an allyl group was successfully cyclised with the major component possessing the desired 
stereochemistry at the vital C-6 position. 
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Chapter 4 
Towards Asperparaline C 
 
4.1 Retrosynthetic Analysis 
While we were pleased with the success of our model system studies, we were keen to 
construct more complex systems that would allow us to make progress toward the synthesis of 
asperparaline C. As described in Chapter 3, we hoped that a DKP such as 229 would undergo 
a radical cascade to form the core bicyclo[2.2.2]diazaoctane along with the spiro fused 
succinimide (Scheme 4.1). We hoped that 229 would arise from oxidation and syn elimination 
of sulfide 230, itself a product of a Barton decarboxylation and intermolecular radical addition 
to N-methylmaleimide starting from a suitable carboxylic acid such as 231. DKP 231 should 
be relatively straightforward to synthesise from protected aspartic acid 232 and modified 
proline 233 using a similar series of reactions to those described previously. 
 
Scheme 4.1 
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Several protected aspartic acids are commercially available and we expected to be able to 
synthesise substituted proline 233 using the same Seebach chemistry we had previously 
employed. However, in this case the required electrophile (a prenyl group substituted with 
two bromines) is not commercially available. This component has to be synthesised from 
prenyl alcohol 234 by bromination to give first 235[105] then the desired compound 236 
(Scheme 4.2).[106] 
 
Scheme 4.2 
 
As this piece is somewhat valuable, we also considered introducing it later in the synthesis. 
Previous work in our group has shown that substitutions on mixed DKPs of this type proceed 
with total regioselectivity for the proline residue and give solely the anti diastereomer. For 
example, deprotonation of a protected proline-phenylalanine DKP (237) with lithium 
bis(trimethylsilyl)amide followed by an external quench with prenyl bromide afforded 238 in 
82% yield (Scheme 4.3).[96] 
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Scheme 4.3 
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In our case this would require substitution of a DKP such as 239 incorporating a maleimide 
along with a simple proline (Scheme 4.4). However, there is an additional complication as 
DKP 239 possesses an acidic methylene unit adjacent to the maleimide. 
 
Scheme 4.4 
 
Whether using the Seebach method or a late-stage prenylation, we envisaged synthesising 
cyclisation precursor 229 in 5 or 6 steps from commercially available starting materials. 
 
4.2 Initial Studies 
In our first approach, commercially available L-proline O-methyl ester 240 was coupled with 
an aspartic acid piece. Our early studies used the aspartic acid O-methyl ester, but after 
difficulties with deprotection we changed to the O-benzyl series. Thus, amide bond formation 
in the presence of HATU and Hünig’s base afforded dipeptide 241 in 91% yield (Scheme 
4.5). As previously described, DKP formation was accomplished by acid-mediated Boc 
removal followed by heating in a mixture of toluene and 2-butanol to furnish 242 after Boc 
protection. Finally, hydrogenation of the benzyl ester gave free carboxylic acid 243 in a total 
of four steps. 
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Scheme 4.5 
 
With DKP 243 in hand we were ready to introduce the maleimide moiety. Barton and co-
workers have previously demonstrated this reaction on a simple aspartic acid (Scheme 
4.6).[107] In their work, coupling of 244 with the sodium salt of 2-mercaptopyridine N-oxide 
was achieved via formation of a mixed anhydride with isobutyl chloroformate. The resulting 
ester 245 was not isolated but irradiated in the presence of maleimide to afford succinimide 
246 in 59% yield. This proceeds through radical scission of the ester to give a carbon centred 
radical along with loss of carbon dioxide and a 2-mercaptopyridine radical. Addition to the 
maleimide is followed by trapping through a sulfur radical to give the desired compound. To 
complete the process, oxidation of the sulfide to its corresponding sulfoxide was followed by 
syn elimination giving protected amino acid 249 in 79% yield. 
 
Scheme 4.6 
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Applying this to our system, DKP 243 was treated with N-methyl morpholine (NMM) and 
isobutyl chloroformate (Scheme 4.7). After addition of a solution of 2-mercaptopyridine N-
oxide and triethylamine the mixture was stirred in the dark to prevent any premature 
photolysis of the intermediate ester. At this stage we were able to identify a peak possessing 
the correct mass for 250 by LC-MS. Unfortunately, however, after irradiation of the mixture 
in the presence of N-methyl maleimide, we were unable to isolate any of the desired 
compound, 251. 
 
Scheme 4.7 
 
As we could isolate no clean compounds, it is difficult to identify what alternative process is 
interfering with the desired reaction. Assuming that the intermediate radical is generated, the 
desired next step is an intermolecular addition to an electron poor olefin. However, it is 
possible that one or more rapid intramolecular hydrogen atom abstractions can occur before 
this happens. Transfer of the radical centre in 1,2-mode to the captodative position on the 
DKP seems plausible, while abstraction from the pyrrolidine ring looks geometrically 
impossible (Figure 4.1). A 1,5-transfer to the alternative captodative position looks unlikely 
as the hydrogen on this carbon is positioned on the opposite side of the ring from the methyl 
radical we expect to generate. Lastly, a longer distance transfer in 1,7-mode from the Boc 
group is an outside possibility. If one or more of these processes did occur, we would expect a 
complex mixture of products as the chain process could terminate by addition of maleimide to 
various positions of the molecule. As the rate of intermolecular addition to an olefin is 
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concentration dependent, it is difficult to compare the rate constant to that of an 
intramolecular hydrogen atom transfer. However, qualitatively we would expect the 
intramolecular reaction to be considerably faster. 
 
Figure 4.1 
 
As the shape of the molecule is often an important part of hydrogen atom transfers we also 
synthesised carboxylic acid 253 by hydrogenation of the benzyl ester of dipeptide 241 
(Scheme 4.8). Unfortunately, however, we were again unable to isolate the desired compound 
incorporating a maleimide.  
 
Scheme 4.8 
 
With no obvious solution to this problem we abandoned this approach in favour of a more 
convergent synthesis of our key DKP. 
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4.3 Progress Towards Asperparaline C 
We hoped to synthesise an amino acid incorporating a maleimide that we could then couple 
with a proline piece to form our desired cyclisation precursor. Thus, using a modification of 
Barton’s procedure reported by Johnson,[108] N-Boc aspartic acid O-benzyl ester 255 was 
decarboxylated in the presence of N-methylmaleimide to afford 256 in good yield (Scheme 
4.9). Oxidation of the sulfide to the corresponding sulfoxide was accomplished with mCPBA 
before syn elimination on heating in toluene to give maleimide 257 in 83% yield. 
 
Scheme 4.9 
 
To convert amino acid 257 into a suitable partner for coupling with a proline moiety, we 
hoped to cleave the benzyl ester to give a free carboxylic acid. Unfortunately, cleavage under 
standard conditions (hydrogen gas in the presence of palladium on carbon) resulted in 
concurrent reduction of the maleimide double bond to give succinimide 258 in near-
quantitative yield (Scheme 4.10). Other standard conditions for the saponification of esters 
(e.g. LiOH) also failed, leading to rapid degradation of the starting material. 
 
Scheme 4.10 
Chapter 4   Towards Asperparaline C 
    
 
83 
 
Instead, we opted to cleave the N-Boc group to afford a suitable amine for coupling with N-
Boc proline 260. Thus, treatment of 257 with a solution of HCl in 1,4-dioxane led to rapid 
formation of 259 (Scheme 4.11). The subsequent peptide coupling proceeded well under the 
conditions we had previously used to give dipeptide 261 in near-quantitative yield. 
 
Scheme 4.11 
 
Next, we hoped that removal of the pyrrolidine Boc group would be followed by DKP 
formation on heating in a suitable solvent. Treatment with acid led to smooth deprotection to 
give secondary amine 262 (Scheme 4.12). However, under our usual conditions for DKP 
formation (refluxing in 2-butanol/toluene) we recovered only starting material. Switching to 
the higher boiling m-xylene resulted in decomposition and mixtures of these solvents were 
similarly ineffective. Attempts to effect cyclisation in a sealed tube or microwave reactor had 
the same outcome – no reaction at low temperatures and decomposition under harsher 
conditions. 
 
Scheme 4.12 
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When taken together with the corresponding allylglycine derived dipeptide 223 (Chapter 3) 
these results demonstrate the difficulty in forming DKPs in this manner. Realising we could 
avoid this problem if we could selectively hydrolyse the ester of 257 we turned our attention 
to other protecting groups. We were keen to use a commercially available amino acid as the 
two carboxyl groups of aspartic acid complicate selective protection of one over the other. 
With this in mind, the tert-butyl ester was identified as a possibility. While we were initially 
reluctant to use a compound with two similarly reactive protecting groups (N-Boc vs.  
tert-butyl ester) a search of the literature revealed several methods for selective ester 
hydrolysis in the presence of a Boc group. For example, Marcantoni and co-workers reported 
a cerium mediated ester cleavage on a range of simple N-Boc amino acids.[109] They were able 
to isolate clean carboxylic acids in good to excellent yield (Table 4.1). Similarly, the group of 
Wu published a method for tert-butyl ester cleavage using zinc bromide,[110] while Yadav has 
employed montmorillonite KSF clay.[111] 
 
entry conditions R yield reference 
1 CeCl3·7H2O-NaI Bn 78 
[109] 
2 ZnBr2 H 86 
[110] 
3 KSF clay Bn 85 [111] 
 
Table 4.1 
 
Our synthesis began with decarboxylation of aspartic acid tert-butyl ester 264 to afford 265 in 
30% isolated yield (Scheme 4.13). The low yield in this case can be accounted for by the 
difficulty in separating the product from the remaining excess of N-methylmaleimide. Still, 
we were able to synthesise gram quantities of 265 to carry through to further steps. Thus, 
oxidation with mCPBA followed by syn elimination of the sulfur gave known maleimide 266 
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with moderate efficiency.[108] With this compound in hand, we were disappointed to find that 
all attempts at ester cleavage using the reported conditions were unsuccessful. As would be 
expected, treatment with protic acids gave only global deprotection forcing us to abandon this 
approach and consider other routes to 267. 
 
Scheme 4.13 
 
To better differentiate between the two protecting groups, we wanted to introduce a base-
labile ester that could be readily removed without affecting the acid-sensitive Boc group. The 
9-fluorenylmethyl (Fm) ester seemed suitable especially as a one-step access has been 
reported via the cyclic anhydride corresponding to N-Boc aspartic acid.[112] Treatment of 
diacid 268 with DCC in the presence of Hünig’s base afforded 269 which was immediately 
treated with 9-fluorenylmethanol to give exclusively the alpha Fm ester 270. 
 
Scheme 4.14 
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Next, Barton decarboxylation under the established conditions was followed by oxidation and 
elimination to give maleimide 272 in good yield. However, we were surprised to discover that 
treatment with piperidine led to immediate degradation of the material – even after only a few 
minutes at 0 °C. Other common conditions for the removal of fluorenylmethyl esters such as 
diethylamine and TBAF had similar effects. 
 
Scheme 4.15 
 
Contemporaneously with these studies, we had synthesised aspartic acid 275 possessing an 
acid-labile tert-butyl ester along with an N-Fmoc protecting group. Two steps were necessary 
for this – esterification of benzyl ester 273 followed by hydrogenation to afford acid 275 
(Scheme 4.16). 
 
Scheme 4.16 
 
Again, installation of the maleimide proceeded with modest yield through radical 
decarboxylation followed by sulfoxide formation and syn elimination (Scheme 4.17). This 
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time, however, exposure to neat formic acid led to clean ester hydrolysis to yield 278 without 
affecting the Fmoc protected amine. 
 
Scheme 4.17 
 
We were pleased to find that peptide coupling under our established conditions (HATU, 
Hünig’s base) afforded dipeptide 279 in 76% yield (Scheme 4.18). Frustratingly, all attempts 
at Fmoc cleavage and DKP formation were unsuccessful despite screening numerous bases 
(piperidine, diethylamine, TBAF, TMP, sodium methoxide, DBU). 
 
Scheme 4.18 
 
During this work, we frequently observed rapid degradation of compounds possessing a 
maleimide upon treatment with base. While we were unable to isolate any clean by-products, 
we hypothesised that base-promoted Michael addition of nitrogen onto the maleimide could 
be responsible. Maleimides are well known Michael acceptors. For example, Igarashi and 
Watanabe found that treatment of sulfur substituted maleimides such as 280 with 5 
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equivalents of triethylamine led to intramolecular 1,4-addition to afford tricycle 281 in 71% 
yield (Scheme 4.19).[113] Interestingly, the reaction proceeded with similar efficiency when 
sub-stoichiometric (10 mol%) quantities of base were used. This implies that this system is 
primed for cyclisation even under mild conditions. 
 
Scheme 4.19 
 
With this hypothesis in mind, we focused our literature studies on systems incorporating both 
an ester and Michael acceptor. Alongside numerous examples using common ester hydrolysis 
conditions (e.g. LiOH or NaOH) we found an isolated example reported by the group of 
Nicolaou employing trimethyltin hydroxide.[114] In particular, the example shown in Scheme 
4.20 was of interest. Methyl ester 282 was converted to the corresponding carboxylic acid 283 
by treatment with trimethyltin hydroxide in dichloroethane at 80 °C. While the authors noted 
a minor by-product caused by intramolecular conjugate addition of the carboxylate group to 
the neighbouring Michael acceptor, the desired compound was obtained in 77% yield. The 
same conditions were reported to be successful on a range of esters including benzyl, ethyl 
and allyl derivatives. 
 
Scheme 4.20 
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Applying these conditions to benzyl ester 257, we were delighted to obtain carboxylic acid 
267 after 20 hours at 80 °C (Scheme 4.21). Unfortunately this compound proved to be 
unstable on silica gel but we were able to isolate reasonably clean material by repeated 
washes with dilute acid. With a free carboxylic acid finally in hand, we were eager to 
continue our synthesis. Thus, coupling of 267 with substituted proline 188 was carried out 
under standard conditions. We were disappointed that, after purification, the yield over these 
two steps was only 26%, possibly due to impurities remaining with acid 267. Still, the brevity 
of this route (4 steps is the longest linear sequence to 284) allowed us to carry through 
sufficient material to continue. 
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Scheme 4.21 
 
Having obtained suitably protected dipeptide 284, formation of the corresponding DKP was 
trivial. Cleavage of the Boc group with formic acid was followed by heating in 2-butanol and 
toluene to afford 285 in 92% yield (Scheme 4.22). Attempted Boc protection of 285 again 
demonstrated the sensitivity of these compounds to base – this time exposure to 0.1 
equivalents of 4-DMAP led to degradation of the starting material. 
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Scheme 4.22 
 
As we were unable to protect the lactam N-H of 285, we carried out our key cyclisation with 
the N-H DKP. This reaction is considerably more complex than many of those we had 
previously carried out as we hoped to generate two new carbon-carbon bonds along with three 
new stereocentres. Although we obtained a complex mixture of compounds, we were 
delighted to find that the major component possessed a bridged bicyclo[2.2.2]diazaoctane 
core along with a spiro-fused succinimide (Scheme 4.23). 
 
Scheme 4.23 
 
While deducing the basic structure of 287 was relatively straightforward, assigning the 
stereochemistry proved more difficult. We found that 1H NMR spectra recorded in deuterated 
chloroform had peaks corresponding to H-6, H-10 and one H-13 within a region spanning just 
0.2 ppm. While heteronuclear correlation experiments (HSQC/HMBC) allowed us to assign 
the individual peaks, we were unable to selectively excite each proton for nOe studies. 
However, we were pleased to find that recording spectra in benzene-d6 resulted in some of 
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these peaks spreading further apart. We were then able to carry out nOe experiments to 
determine the stereochemistry of 287. As we knew the stereochemistry of the proline residue, 
we hoped to use the amide N-H of the DKP to establish the configuration at C-6, C-10 and  
C-11. While H-6 was still in a cluttered area of the spectrum, exciting one H-12 showed a 
strong nOe correlation to both H-6 and the N-H, along with a coupling to the other geminal 
H-12 (blue spectrum, Figure 4.2). This established the stereochemistry at C-6 as well as 
differentiating between the H-12a and H-12b. Next we needed to determine the configuration 
at the spiro ring junction. After studying models of 287, we reasoned that if C-13 was ‘up’  
H-13b would be positioned close to H-12a, while if C-13 was ‘down’ the correlation would be 
between H-13b and H-12b. We were delighted to find that excitation of one H-13 showed an 
nOe to H-12a, along with coupling to the other geminal H-13 (red spectrum, Figure 4.2).  
 
 
Figure 4.2 
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Unfortunately, we were unable to establish the configuration adjacent to the sulfur (C-10) but 
as the natural product bears a gem-dimethyl group at this position this stereocentre is of little 
importance. Taken together, our nOe experiments allowed us to confirm that the vital 
stereocentres of 287 match with those of the asperparalines. 
 
The sequence to 287 is exceptionally short – just 6 steps in the longest linear sequence from 
commercially available N-Boc aspartic acid benzyl ester. While several of the yields are 
modest, this represents the first synthesis of a compound incorporating a DKP along with a 
spiro-succinimide so is a significant step towards a total synthesis of the asperparalines. 
 
4.4 Further Work and Alternative Routes 
Having accomplished the construction of the asperparaline core, we hoped that installing 
vinyl bromide 236 would allow incorporation of the missing gem-dimethyl group. Although 
the original plan was to introduce 236 by deprotonation of a DKP, the sensitivity of our 
substrates to basic conditions forced us to reconsider this and again use oxazolidinone 186. 
Thus, deprotonation of 186 with LDA was followed by an electrophilic quench with vinyl 
bromide 233 to afford 288 in 54% yield (Scheme 4.24). However, attempted ring-opening 
under our usual conditions (acetyl chloride in refluxing methanol) did not give clean 289. The 
product of this reaction had ambiguous spectral data, although analysis by mass spectrometry 
suggested the correct molecular formula.[115] 
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Scheme 4.24 
 
We hoped that by coupling this compound to maleimide 267 we would be able to purify the 
product and resolve this ambiguity. However, we were unable to isolate the desired dipeptide 
from this reaction but instead obtained a by-product tentatively identified as triazole 290 in 
14% yield (Scheme 4.25). All attempts to convert this to DKP 291 by heating at high 
temperatures were unsuccessful leading to recovery of the starting material. 
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Scheme 4.25 
 
Triazoles analogous to 290 have previously been synthesised by Brown and Schafmeister by 
treating carboxylic acids such as 292 with 1-hydroxy-7-azabenzotriazole (HOAt) in the 
presence of diisopropylcarbodiimide (DIC) to obtain 293 (Scheme 4.26).[116] They reported 
that these compounds were surprisingly stable to self-condensation despite the presence of a 
relatively nucleophilic secondary amide and could only be made to react under harsh thermal 
conditions. 
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Scheme 4.26 
 
If this problem cannot be solved, an alternative approach could be to prenylate a simpler 
protected proline such as 294 to obtain 295 as a racemate (Scheme 4.27). This would avoid 
the problematic cleavage of the Seebach oxazolidinone and Baran has previously shown that 
deprotection using para-toluenesulfonic acid can be followed by coupling promoted by BOP 
chloride to give dipeptide products.[57c] Separation of the resulting diastereomers and DKP 
formation would then afford our key cyclisation precursor 291. 
 
Scheme 4.27 
 
In addition to the problems in forming DKP 291, recent studies in our laboratory have 
identified difficulties in initiating a radical from a fully substituted vinyl halide. Treatment of 
297 with AIBN and tributyltin hydride resulted in recovery of the starting material without 
any trace of 298 or reduction of the vinyl bromide (Scheme 4.28). 
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Scheme 4.28 
 
In light of this, we have also considered alternative methods for generating a radical at the 
desired position of our DKP. For example, instead of relying on a 1,6-H abstraction, scission 
of a suitable substituent on the DKP (ie. X = SPh, CO2R) could directly give intermediate 165 
which would then cyclise to give bridged DKP 228 (Scheme 4.29). 
 
Scheme 4.29 
 
Maleimide 299 could arise from addition of a suitable electrophile to the enolate of a 
prenylated DKP such as 300. This, in turn, should be accessible by substitution of the simple 
proline-glycine DKP 302 which is similar to compounds we have previously synthesised 
(Scheme 4.30). 
 
Scheme 4.30 
Chapter 4   Towards Asperparaline C 
    
 
96 
 
If one of these approaches does give access to the bridged core structure of the asperparalines, 
reduction of the extra carbonyl could still be a significant problem. While we expect any 
approach incorporating a hydrogen atom abstraction to require the captodative position of the 
DKP, a cyclisation based on direct radical formation might be possible without this in place 
(Scheme 4.31). 
 
Scheme 4.31 
 
While the MKP precursor 303 for this reaction could be challenging to synthesise, if a 
successful strategy was developed it would lead directly to asperparaline C without requiring 
any later-stage functional group modifications. 
 
4.5  Summary 
We have demonstrated a radical cascade for the synthesis of the asperparaline core structure 
incorporating a bridged DKP along with a spiro-fused succinimide in just 6 steps. At present 
the sequence to this compound is compromised by several moderate yields, but we hope that 
future modification of our route will lead to the total synthesis of this fascinating compound. 
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Chapter 5 
Experimental 
 
5.1 General Methods 
All reactions were performed under an atmosphere of nitrogen or argon in dry glassware 
unless otherwise stated. THF was distilled immediately prior to use from sodium and 
benzophenone; CH2Cl2 was distilled from calcium hydride. All other solvents and reagents 
were used as received from commercial suppliers unless otherwise stated. Solvents and 
solutions for radical reactions were degassed before use by bubbling a steady stream of dry N2 
gas through them for 30 minutes. Infra-red spectra were recorded neat on a Perkin-Elmer 
Spectrum 100 FTIR spectrometer. Wavelengths (ν) are reported in cm-1. Optical rotations 
were recorded as dilute solutions in the indicated solvent in a 25 mm glass cell using a 
JASCO DIP370 digital polarimeter at 294 nm. Mass spectra were obtained using a VG 
Micromass 70E or VG Micron Autospec spectrometer, using electrospray ionization (ESI) 
with meta-nitrobenzyl alcohol as matrix. All 1H NMR and 13C NMR experiments were 
recorded using Bruker AVIII300, AVIII400, and DRX500 spectrometers at 300 K. 13C NMR 
were recorded using the PENDANT pulse sequence from the Bruker standard pulse program 
library. Chemical shifts (δ) are quoted in ppm and coupling constants (J) are quoted in Hz to 
one decimal place. For spectra recorded in chloroform-d the 7.27 ppm resonance of residual 
CHCl3 for proton spectra and 77.16 ppm resonance of CDCl3 for carbon spectra were used as 
internal references. For spectra recorded in methanol-d4 the 3.34 ppm resonance of residual 
CH3OH for proton spectra and 49.86 ppm resonance of CD3OD for carbon spectra were used 
as internal references. Spectral data for 1H NMR is reported as follows: chemical shift 
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(multiplicity, coupling constant, number of protons, assignment); and for 13C NMR: chemical 
shift (assignment). The following abbreviations were used for multiplicity in 1H NMR: s 
(singlet), d (doublet), t (triplet), q (quadruplet), dd (doublet of doublets), td (triplet of 
doublets), qd (quadruplet of doublets), br (broad), app. (signal with well defined multiplicity 
that may not be expected). In the case of ambiguous assignments, 2-dimensional homonuclear 
(1H-1H) and heteronuclear (1H-13C) NMR experiments were used. For simplicity of 
assignments all atoms are labelled, although these numbers do not necessarily follow IUPAC 
naming conventions. Melting points were recorded on a Gallenkamp melting point apparatus 
and are uncorrected. Reaction progress was monitored by thin layer chromatography (TLC) 
performed on plastic plates coated with keiselgel F254 with 0.2 mm thickness. Visualisation 
was achieved by a combination of ultraviolet light (254 nm) and acidic potassium 
permanganate or anisaldehyde. Flash column chromatography was performed using silica gel 
60 (230-400 mesh, Merck and Co.). 
 
5.2 Experimental for Chapter 3 
Oxazolidinone 186 
 
A solution of L-proline (7.6 g, 66.0 mmol, 1.0 eq.) in chloroform (100 mL) was treated with 
anhydrous trichloroacetaldehyde (9.66 mL, 99.0 mmol, 1.5 eq.). The flask  was fitted with a 
Dean-Stark receiver and the reaction heated at reflux for 4 hours. The resulting brown 
solution was cooled to room temperature, washed with water (2 x 40 mL) and the aqueous 
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phases extracted with dichloromethane (2 x 40 mL). The combined organic layers were dried 
over MgSO4 and concentrated under reduced pressure. The resulting brown solid was purified 
by recrystallisation from ethanol to yield the title compound 186 as white crystalline needles 
(12.34 g, 50.5 mmol, 76%). 
(186, white needles) m.p. 106 °C – 110 °C [lit. 108 °C – 109 °C];[117] [α]D
20 +44.0 (c 0.50, 
CHCl3) [lit. +34.0 (c 2.00, C6H6);
[117] FTIR (film) νmax 2961, 1781, 1450, 1322, 1245, 1175, 
1001, 958; 1H NMR (300 MHz, CDCl3) δ 5.15 (s, 1H, H-6), 4.08 (dd, J=8.8, 4.8, 1H, H-4), 
3.39 (ddd, J=10.9, 7.9, 6.3, 1H, H-1), 3.12 (dd, J=11.2, 5.7, 1H, H-1), 2.00 (m, 4H, H-2,3);  
13C NMR (75 MHz, CDCl3) δ 175.3 (C-5), 103.4 (C-6), 101.0 (C-7), 62.3 (C-4), 57.7 (C-1), 
29.8 (C-3), 25.2 (C-2); HRMS (ESI) calculated for C7H8Cl3NO2 [M+Na]
+ 265.9518 found 
265.9520. 
Data in agreement with those previously reported.[85, 87, 117-118] 
 
Propargylated Oxazolidinone 187 
N
O
OH
Cl
Cl
Cl
LDA, THF, 0oC
186 187
Br
N
O
O
Cl
Cl
Cl
1
2
3
4
5
8
7
6
10
9
(71%)
 
A solution of diisopropylamine (9.63 mL, 68.71 mmol) in THF (120 mL) was cooled to  
–78 °C and treated with n-butyllithium (1.6M solution in hexanes, 42.9 mL, 68.71 mmol). 
The resulting LDA solution was allowed to stir for 30 minutes. Oxazolidinone 186 (12.0 g, 
49.08 mmol) in THF (90 mL) was added via cannula and the reaction mixture stirred for 1 
hour before addition of propargyl bromide (80% wt. solution in toluene, 27.4 mL, 245.4 
mmol). After 4 hours at -78 °C the reaction was quenched with NH4Cl (saturated aqueous 
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solution, 15 mL) and allowed to warm to room temperature. The volatile organics were 
removed under reduced pressure and the resulting oily residue partitioned between 
dichloromethane and water. The layers were separated and the aqueous phase extracted with 
dichloromethane (3 x 100 mL). The combined organic phases were dried over MgSO4 and 
concentrated under reduced pressure. Purification of the brown oily residue by column 
chromatography (eluent petroleum ether/ethyl acetate, 9/1 gradually to 8/2) afforded the title 
compound 187 as a white solid (9.9 g, 35.04 mmol, 71%). 
(187, white solid) m.p. 87 °C – 90 °C; [α]D
20 +32.6 (c 1.13, CHCl3); FTIR (film) νmax 3298, 
2970, 1784, 1328, 1194, 1104, 834, 631; 1H NMR (300 MHz, CDCl3) δ 1.61-2.45 (m, 4H, H-
2, H-3), 2.06 (t, J=2.9, 1H, H-7), 2.81 (d, J=2.9, 2H, H-5), 3.24-3.48 (m, 2H, H-1), 4.99 (s, 
1H, H-9); 13C NMR (75 MHz, CDCl3) δ 174.8 (C-8), 101.9 (C-9), 78.8 (C-10), 71.1 (C-7), 
70.5 (C-6), 60.2 (C-4), 58.5 (C-1), 35.6 (C-3), 28.0 (C-5), 25.2 (C-2); HRMS (ESI) calculated 
for C10H10Cl3NO2 [M+Na]
+ 303.9675 found 303.9665. 
 
Propargylated Proline O-Methyl Ester 188 
 
A stirred solution of 187 (9.9 g, 35.04 mmol) in methanol (200 mL) was treated with a 
solution of acetyl chloride (5.23 mL, 73.58 mmol) in methanol (100 mL). The resulting 
mixture was heated at reflux for 20 hours before concentration under reduced pressure. The 
residue was dried by azetrope with toluene to afford proline O-methyl ester 188 as an off-
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white solid (7.27 g, ~quantitative) that was used without further purification in subsequent 
steps. 
(188, off-white solid) m.p. 180 °C (dec.); [α]D
20 −63.7 (c 0.91, MeOH); FTIR (film) νmax 
3171, 2918, 2647, 1757, 1416, 1219, 1098; 1H NMR (300 MHz, CD3OD) δ 3.88 (s, 3H, H-9), 
3.40-3.45 (m, 2H, H-1), 3.13 (dd, J=17.7, 2.6, 1H, H-5), 2.84 (dd, J=17.7, 2.6, 1H, H-5), 2.73 
(t, J=2.6, 1H, H-7), 1.97-2.19 (m, 4H, H-2, H-3); 13C NMR (75 MHz, CD3OD) δ 108.7 (C-8), 
77.4 (C-6), 75.3 (C-7), 73.0 (C-4), 54.8 (C-9), 47.7 (C-1), 35.6 (C-3), 26.3 (C-5), 24.3 (C-2); 
HRMS (ESI) calculated for C9H14NO2 (free amine) [M+H]
+ 168.1025 found 168.1027. 
 
Acylated Proline O-Methyl Ester 189 
 
A suspension of crude 188 (3.8 g, ~18.66 mmol) in chloroform (50 mL) was cooled to  
–10 °C and treated sequentially with triethylamine (6.22 mL, 44.78 mmol) and bromoacetyl 
bromide (3.90 mL, 44.78 mmol) in chloroform (50 mL). After stirring for 3 hours the reaction 
was quenched with water (50 mL) and the layers separated. The organic phase was washed 
with sodium hydrogen carbonate (sat. aq. soln., 50 mL), brine (50 mL) and dried over 
MgSO4. Removal of the solvent under reduced pressure afforded a brown oil which was 
purified by column chromatography (eluent petroleum ether/ethyl acetate, 8/2 then 7/3) to 
yield the title compound 189 as a colourless oil (3.5 g, 1.18 mmol, 65%). 
(189, colourless oil) [α]D
20 +52.0 (c 1.00, CHCl3); FTIR (film) νmax 3236, 2958, 1733, 1635, 
1417, 1263, 1216; 1H NMR (300 MHz, CDCl3) δ 3.85 (d, J=2.9, 2H, H-11), 3.72 (s, 3H, H-9), 
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3.66-3.89 (m, 2H, H-1), 3.45 (dd, J=17.3, 2.8, 1H, H-5), 2.86 (dd, J=17.3, 2.8, 1H, H-5), 2.04-
2.51 (m, 4H, H-2, H-3), 1.96 (t, J=2.8, 1H, H-7); 13C NMR (75 MHz, CDCl3) δ 172.5 (C-
8/10), 164.9 (C-8/10), 79.9 (C-6), 70.6 (C-7), 67.8 (C-4), 52.6 (C-9), 49.6 (C-1), 35.7 (C-3), 
27.5 (C-5), 26.4 (C-11), 23.9 (C-2); HRMS (ESI) calculated for C12H14BrNO3 [M+Na]
+ 
310.0055 found 310.0057. 
 
Proline-Glycine N-H DKP 190a 
 
Bromide 189 (1.06 g, 3.68 mmol) was dissolved in an ammonia solution (2M in methanol; 
18.4 mL, 36.8 mmol) and allowed to stir at room temperature for 4.5 hours. The volatiles 
were removed under reduced pressure and DCM was added to the residue. The resulting 
precipitate was removed by filtration and the filtrate was concentrated under reduced pressure 
to afford the title compound 190a (716 mg ~quantitative) as a sticky yellow oil that was dried 
under high vacuum then used without further purification. 
(190a, yellow oil) [α]D
20 −138.8 (c 1.00, CHCl3); FTIR (film) νmax 3262, 2982, 2941, 1776, 
1724, 1645, 1440, 1148; 1H NMR (300 MHz, CDCl3) δ 6.70 (s, br, 1H, N-H), 4.38 (d, J=17.0, 
2H, H-10), 3.93-3.79 (m, 2H, H-1), 2.77 (dd, J=16.9, 2.7, 1H, H-5), 2.61 (dd, J=16.9, 2.7, 1H, 
H-5), 2.23-2.14 (m, 2H, H-3), 2.08 (t, J=2.7, 1H, H-7), 2.05-1.94 (m, 2H, H-2); 13C NMR (75 
MHz, CDCl3) δ 170.5 (C-8/9), 161.8 (C-8/9), 76.6 (C-6), 70.5 (C-7), 64.7 (C-4), 45.1 (C-10), 
43.3 (C-1), 33.1 (C-3), 26.4 (C-5), 18.4 (C-2); HRMS (ESI) calculated for C10H12N2O2 
[M+Na]+ 215.0796 found 215.0784. 
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Proline-Glycine N-Methyl DKP 190b 
 
Bromide 189 (1.90 g, 6.58 mmol) in methanol (10 mL) was treated with a methylamine 
solution (2M in methanol; 33.0 mL, 65.8 mmol) at 0 °C. After 1.5 hours the reaction mixture 
was concentrated under reduced pressure and the resulting yellow residue treated with 
dichloromethane (20 mL). The resulting white precipitate was removed by filtration and the 
filtrate concentrated under reduced pressure. The residue was purified by column 
chromatography (eluent 100% ethyl acetate then ethyl acetate/methanol, 9/1) to afford the title 
compound 190b as a white solid (1.17 g, 6.09 mmol, 93%). 
(190b, white solid) m.p. 128 °C – 130 °C; [α]D
20 −106.8 (c 1.00, CHCl3); FTIR (film) νmax 
3284, 2974, 2888, 1651, 1454, 1408, 1339, 1311, 1224, 1013; 1H NMR (300 MHz, CDCl3) δ 
4.46 (d, J=16.9, 1H, H-11), 3.89 (m, 1H, H-1), 3.80 (d, J=16.9, 1H, H-11), 3.57 (m, 1H, H-1), 
3.02 (s, 3H, H-9), 2.79 (dd, J=17.3, 2.7, 1H, H-5) 2.59 (dd, J=17.3, 2.7, 1H, H-5), 2.20-1.95 
(m, 4H, H-2, H-3), 2.05 (t, J=2.7, 1H, H-7); 13C NMR (75 MHz, CDCl3) δ 168.2 (C-8/10), 
162.9 (C-8/10), 78.6 (C-6), 72.0 (C-7), 66.7 (C-4), 53.8 (C-11), 44.8 (C-1), 35.3 (C-3), 33.5 
(C-9), 28.4 (C-5), 20.1 (C-2); HRMS (ESI) calculated for C11H14N2O2 [M+Na]
+ 229.0953 
found 229.0947. 
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Proline-Glycine N-PMB DKP 190c 
 
Bromide 189 (211 mg, 0.73 mmol, 1.0 eq.) was dissolved in methanol (3.7 ml) and treated 
with 4-methoxybenzyl amine (956 µL, 7.32 mmol, 10.0 eq.). The resulting solution was 
allowed to stir at room temperature for 2.5 hours, then the volatiles removed under reduced 
pressure. DCM was added to the residue and the resulting white solid precipitate removed by 
filtration. The filtrate was concentrated under reduced pressure and the residue purified by 
column chromatography (eluent petroleum ether/ethyl acetate, 1/1 gradually to 100% ethyl 
acetate) to afford the title compound 190c as a white solid (202 mg, 0.65 mmol, 89%). 
(190c, white solid) m.p. 112 °C – 114 °C; [α]D
20 –72.8 (c 0.50, CHCl3); FTIR (film) νmax 
3234, 2962, 1662, 1641, 1512, 1436, 1330, 1244, 1112; 1H NMR (300 MHz, CDCl3) δ 7.24-
7.12 (m, 2H, H-13/14), 6.84-6.79 (m, 2H, H-13/14), 4.80 (d, J=14.3, 1H, H-10), 4.25 (d, 
J=14.3, 1H, H-10), 4.17 (d, J=17.1, 1H, H-11), 3.82 (m, 1H, H-1), 3.75 (s, 3H, H-16), 3.66 (d, 
J=17.1, 1H, H-11), 3.49 (m, 1H, H-1), 2.78 (dd, J=16.9, 2.7, 1H, H-5), 2.56 (dd, J=16.9, 2.7, 
1H, H-5), 2.24-2.07 (m, 2H, H-3), 2.01-1.90 (m, 2H, H-2), 1.86 (t, J=2.7, 1H, H-7); 13C NMR 
(75 MHz, CDCl3) δ 168.0 (C-8/9), 163.1 (C-8/9), 159.3 (C-15), 129.9 (C-13), 127.2 (C-12), 
114.0 (C-14), 78.3 (C-6), 72.1 (C-7), 66.6 (C-4), 55.1 (C-16), 50.9 (C-10), 48.9 (C-11), 44.7 
(C-1), 35.3 (C-3), 28.2 (C-5), 20.0 (C-2); HRMS (ESI) calculated for C18H20N2O3 [M+Na]
+ 
335.1372 found 335.1381. 
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Proline-Glycine N-Boc DKP 190d 
 
DKP 190a (134 mg, 0.70 mmol) and Boc2O (229 mg, 1.05 mmol) were dissolved in THF (10 
mL) and treated with triethylamine (146 µL, 1.05 mmol) and 4-DMAP (17 mg, 0.14 mmol). 
The reaction mixture was allowed to stir at room temperature overnight then concentrated 
under reduced pressure. The residue was partitioned between water (20 mL) and 
dichloromethane (20 mL) and the layers separated. The aqueous phase was extracted with 
dichloromethane (2 x 20 mL) and the combined organic layers dried over MgSO4. The 
volatile organics were removed under reduced pressure and the residue purified by column 
chromatography (eluent petroleum ether/ethyl acetate, 1/1 gradually to 100% ethyl acetate) to 
afford the desired compound 190d as a colourless oil (168 mg, 0.57 mmol, 82%). 
(190d, colourless oil) [α]D
20 −50.5 (c 1.00, CHCl3); FTIR (film) νmax 2984, 1777, 1726, 1661, 
1369, 1288, 1147; 1H NMR (400 MHz, CDCl3) δ 4.42 (d, J=2.5, 2H, H-10), 3.77 (m, 1H, H-
1), 3.52 (m, 1H, H-1), 2.73 (dd, J=17.0, 2.7, 1H, H-5), 2.58 (dd, J=17.0, 2.7, 1H, H-5), 2.32-
2.16 (m, 2H, H-3), 2.07 (t, J=2.7, 1H, H-7), 2.04-1.87 (m, 2H, H-2), 1.48 (s, 9H, H-13); 13C 
NMR (75 MHz, CDCl3) δ 168.3 (C-8/9), 162.7 (C-8/9), 150.0 (C-11), 84.5 (C-12), 77.7 (C-6), 
72.7 (C-7), 67.8 (C-4), 49.7 (C-10), 45.2 (C-1), 35.4 (C-3), 28.0 (C-5), 27.7 (C-13), 20.4 (C-
2); HRMS (ESI) calculated for C15H20N2O4 [M+Na]
+ 315.1321 found 315.1325. 
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General Procedure A:  Thiophenol Mediated Radical Cyclisation of DKPs 
To a refluxing solution of DKP (1.0 eq.) in tert-butanol (50 mL) was added AIBN (2.0 eq.) in 
toluene (10 mL) and thiophenol (2.0 eq.) in toluene (10 mL) over 20 hours via a syringe 
pump. Once the addition was complete, the reaction was kept at reflux for a further 2 hours, 
cooled to room temperature, and concentrated under reduced pressure. The residue was 
purified by column chromatography (eluent petroleum ether/ethyl acetate, 1/1 gradually to 
100% ethyl acetate) to afford the bridged bicyclo[2.2.2]diazaoctanes. 
 
N-Methyl Bridged DKPs 193a and 193b 
 
General procedure A was followed with DKP 190b (119 mg, 0.58 mmol), AIBN (189 mg, 
1.15 mmol) and thiophenol (127 µL, 1.15 mmol) to afford the title compounds 193a and 193b 
as a colourless oil (114 mg, 0.36 mmol, 62%) and a 5:4 mixture of inseparable diastereomers. 
(193a/193b, colourless oil) [α]D
22 +17.0 (c 1.00, CHCl3); FTIR (film) νmax 2962, 2882, 1674, 
1582, 1482, 1426, 1396, 1209; 1H NMR (500 MHz, CDCl3) (193a) δ 7.32 (m, 1H, H-13) 7.26 
(t, J=7.7, 2H, H-14), 7.20 (m, 2H, H-15), 3.90 (d, J=3.3, 1H, H-8), 3.48-3.39 (m, 2H, H-1), 
2.97 (s, 3H, H-10), 2.92 (m, 1H, H-7), 2.80 (m, 1H, H-7), 2.70 (dt, J=13.3, 6.2, 2H, H-3), 2.39 
(m, 1H, H-6), 2.12 (dd, J=12.6, 9,1, 1H, H-5), 1.94-1.87 (m, 2H, H-2), 1.71 (m, 1H, H-3), 
1.51 (m, 1H, H-5); (193b) δ 7.32 (m, 1H, H-13) 7.26 (t, J=7.7, 2H, H-14), 7.22-7.17 (m, 2H, 
H-15), 4.06 (d, J=1.4, 1H, H-8), 3.39-3.31 (m, 2H, H-1), 2.91 (s, 3H, H-10), 2.93 (m, 1H, H-
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7), 2.76 (m, 1H, H-7), 2.70 (dt, J=13.3, 6.2, 2H, H-3), 2.39 (m, 1H, H-6), 2.08 (dd, J=12.6, 
8.9, 1H, H-5), 1.98-1.90 (m, 2H, H-2), 1.75 (m, 1H, H-3), 1.55 (m, 1H, H-5); 13C NMR (125 
MHz, CDCl3) (193a) δ 170.7 (C-11), 167.5 (C-9), 134.3 (C-12), 130.5 (C-13), 129.1/129.0 
(C-14), 127.0/126.8 (C-15), 67.0 (C-4), 65.0 (C-8), 43.4 (C-1), 37.2 (C-7), 37.0 (C-6), 36.8 
(C-5) 33.5 (C-10), 29.0 (C-3), 24.4 (C-2); (193b) δ 170.8 (C-11), 166.0 (C-9), 134.5 (C-12), 
130.3 (C-13), 129.1/129.0 (C-14), 127.0/126.8 (C-15), 66.8 (C-4), 65.7 (C-8), 43.6 (C-1), 
37.6 (C-7), 37.3 (C-6), 36.8 (C-5) 31.9 (C-10), 29.1 (C-3), 24.3 (C-2); HRMS (ESI) 
calculated for C17H20N2O2S [M+Na]
+ 339.1143 found 339.1139. 
 
N-Methyl Bridged DKPs 194a and 194b 
N
N
O
O
Bu3SnH, AIBN,
benzene
190b
N
N
O
O
194a
1
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56
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N
N
O
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1
2
3
4
56
9
8
10
11
7
12
13
14
15
Sn
+
(28%)
d.r. 5:3
 
Diketopiperazine 190b (119 mg, 0.58 mmol) was dissolved in benzene (50 mL) and heated at 
reflux. Solutions of tributyltin hydride (310 µL, 1.15 mmol) in benzene (10 mL) and AIBN 
(189 mg, 1.15 mmol) in benzene were added over 20 hours via syringe pump then the reaction 
mixture kept at reflux for a further 2 hours. The volatile organics were removed under 
reduced pressure and the residue purified by column chromatography (eluent petroleum 
ether/ethyl acetate, 1/1 then 100% ethyl acetate) to afford the desired compounds 194a and 
194b as a colourless oil (80 mg, 0.16 mmol, 28%) and 5:3 mixture of diastereoisomers. 
(194a/194b, colourless oil) [α]D
20 +13.2 (c 1.00, CHCl3); FTIR (film) νmax 2923, 1685, 1422, 
1395, 1220, 1069; 1H NMR (500 MHz, CDCl3) (194a) δ 3.58 (d, J=3.5, 1H, H-8), 3.50-3.43 
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(m, 2H, H-1), 2.98 (s, 3H, H-10), 2.79-2.64 (m, 2H, H-3), 2.42 (m, 1H, H-6), 2.18 (dd, 
J=12.8, 9.6, 1H, H-5), 1.96 (td, J=7.0, 3.5, 2H, H-2), 1.78-1.67 (m, 2H, H-3), 1.52-1.37 (m, 
6H, H-13), 1.28 (dd, J=14.7, 7.3, 6H, H-14), 1.20 (d, J=4.6, 1H, H-5), 0.95 (dd, J=13.0, 4.3, 
1H, H-7), 0.88 (t, J=7.4, 9H, H-15), 0.85-0.80 (m, 6H, H-12), 0.74 (m, 1H, H-7); (194b, only 
signals that differ from 194a) δ 3.59 (d, J=1.4, 1H, H-8), 3.40 (t, J=6.8, 2H, H-1), 3.08 (s, 3H, 
H-10), 2.05 (dd, J=12.9, 9.5, 1H, H-5), 1.22 (d, J=4.6, 1H, H-5); 13C NMR (125 MHz, 
CDCl3) (194a) δ 171.1 (C-11), 167.1 (C-9), 70.3 (C-8), 67.0 (C-4), 43.7 (C-1), 40.5 (C-5), 
36.8 (C-6), 32.2 (C10), 29.6 (C-3), 29.3 (C-13), 27.5 (C-14), 24.6 (C-2), 14.8 (C-7), 13.8 (C-
15), 9.4 (C-12); (194b) δ 170.9 (C-11), 168.7 (C-9), 71.5 (C-8), 67.5 (C-4), 43.6 (C-1), 40.2 
(C-5), 36.6 (C-6), 34.6 (C-10), 29.4 (C-3), 29.2 (C-13), 27.5 (C-14), 24.7 (C-2), 14.4 (C-7), 
13.8 (C-15), 9.4 (C-12); HRMS (ESI) calculated for C23H42N2O2 [M+Na]
+ 521.2166 found 
521.2176. 
 
N-PMB Bridged DKPs 195a and 195b 
 
General procedure A was followed with DKP 190c (157 mg, 0.50 mmol), thiophenol (103 µL, 
1.00 mmol) and AIBN (165 mg, 1.00 mmol) to afford the title compounds 195a and 195b as a 
colourless oil (114 mg, 0.27 mmol, 53%) and 2:1 mixture of inseparable diastereoisomers. 
(195a/195b, colourless oil) [α]D
20 −24.7 (c 1.20, CHCl3); FTIR (film) νmax 2930, 1677, 1511, 
1414, 1244, 1175, 1026; 1H NMR (400 MHz, CDCl3) (195a) δ 7.27-7.09 (m, 7H, H-Ar), 6.77 
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(m, 1H, H-Ar), 4.81 (d, J=14.4, 1H, H-11), 4.10 (d, J=14.4, 1H, H-11), 4.04 (d, J=3.1, 1H, H-
8), 3.78 (s, 3H, H-16), 3.53-3.43 (m, 2H, H-1), 2.85-2.72 (m, 2H, H-3, H-7), 2.66 (d, J=7.9, 
1H, H-7), 2.27 (m, 1H, H-6), 2.15 (dd, J=12.7, 9.6, 1H, H-5), 2.98 (m, 1H, H-2), 1.79 (m, 1H, 
H-3), 1.52 (m, 1H, H-5); (195b, only signals that differ from 195a) δ 6.84 (m, 1H, H-Ar), 
4.59 (d, J=14.4, 1H, H-11), 4.36 (d, J=14.4, 1H, H-11), 4.10 (d, J=1.4, 1H, H-8), 3.76 (s, 3H, 
H-16), 2.10 (dd, J=12.2, 8.4, 1H, H-5); 13C NMR (125 MHz, CDCl3) (195a) δ 170.6 (C-10), 
166.3 (C-9), 159.3 (C-15), 134.5 (C-17), 130.2 (C-19), 129.5 (C-13), 129.0 (C-18), 127.9 (C-
12), 126.7 (C-20), 114.2 (C-14), 67.3 (C-4), 63.3 (C-8), 55.1 (C-16), 48.0 (C-11), 43.7 (C-1), 
37.8 (C-6), 36.8 (C-5), 36.6 (C-7), 29.3 (C-3), 24.5 (C-2); (195b) δ 170.8 (C-10), 167.9 (C-9), 
159.5 (C-15), 134.8 (C-17), 130.1 (C-19), 129.9 (C-13), 129.1 (C-18), 128.3 (C-12), 126.7 
(C-20), 114.3 (C-14), 67.1 (C-4), 63.4 (C-8), 55.2 (C-16), 49.2 (C-11), 43.6 (C-1), 37.8 (C-6), 
36.8 (C-5), 36.8 (C-7), 29.2 (C-3), 24.5 (C-2); HRMS (ESI) calculated for C24H26N2O3S 
[M+Na]+ 445.1562 found 445.1554. 
 
N-PMB Bridged DKP 198 
 
A solution of diketopiperazine 190c (184 mg, 0.59 mmol) in benzene (50 mL) was heated to 
reflux and treated with solutions of AIBN (194 mg, 1.18 mmol) in benzene (10 mL) and 
tributyltin hydride (317 µL, 1.18 mmol) in benzene (10 mL) over 20 hours via syringe pump. 
Once the addition was complete the reaction mixture was allowed to stir at reflux for a further 
two hours then cooled to room temperature and concentrated under reduced pressure. The 
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residue was purified by column chromatography (eluent petroleum ether/ethyl acetate, 1/1 
gradually to 100% ethyl acetate) to afford the title compound 198 as a colourless oil (37 mg, 
0.12 mmol, 20%). 
(198, colourless oil) [α]D
20 −33.6 (c 0.25, CHCl3); FTIR (film) νmax 2921, 2852, 1689, 1514, 
1413, 1249, 1023; 1H NMR (400 MHz, CDCl3) δ 7.12 (d, J=8.6, 2H, H-13), 6.83 (d, J=8.7, 
2H, H-14), 4.97 (t, J=2.2, 1H, H-7), 4.91 (t, J=2.2, 1H, H-7), 4.63 (d, J=14.7, 1H, H-11), 4.41 
(d, J=14.7, 1H, H-11), 4.15 (s, 1H, H-8), 3.78 (s, 3H, H-16), 3.54-3.36 (m, 2H, H-1), 2.82 (dt, 
J=13.3, 6.8, 1H, H-3), 2.66-2.45 (m, 2H, H-5), 2.09-1.94 (m, 2H, H-2), 1.85 (m, 1H, H-3); 13C 
NMR (75 MHz, CDCl3) δ 170.6 (C-10), 166.4 (C-9), 159.5 (C-15), 138.6 (C-6), 129.7 (C-13), 
127.9 (C-12), 114.2 (C-14), 112.8 (C-7), 67.6 (C-8), 67.4 (C-4), 55.4 (C-16), 48.1 (C-11), 
43.9 (C-1), 37.1 (C-5), 29.0 (C-3), 24.8 (C-2); HRMS (ESI) calculated for C18H20N2O3 
[M+Na]+ 335.1372 found 335.1367. 
 
N-Boc Bridged DKPs 199a and 199b 
 
General procedure A was followed with DKP 190d (168 mg, 0.57 mmol), thiophenol (117 
µL, 1.14 mmol) and AIBN (187 mg, 1.14 mmol) to afford the title compounds 199a and 199b 
as a colourless oil (125 mg, 0.31 mmol, 55%) and 5:4 mixture of inseparable 
diastereoisomers. 
Chapter 5    Experimental 
     
 
111 
 
(199a/199b, colourless oil) [α]D
20 +8.80 (c 1.00, CHCl3); FTIR (film) νmax 2978, 1780, 1692, 
1649, 1439, 1366, 1251, 1144; 1H NMR (400 MHz, CDCl3) δ (199a) 7.45-7.18 (m, 5H, H-
Ar), 5.03 (d, J=3.3, 1H, H-8), 3.59-3.35 (m, 2H, H-1), 3.03 (m, 1H, H-7), 2.84-2.69 (m, 2H, 
H-3, H-7), 2.44 (m, 1H, H-6), 2.21 (dd, J=13.8, 9.8, 1H, H-5), 2.03-1.92 (m, 2H, H-2), 1.79 
(m, 1H, H-3), 1.70 (m, 1H, H-5), 1.55 (s, 9H, H-13); (199b, only signals that differ from 
199a) δ 5.05 (d, J=1.5, 1H, H-8), 2.12 (dd, J=13.9, 10.3, 1H, H-5), 1.52 (s, 9H, H-13); 13C 
NMR (75 MHz, CDCl3) (199a) δ 168.7 (C-10), 166.3 (C-9), 149.5 (C-11), 134.3 (C-14), 
130.5 (C-15), 129.1 (C-16), 126.9 (C-17), 84.5 (C-12), 68.1 (C-4), 61.0 (C-8), 43.7 (C-1), 
36.7 (C-5), 36.1 (C-6),  35.7 (C-7), 29.2 (C-3), 27.8 (C-13), 24.2 (C-2); (199b) δ 168.5 (C-
10), 165.0 (C-9), 148.0 (C-11), 134.2 (C-14), 130.3 (C-15), 129.0 (C-16), 126.9 (C-17), 84.4 
(C-12), 68.0 (C-4), 60.9 (C-8), 43.8 (C-1), 37.7 (C-5), 37.1 (C-6), 35.8 (C-7), 29.3 (C-3), 27.8 
(C-13), 24.1 (C-2); HRMS (ESI) calculated for C21H26N2O4S [M+Na]
+ 425.1511 found 
425.1509. 
 
General Procedure B: Peptide Coupling with N-Boc Amino Acids 
To a stirred suspension of a carboxylic acid (1 eq.), an N-Boc amino acid (1 eq.) and HATU 
(1.1 eq.) in acetonitrile was added diisopropylethylamine (2.1 eq.) causing a dark yellow 
solution to form. This solution was allowed to stir at room temperature overnight then 
concentrated under reduced pressure. The resulting brown oily residue was purifed by column 
chromatography (eluent petroleum ether/ethyl acetate, 8/2 gradually to 1/1) to afford the 
dipeptide products. 
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Proline-Tryptophan Dipeptide 201 
 
General procedure B was followed with modified proline 188 (1.0 g, 4.91 mmol), Boc-
Trp(NH)-OH (1.5 g, 4.91 mmol), HATU (2.0 g, 5.40 mmol) and diisopropylethylamine (1.8 
mL, 10.3 mmol) to afford the title compound as a colourless oil (1.63 g, 3.60 mmol, 73%). 
(201, colourless oil) [α]D
20 +17.6 (c 0.50, CHCl3); FTIR (film) νmax 3305, 2978, 1738, 1694, 
1636, 1433, 1163, 729; 1H NMR (300 MHz, CDCl3) δ 8.83 (s, 1H, N-H), 7.67 (d, J=7.5, 1H, 
H-Ar), 7.32 (d, J= 7.5, 1H, H-Ar), 7.20-7.01 (m, 3H, H-Ar), 5.40 (d, J=9.1, 1H, N-H), 4.82 
(dd, J=15.3, 7.4, 1H, H-11), 3.71-3.47 (m, 2H, H-1), 3.60 (s, 3H, H-9), 3.36 (dd, J=17.2, 2.6, 
1H, H-5), 3.20 (dd, J=14.6, 6.8, 1H, H-12), 3.06 (dd, J=14.6, 6.8, 1H, H-12), 2.83 (dd, 
J=17.2, 2.6, 1H, H-5), 2.37-1.63 (m, 4H, H-2, H-3), 1.92 (t, J=2.6, 1H, H-7); 13C NMR (100 
MHz, CDCl3) δ 173.0 (C-8/10), 170.9 (C-8/10), 155.4 (C-21), 136.2 (C-14/19), 128.0 (C-
14/19), 123.4 (CH-Ar), 122.1 (CH-Ar), 119.7 (CH-Ar), 118.9 (CH-Ar), 111.2 (CH-Ar), 110.7 
(C-13), 79.6 (C-6), 70.7 (C-7), 67.7 (C-22), 60.5 (C-4), 52.61 (C-9/11), 52.58 (C-9/11), 48.9 
(C-1), 36.0 (C-3), 28.7 (C-12), 28.5 (C-23), 24.4 (C-5), 24.0 (C-2); HRMS (ESI) calculated 
for C25H31N3O5 [M+Na]
+ 476.2161 found 476.2163. 
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Methylated Proline-Tryptophan DKP 203 
 
Dipeptide 201 (1.57 g, 3.47 mmol) was dissolved in dichloromethane (7.6 mL) and treated 
with trifluoroacetic acid (7.6 mL) then water (80 µL). The resulting mixture was stirred at 
room temperature for 2 hours then concentrated under reduced pressure. The residue was 
dissolved in ethanol and exaporated to dryness; then dissolved in toluene and exaporated to 
dryness. The final residue was dissolved in ethanol and the pH adjusted to 9 with potassium 
carbonate. The reaction mixture was heated at reflux for 16 hours then cooled to room 
temperature and filtered through Celite®. The filtrate was concentrated under reduced pressure 
to afford the DKP 202 as a yellow oil (1.14 g). A solution of this compound in 
tetrahydrofuran (5 mL) was added to a solution of sodium hydride (60% dispersion in mineral 
oil; 416 mg, 10.4 mmol) in tetrahydrofuran (10 mL) at 0 °C. Methyl iodide (2.2 mL, 34.7 
mmol) was added dropwise and the reaction mixture allowed to warm to room temperature 
and stir overnight. Water (1 mL) was added and the volatiles removed under reduced 
pressure. The residue was partitioned between water (20 mL) and dichloromethane (20 mL) 
and the layers separated. The aqueous phase was extracted with dichloromethane (2 x 20 mL) 
and the combined organic layers dried over MgSO4 then concentrated under reduced pressure 
to afford the desired N-methyl DKP as an off-white foam (824 mg, 2.36 mmol, 70%) and 1:1 
mixture of diastereoisomers. A portion of the material was purified by preparative HPLC to 
afford the desired diastereomer 203 as a white solid. 
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(203, white solid) m.p. 211 °C (dec.); [α]D
20 +3.0 (c 1.00, CHCl3); FTIR (film) νmax 3192, 
2928, 1642, 1547, 1455, 1428, 1404, 1326; 1H NMR (300 MHz, CDCl3) δ 7.67-7.62 (m, 1H, 
H-Ar), 7.35-7.03 (m, 3H, H-Ar), 6.76 (s, 1H, H-20), 4.33 (dd, J=4.3, 2.5, 1H, H-9), 3.73 (s, 
3H, H-21), 3.72 (m, 2H, H-12), 3.46 (m, 1H, H-1), 3.28 (dd, J=14.8, 4.5, 1H, H-12), 3.16 (s, 
3H, H-11), 3.06 (m, 1H, H-1), 2.61 (dd, J=16.7, 2.6, 1H, H-5), 2.29 (dd, J=16.7, 2.6, 1H, H-
5), 2.00 (t, J=2.6, 1H, H-7), 1.66-1.25 (m, 4H, H-2, H-3); 13C NMR (75 MHz, CDCl3) δ 167.8 
(C-8/10), 164.5 (C-8/10), 136.6 (C-14/19), 128.3 (C-14/19), 127.9 (C-20), 122.0 (CH-Ar), 
120.0 (CH-Ar), 119.2 (CH-Ar), 109.0 (CH-Ar), 107.0 (C-13), 78.5 (C-6), 72.1 (C-7), 66.7 (C-
4), 63.4 (C-9), 43.6 (C-1), 33.6 (C-3), 32.8 (C-11/21), 32.6 (C-11/21), 28.9 (C-12), 27.7 (C-
5), 18.9 (C-2); HRMS (ESI) calculated for C21H23N3O2 [M+Na]
+ 372.1688 found  
372.1696. 
 
Proline-Alanine Dipeptide 204a 
 
General procedure B was followed with modified proline 188 (1.03 g, 5.06 mmol), Boc-Ala-
OH (957 mg, 5.06 mmol), HATU (2.11 g, 5.57 mmol) and diisopropylethylamine (1.85 mL, 
10.6 mmol) to afford the title compound 204a as a colourless oil (1.29 g, 3.80 mmol, 75%). 
(204a, colourless oil) [α]D
20 +14.0 (c 1.00, CHCl3); FTIR (film) νmax 3307, 2985, 2887, 1741, 
1702, 1645, 1432, 1243, 1161, 1025; 1H NMR (400 MHz, CDCl3) δ 5.38 (d, J=8.2, 1H, N-H), 
4.45 (m, 1H, H-11), 3.74-3.63 (m, 2H, H-1), 3.65 (s, 3H, H-9), 3.35 (dd, J=17.2, 2.7, 1H, H-
5), 2.83 (dd, J=17.2, 2.7, 1H, H-5), 2.33 (m, 1H, H-2), 2.15 (m, 1H, H-3), 2.08 (m, 1H, H-2), 
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1.99 (m, 1H, H-3), 1.92 (t, J=2.7, 1H, H-7), 1.38 (s, 9H, H-15), 1.26 (d, J=6.8, 3H, H-12); 13C 
NMR (75 MHz, CDCl3) δ 172.7 (C-8/10), 171.3 (C-8/10), 155.0 (C-13), 80.0 (C-6), 79.4 (C-
14), 70.7 (C-7), 67.7 (C-4), 52.5 (C-9), 48.7 (C-1), 47.9 (C-11), 35.7 (C-3), 28.3 (C-15), 24.5 
(C-5), 23.9 (C-2), 17.9 (C-12); HRMS (ESI) calculated for C17H26N2O5 [M+Na]
+ 361.1739 
found 361.1747. 
 
Proline-Leucine Dipeptide 204b 
 
General procedure B was followed with modified proline 188 (640 mg, 3.14 mmol), Boc-Leu-
OH (727 mg, 3.14 mmol), HATU (1.31 g, 3.45 mmol) and diisopropylethylamine (1.15 mL, 
6.59 mmol) to afford the title compound 204b as a slightly yellow oil (864 mg, 2.27 mmol, 
72%). 
(204b, yellow oil) [α]D
20 +11.2 (c 1.00, CHCl3); FTIR (film) νmax 3329, 3292, 3226, 2956, 
1738, 1690, 1644, 1526, 1424, 1246, 1160, 1048; 1H NMR (400 MHz, CDCl3) δ 5.23 (s, br, 
N-H), 4.43 (q, J=8.5, 1H, H-11), 3.76 (m, 1H, H-1), 3.63 (m, 1H, H-1), 3.60 (s, 3H, H-9), 
3.29 (dd, J=17.2, 2.4, 1H, H-5), 2.78 (dd, J=17.2, 2.4, 1H, H-5), 2.20 (m, 1H, H-3), 2.15 (m, 
1H, H-2), 2.05 (m, 1H, H-3), 1.97 (m, 1H, H-2), 1.87 (t, J=2.4, 1H, H-7), 1.63 (m, 1H, H-13), 
1.36 (s, 2H, H-12), 1.34 (s, 9H, H-18), 0.91 (d, J=6.5, 3H, H-14/15), 0.87 (d, J=6.5, 3H, H-
14/15); 13C NMR (100 MHz, CDCl3) δ 173.0 (C-8/10), 171.7 (C-8/10), 155.7 (C-16), 80.2 (C-
6), 79.6 (C-17), 70.7 (C-7), 67.9 (C-4), 52.6 (C-9), 50.6 (C-11), 48.9 (C-1), 41.8 (C-3), 36.0 
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(C-12), 28.5 (C-18), 24.6 (C-5), 24.1 (C-2), 23.5 (C-14/15), 23.0 (C-13), 22.1 (C-14/15); 
HRMS (ESI) calculated for C20H32N2O5 [M+Na]
+ 403.2209 found 403.2211. 
 
Proline-Aspartic Acid O-Benzyl Ester Dipeptide 204c 
 
General procedure B was followed with modified proline 188 (1.0 g, 4.91 mmol), Boc-
Asp(OBn)-OH (1.59 g, 4.91 mmol), HATU (2.05 g, 5.40 mmol) and diisopropylethylamine 
(1.80 mL, 10.31 mmol) to afford the title compound 204c as a colourless oil (1.43 g, 3.26 
mmol, 72%). 
(204c, colourless oil) [α]D
20 +5.2 (c 1.00, CHCl3); FTIR (film) νmax 3300, 2976, 1735, 1646, 
1434, 1244, 1161, 1022; 1H NMR (400 MHz, CDCl3) δ 7.32-7.16 (m, 5H, H-Ar), 5.38 (d, 
J=9.7, 1H, N-H), 5.05 (d, J=4.4, 2H, H-14), 4.84 (dt, J=9.6, 6.6, 1H, H-11), 3.83 (m, 1H, H-
1), 3.68 (m, 1H, H-1), 3.55 (s, 3H, H-9), 3.32 (dd, J=17.2, 2.6, 1H, H-5), 2.81-2.69 (m, 2H, 
H-5, H-12), 2.58 (dd, J=16.1, 5.9, 1H, H-12), 2.26-1.87 (m, 4H, H-2, H-3), 1.85 (t, J=2.6, 1H, 
H-7), 1.34 (s, 9H, H-21); 13C NMR (100 MHz, CDCl3) δ 172.8 (C=O), 170.5 (C=O), 169.4 
(C=O), 155.1 (C=O), 135.8 (C-15), 128.6 (CH-Ar),128.4 (CH-Ar), 128.3 (CH-Ar), 80.2 (C-
6), 80.1 (C-4), 70.6 (C-7), 67.8 (C-20), 66.7 (C-14),  52.6 (C-9), 49.3 (C-1, C-11), 37.2 (C-
12), 35.9 (C-3), 28.4 (C-21), 24.3 (C-5), 24.1 (C-2); HRMS (ESI) calculated for C25H32N2O7 
[M+Na]+ 495.2107 found 495.2105. 
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General Procedure C: DKP Formation from Dipeptides 
The dipeptide was dissolved in formic acid (10 mL/g) and allowed to stir at room temperature 
until TLC indicated complete consumption of the starting material (ca. 3-4 hours). The 
volatiles were removed under reduced pressure and the residue dissolved in toluene (7 mL/g) 
and 2-butanol (20 mL/g). The resulting solution was heated at reflux for 2 hours then 
concentrated under reduced pressure to afford the DKP that could be used without further 
purification. 
 
Proline-Alanine N-H DKP 206a 
 
General procedure C was followed with dipeptide 204a (820 mg, 2.68 mmol) to afford the 
title compound 206a as a white solid (550 mg, ~quantitative). 
(206a, white solid) m.p. 109 °C – 111 °C; [α]D
20 −49.6 (c 0.50, CHCl3); FTIR (film) νmax 
3242, 2982, 2893, 2245, 1645, 1420, 1160, 1128, 727; 1H NMR (300 MHz, CDCl3) δ 7.65 (s, 
br, 1H, N-H), 4.39 (q, J=6.9, 1H, H-9), 3.78 (m, 1H, H-1), 3.48 (m, 1H, H-1), 2.70 (dd, 
J=17.0, 2.7, 1H, H-5), 2.55 (dd, J=17.0, 2.7, 1H, H-5), 2.16-2.07 (m, 2H, H-3), 2.02 (t, J=2.7, 
1H, H-7), 2.00-1.86 (m, 2H, H-2), 1.38 (d, J=6.9, 3H, H-11); 13C NMR (75 MHz, CDCl3) δ 
171.1 (C-8/10), 166.6 (C-8/10), 78.4 (C-6), 72.0 (C-7), 67.0 (C-4), 51.1 (C-9), 45.1 (C-1), 
34.6 (C-3), 27.3 (C-5), 20.1 (C-2), 17.0 (C-11); HRMS (ESI) calculated for C11H14N2O2 
[M+Na]+ 229.0953 found 229.0955. 
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Proline-Leucine N-H DKP 206b 
 
General procedure C was followed with dipeptide 204b (680 mg, 1.79 mmol) to afford the 
title compound 206b as an off-white solid (500 mg, ~quantitative). 
(206b, off-white solid) m.p. 103 °C – 105 °C; [α]D
20 −79.2 (c 0.50, CHCl3); FTIR (film) νmax 
3310, 3242, 2958, 2878, 1651, 1422, 910; 1H NMR (400 MHz, CDCl3) δ 6.63 (s, br, 1H, N-
H), 4.38 (dd, J=9.4, 3.8, 1H, H-9), 3.85 (m, 1H, H-1), 3.56 (m, 1H, H-1), 2.77 (dd, J=16.9, 
2.7, 1H, H-5), 2.63 (dd, J=16.9, 2.7, 1H, H-5), 2.27-2.14 (m, 2H, H-3), 2.06 (t, J=2.7, 1H, H-
7), 2.03 (m, 1H, H-11), 2.00-1.92 (m, 2H, H-2), 1.55 (m, 1H, H-11), 1.49-1.41 (m, 2H, H-12), 
0.97 (d, J=6.6, 3H, H-13/14), 0.93 (d, J=6.6, 3H, H-13/14); 13C NMR (75 MHz, CDCl3) δ 
171.2 (C-8/10), 166.2 (C-8/10), 78.4 (C-6), 72.1 (C-7), 66.0 (C-4), 53.6 (C-9), 45.2 (C-1), 
39.8 (C-11), 34.8 (C-3), 27.6 (C-5), 24.4 (C-12), 23.2 (C-13/14), 21.1 (C-13/14), 20.2 (C-2); 
HRMS (ESI) calculated for C14H20N2O2 [M+Na]
+ 271.1422 found 271.1425. 
 
Proline-Aspartic Acid N-H DKP 206c 
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Dipeptide 204c (1.48 g, 3.13 mmol) was dissolved in formic acid (10 mL) and allowed to stir 
at room temperature for 4 hours then concentrated under reduced pressure. The residue was 
dissolved in xylene (30 mL, mixture of isomers) and 2-butanol (5 mL) then heated at reflux 
for 3 hours. The volatiles were removed under reduced pressue to afford the desired 
compound 206c as an orange oil that could be used without further purifcation (1.33 g, 
~quantitative) 
(206c, orange oil) [α]D
20 −85.0 (c 1.00, CHCl3); FTIR (film) νmax 2963, 1716, 1483, 1396, 
1258, 1008; 1H NMR (400 MHz, CDCl3) δ 7.33-7.21 (m, 5H, H-Ar), 5.07 (d, J=2.2, 2H, H-
13), 4.66 (dd, J=7.8, 4.1, 1H, H-10), 3.74 (dt, J=12.3, 8.4, 1H, H-1), 3.54 (d, J=4.8, 1H, N-H), 
3.45 (m, 1H, H-1), 3.11 (dd, J=17.4, 4.1, 1H, H-11), 2.73 (dd, J=17.4, 7.8, 1H, H-11), 2.68 
(dd, J=17.0, 2.6, 1H, H-5), 2.51 (dd, J=17.0, 2.6, 1H, H-5), 2.05-1.99 (m, 2H, H-3), 1.98 (t, 
J=2.6, 1H, H-7), 1.92-1.74 (m, 2H, H-2); 13C NMR (100 MHz, CDCl3) δ 170.7 (C-8/9), 170.5 
(C-8/9), 164.7 (C-12), 135.4 (C-14), 128.7 (C-15/16/17), 128.5 (C-15/16/17), 128.4 (C-
15/16/17), 78.5 (C-6), 72.4 (C-7), 67.1 (C-4), 67.0 (C-13), 52.4 (C-10), 45.2 (C-1), 36.4 (C-
11), 34.8 (C-3), 28.0 (C-5), 20.1 (C-2); HRMS (ESI) calculated for C19H20N2O4 [M+Na]
+ 
363.1321 found 363.1315. 
 
General Procedure D: N-Boc Protection of DKPs 
A solution of DKP (1.0 eq.), 4-DMAP (0.1 eq.) and Boc2O (1.7 eq.) in acetonitrile (20 mL/g) 
was allowed to stir at room temperature overnight. The mixture was diluted with ethyl acetate 
and washed with HCl (0.5 N aq. soln.), NaHCO3 (sat. aq. soln.) and NaCl (sat. aq. soln.) then 
dried over MgSO4 and concentrated under reduced pressure. The residue was purified by 
column chromatography (eluent petroleum ether/ethyl acetate, 8/2 gradually to 3/7) to afford 
the desired N-Boc DKPs. 
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Proline-Alanine N-Boc DKP 207a 
 
General procedure D was followed with DKP 206a (203 mg, 0.99 mmol), 4-DMAP (12 mg, 
0.10 mmol) and Boc2O (367 mg, 1.68 mmol) to afford the title compound 207a as a 
colourless oil (145 mg, 0.47 mmol, 48% from 204a). 
(207a, colourless oil) [α]D
22 +31.5 (c 1.00, CHCl3); FTIR (film) νmax 2986, 1741, 1685, 1655, 
1391, 1372, 1248, 1146; 1H NMR (300 MHz, CDCl3) δ 4.74 (q, J=6.7, 1H, H-9), 3.86 (m, 1H, 
H-1), 3.50 (m, 1H, H-1), 2.70 (dd, J=17.0, 2.7, 1H, H-5), 2.58 (dd, J=17.0, 2.7, 1H, H-5), 
2.24-2.07 (m, 2H, H-3), 2.05 (t, J=2.7, 1H, H-7), 2.01-1.84 (m, 2H, H-2), 1.49 (s, 9H, H-14), 
1.48 (d, J=6.8, 3H, H-11); 13C NMR (75 MHz, CDCl3) δ 168.6 (C-8/10), 165.1 (C-8/10), 
150.9 (C-12), 84.6 (C-6), 77.7 (C-13), 72.6 (C-7), 67.4 (C-4), 55.6 (C-9), 44.9 (C-1), 35.0 (C-
3), 28.8 (C-5), 27.6 (C-14), 19.7 (C-2), 18.2 (C-11); HRMS (ESI) calculated for C16H22N2O4 
[M+Na]+ 329.1477 found 329.1471. 
 
Proline-Leucine N-Boc DKP 207b 
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General procedure D was followed with DKP 206b (276 mg, 1.11 mmol), 4-DMAP (14 mg, 
0.11 mmol) and Boc2O (412 mg, 1.89 mmol) to afford the title compound 207b as a white 
solid (180 mg, 0.52 mmol, 47% from 204b). 
(207b, white solid) m.p. 82 °C – 85 °C; [α]D
20 +68.8 (c 1.00, CHCl3); FTIR (film) νmax 3274, 
2960, 2872, 1777, 1726, 1662, 1368, 1245, 1155; 1H NMR (300 MHz, CDCl3) δ 4.79 (dd, 
J=5.2, 4.3, 1H, H-9), 3.88 (m, 1H, H-1), 3.52 (m, 1H, H-1), 2.70 (dd, J=16.9, 2.6, 1H, H-5), 
2.60 (dd, J=16.9, 2.6, 1H, H-5), 2.19-2.09 (m, 2H, H-3), 2.06 (t, J=2.6, 1H, H-7), 2.02-1.92 
(m, 2H, H-11), 1.92-1.88 (m, 2H, H-2), 1.72 (m, 1H, H-12), 1.52 (s, 9H, H-17), 0.88 (d, 
J=6.6, 3H, H-13/14), 0.81 (d, J=6.6, 3H, H-13/14); 13C NMR (100 MHz, CDCl3) δ 168.8 (C-
8/10), 165.0 (C-8/10), 150.5 (C-15), 84.2 (C-6), 77.6 (C-16), 72.7 (C-7), 67.7 (C-4), 59.1 (C-
9), 44.7 (C-1), 41.2 (C-3), 34.7 (C-11), 29.4 (C-5), 27.8 (C-17), 24.5 (C-12), 23.6 (C-13/14), 
22.0 (C-13/14), 19.2 (C-2); HRMS (ESI) calculated for C19H28N2O4 [M+Na]
+ 371.1947 found 
371.1942. 
 
Proline-Aspartic Acid N-Boc DKP 207c 
 
General procedure D was followed with DKP 206c (1.33 g, 3.91 mmol), 4-DMAP (48 mg, 
0.39 mmol) and Boc2O (1.45 g, 6.65 mmol) to afford the title compound 207c as a yellow oil 
(821 mg, 1.87 mmol, 48% from 204c). 
(207c, yellow oil) [α]D
20 +153.2 (c 1.00, CHCl3); FTIR (film) νmax 3259, 2979, 1727, 1656, 
1455, 1369, 1242, 1148; 1H NMR (400 MHz, CDCl3) δ 7.36-7.24 (m, 5H, H-Ar), 5.02 (d, 
Chapter 5    Experimental 
     
 
122 
 
J=7.9, 2H, H-13), 4.84 (dd, J=3.8, 3.2, 1H, H-9), 3.87 (dt, J=12.3, 8.8, 1H, H-1), 3.48 (m, 1H, 
H-1), 3.37 (dd, J=18.1, 3.1, 1H, H-5), 3.09 (dd, J=18.1, 3.1, 1H, H-5), 2.63 (dd, J=2.6, 1.1, 
2H, H-11), 2.32 (m, 1H, H-3), 2.06 (t, 1H, J=3.1, H-7), 2.03 (m, 1H, H-3), 1.99-1.81 (m, 2H, 
H-2), 1.49 (s, 9H, H-20); 13C NMR (100 MHz, CDCl3) δ 170.9 (C-8/10/12), 169.1 (C-
8/10/12), 164.5 (C-8/10/12), 150.4 (C-18), 135.2 (C-14), 128.6 (C-15/16/17), 128.4 (C-
15/16/17), 128.3 (C-15/16/17), 84.1 (C-6), 77.9 (C-19), 72.3 (C-7), 68.8 (C-4), 66.8 (C-13), 
56.6 (C-9), 45.6 (C-1), 36.8 (C-3), 33.8 (C-11), 29.9 (C-5), 27.9 (C-20), 19.8 (C-2); HRMS 
(ESI) calculated for C24H28N2O6 [M+Na]
+ 463.1845 found 463.1854. 
 
Alanine-Derived Bridged DKPs 208a and 208b 
 
General procedure A was followed with DKP 207a (145 mg, 0.47 mmol), thiophenol (97 µL, 
0.95 mmol) and AIBN (156 mg, 0.95 mmol) to afford the title compounds 208a and 208b as a 
colourless oil (194 mg, 0.47 mmol, 98%) and 2:1 mixture of inseparable diastereoisomers. 
(208a/208b, colourless oil) [α]D
20 +12.5 (c 0.80, CHCl3); FTIR (film) νmax 2985, 2938, 1772, 
1721, 1689, 1369, 1254, 1143; 1H NMR (400 MHz, CDCl3) (208a only) δ 7.39-7.03 (m, 5H, 
H-Ar), 3.60-3.37 (m, 2H, H-1), 3.21 (dd, J=12.5, 3.4, 1H, H-7), 2.73 (m, 1H, H-3), 2.55 (m, 
1H, H-6), 2.35 (t, J=12.3, 1H, H-7), 2.24 (dd, J=13.8, 9.6, 1H, H-5), 1.99-1.88 (m, 2H, H-2), 
1.81 (m, 1H, H-3), 1.62 (s, 3H, H-11), 1.46 (s, 9H, H-14); 13C NMR (75 MHz, CDCl3) (208a) 
δ 170.0 (C-9/10), 165.8 (C-9/10), 150.2 (C-12), 134.6 (C-15), 129.7 (C-Ar), 129.0 (C-Ar), 
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126.6 (C-Ar), 84.6 (C-13), 66.5 (C-4), 65.5 (C-8), 44.4 (C-1), 42.5 (C-6), 37.0 (C-5), 36.8 (C-
7), 29.5 (C-3), 27.7 (C-14), 23.9 (C-2), 15.7 (C-11); (208b) δ 169.6 (C-9/10), 167.4 (C-9/10), 
150.4 (C-12), 134.6 (C-15), 129.7 (C-Ar), 129.0 (C-Ar), 126.6 (C-Ar), 84.6 (C-13), 66.3 (C-
4), 66.1 (C-8), 44.4 (C-1), 40.8 (C-6), 37.0 (C-5), 35.6 (C-7), 29.5 (C-3), 27.7 (C-14), 23.9 
(C-2), 14.9 (C-11); HRMS (ESI) calculated for C22H28N2O4S [M+Na]
+ 439.1667 found 
439.1660. 
 
Leucine-Derived Bridged DKPs 209a and 209b 
 
Thermal Initiation 
General procedure A was followed with DKP 207b (180 mg, 0.52 mmol), thiophenol (106 
µL, 1.03 mmol) and AIBN (169 mg, 1.03 mmol) to afford the title compounds 209a and 209b 
as a colourless oil (227 mg, 0.50 mmol, 96 %) and 4:1 mixture of inseparable 
diastereoisomers. 
Photolytic Initiation 
A solution of DKP 207b (146 mg, 0.42 mmol) in toluene (20 mL) was treated with AIBN 
(138 mg, 0.84 mmol) in toluene (5 mL) and thiophenol (86 µL, 0.84 mmol) in toluene (5 mL) 
over 20 hours via syringe pump. Throughout this period the mixture was irradiated with a 
300W sunlamp while the temperature was maintained below 35 °C. Once the addition was 
complete the mixture was irradiated for a further two hours then concentrated under reduced 
pressure. The residue was purified by column chromatography (eluent petroleum ether/ethyl 
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acetate, 8/2 to 1/1) to afford the title compounds 209a and 209b as a colourless oil (53 mg, 
0.12 mmol, 28%) and 4:1 mixture of inseparable diastereoisomers. 
(209a/209b, colourless oil) [α]D
20 +38.8 (c 1.00, CHCl3); FTIR (film) νmax 2978, 1723, 1687, 
1428, 1368, 1253, 1146; 1H NMR (300 MHz, CDCl3) (209a only) δ 7.43-7.15 (m, 5H, H-Ar), 
3.68-3.40 (m, 2H, H-1), 3.24 (dd, J=12.2, 3.2, 1H, H-7), 2.82-2.67 (m, 2H, H-3, H-6), 2.43-
2.31 (m, 2H, H-7, H-11), 2.24 (dd, J=13.8, 9.4, 1H, H-5), 2.05-1.92 (m, 3H, 2 x H-2, H-11), 
1.90-1.76 (m, 2H, H-3, H-5), 1.62 (m, 1H, H-12), 1.51 (s, 9H, H-17), 0.97 (s, 3H, H-13/14), 
0.95 (s, 3H, H-13/14); 13C NMR (100 MHz, CDCl3) (209a only) δ 171.4 (C-9/10), 165.7 (C-
9/10), 151.4 (C-15), 134.9 (C-18), 129.9 (CH-Ar), 129.0 (CH-Ar), 126.7 (CH-Ar), 84.7 (C-
16), 70.2 (C-4), 66.2 (C-8), 44.3 (C-1), 41.8 (C-6), 37.3 (C-5), 37.1 (C-7), 35.5 (C-11), 29.6 
(C-3), 27.7 (C-17), 24.8 (C-13/14), 24.7 (C-12), 23.8 (C-2), 22.9 (C-13/14); HRMS (ESI) 
calculated for C25H34N2O4S [M+Na]
+ 481.2131 found 481.2137. 
 
Aspartic Acid-Derived Bridged DKPs 210a and 210b 
 
General procedure A was followed with DKP 207c (169 mg, 0.38 mmol), thiophenol (79 µL, 
0.77 mmol) and AIBN (126 mg, 0.77 mmol) to afford the title compounds 210a and 210b as a 
colourless oil (155 mg, 0.28 mmol, 73 %) and 2:1 mixture of inseparable diastereoisomers. 
(210a/210b, colourless oil) [α]D
20 +37.6 (c 0.80, CHCl3); FTIR (film) νmax 2979, 1724, 1692, 
1390, 1363, 1275, 1257, 1148; 1H NMR (300 MHz, CDCl3) (210a only) δ 7.36-7.05 (m, 10H, 
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H-Ar), 5.03 (s, 2H, H-13), 3.67 (d, J=17.1, 1H, H-11), 3.57-3.33 (m, 2H, H-1), 3.33 (dd, 
J=13.0, 3.9, 1H, H-7), 3.12 (dd, J=12.5, 3.7, 1H, H-5), 2.90 (d, J=17.1, 2H, H-11), 2.71 (td, 
J=13.2, 6.6, 1H, H-3), 2.65-2.53 (m, 2H, H-6, H-7), 2.28 (dd, 1H, J=13.8, 9.7, H-5), 1.88 (dt, 
J=9.8, 5.3, 2H, H-2), 1.76 (m, 1H, H-3), 1.37 (s, 9H, H-20, major); 13C NMR (100 MHz, 
CDCl3) (210a) δ 169.5 (C-9/C-10), 169.2 (C-9/C-10), 164.4 (C-12), 151.1 (C-18), 135.8 (C-
14/C-21), 134.6 (C-14/C-21), 130.2 (CH-Ar), 130.1 (CH-Ar), 129.3 (CH-Ar), 128.6 (CH-Ar), 
128.2 (CH-Ar), 127.1 (CH-Ar), 84.5 (C-19), 67.4 (C-4), 66.6 (C-13), 60.5 (C-8), 44.7 (C-1), 
41.7 (C-6), 37.1 (C-7), 37.0 (C-5), 33.6 (C-11), 29.9 (C-3), 27.8 (C-20), 24.0 (C-2); (210b) δ 
170.1 (C-9/C-10), 169.1 (C-9/C-10), 166.0 (C-12), 151.6 (C-18), 135.9 (C-14/C-21), 134.5 
(C-14/C-21), 130.2 (CH-Ar), 130.1 (CH-Ar), 129.3 (CH-Ar), 128.6 (CH-Ar), 128.2 (CH-Ar), 
127.1 (CH-Ar), 84.6 (C-19), 67.8 (C-4), 66.6 (C-13), 66.0 (C-8), 44.6 (C-1), 40.7 (C-6), 37.3 
(C-7), 36.1 (C-5), 33.8 (C-11), 29.8 (C-3), 27.8 (C-20), 24.0 (C-2); HRMS (ESI) calculated 
for C30H34N2O6S [M+Na]
+ 573.2035 found 573.2040. 
 
Leucine-Derived Vinyl Sulfide 211 
 
A solution of DKP 207b (117 mg, 0.34 mmol) and thiophenol (52 µL, 0.50 mmol) in toluene 
(20 mL) was irradiated with a 400W mercury lamp with the temperature maintained below 35 
°C. After 5 hours the volatile organics were removed under reduced pressure and the residue 
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purified by column chromatography (eluent petroleum ether/ethyl acetate, 8/2 to 1/1) to afford 
the title compound 211 as a colourless oil (28 mg, 0.06 mmol, 18%) and 6:1 mixture of E:Z 
isomers. 
(211, colourless oil) [α]D
20 +40.0 (c 0.25, CHCl3); FTIR (film) νmax 2962, 1662, 1260, 1089, 
1018, 797; 1H NMR (400 MHz, CDCl3) (E) δ 7.37-7.20 (m, 5H, H-Ar), 6.28 (d, J=15.1, 1H, 
H-7), 5.61 (dt, J=15.5, 7.9, 1H, H-6), 4.57 (dd, J=6.5, 3.1, 1H, H-9), 3.90 (m, 1H, H-1), 3.47 
(m, 1H, H-1), 2.69-2.45 (m, 2H, H-5), 2.22-2.13 (m, 2H, H-3), 2.06-1.84 (m, 4H, H-2, H-11), 
1.76 (m, 1H, H-12), 1.53 (s, 9H, H-17), 0.91 (d, J=1.8, 3H, H-13/14), 0.85 (d, J=3.9, 3H, H-
13/14); (Z) δ 7.37-7.20 (m, 5H, H-Ar), 6.43 (d, J=9.4, 1H, H-7), 5.70 (m, 1H, H-6), 4.83 (dd, 
J=5.7, 3.6, 1H, H-9), 3.89 (m, 1H, H-1), 3.69 (m, 1H, H-1), 2.82-2.57 (m, 2H, H-5), 2.22- 
2.13 (m, 2H, H-3), 2.06-1.84 (m, 4H, H-2, H-11), 1.76 (m, 1H, H-12), 1.55 (s, 9H, H-17), 
0.90 (d, J=1.7, 3H, H-13/14), 0.83 (d, J=3.9, 3H, H-13/14); 13C NMR (100 MHz, CDCl3) (E) 
δ 169.7 (C-8/10), 164.9 (C-8/10), 150.7 (C-15), 134.4 (C-18), 130.3 (CH-Ar), 130.0 (C-7), 
129.3 (CH-Ar), 127.3 (CH-Ar), 123.7 (C-6), 84.6 (C-16), 69.0 (C-4), 58.7 (C-9), 44.8 (C-1), 
42.3 (C-5), 41.5 (C-11), 34.7 (C-3), 28.0 (C-17), 24.8 (C-12), 23.8 (C-13/14), 22.1 (C-13/14), 
19.8 (C-2); (Z) δ 169.1 (C-8/10), 165.2 (C-8/10), 151.0 (C-15), 133.4 (C-18), 130.2 (CH-Ar), 
129.7 (C-7), 129.3 (CH-Ar), 127.0 (CH-Ar), 124.0 (C-6), 84.5 (C-16), 68.0 (C-4), 59.3 (C-9), 
44.9 (C1), 41.3 (C-11), 34.9 (C-3), 29.6 (C-5), 28.5 (C-17), 24.8 (C-12), 24.0 (C-13/14), 22.1 
(C-13/14), 19.8 (C-2); HRMS (ESI) calculated for C25H34N2O4S [M+Na]
+ 481.2137 found 
481.2122. 
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Triketopiperazine 215 
 
Diketopiperazine 109b (241 mg, 1.17 mmol) in THF (40 mL) at −78 °C was treated with 
LiHMDS (1.0 M solution in THF, 1.23 ml, 1.23 mmol) and stirred for 45 minutes. Allyl 
bromide (202 µL, 2.34 mmol) was added and the reaction mixture allowed to warm to −40 °C 
and stirred for a further two hours. Ammonium chloride (7 mL) was added and the volatiles 
removed under reduced pressure. The residue was partitioned between water and 
dichloromethane and the layers separated. The aqueous phase was extracted with 
dichloromethane (2 x 30 mL) and the organics combined, dried (MgSO4) and concentrated 
under reduced pressure. The residue was purified by column chromatography (eluent 
petroleum ether/ethyl acetate, 1/1 gradually to 100% ethyl acetate) to afford triketopiperazine 
215 as a white solid (26 mg, 0.12 mmol, 10%). See Chapter 3 for a discussion of the 
mechanism. 
(215, white solid) m.p. 174 °C (dec.); [α]D
20 +38.6 (c 1.10, CHCl3); FTIR (film) νmax 2921, 
1674, 1647, 1451, 1417, 1363, 1318, 1086; 1H NMR (300 MHz, CDCl3) δ 3.94 (dt, J=13.0, 
8.6, 1H, H-1), 3.71 (ddd, J=13.2, 9.6, 3.9, 1H, H-1), 3.26 (s, 3H, H-9), 2.72 (t, J=2.5, 2H, H-
5), 2.37-2.24 (m, 2H, H-3), 2.20 (t, J=2.5, 1H, H-7), 2.18-1.94 (m, 2H, H-2); 13C NMR (75 
MHz, CDCl3) δ 170.7 (C-8/10/11), 158.7 (C-8/10/11), 152.3 (C-8/10/11), 77.0 (C-6), 76.0 (C-
7), 68.3 (C-4), 45.2 (C-1), 34.7 (C-3), 30.5 (C-5), 27.2 (C-9), 19.7 (C-2); HRMS (ESI) 
calculated for C11H12N2O3 [M+Na]
+ 243.0746 found 243.0740. 
 
Chapter 5    Experimental 
     
 
128 
 
Glycine Imine 217 
 
Benzophenone imine (9.29 g, 51.3 mmol) and tert-butyl bromoacetate (10.0 g, 51.3 mmol) 
were dissolved in acetonitrile (50 mL). The mixture was treated with diisopropylethylamine 
(8.9 mL, 51.3 mmol) then heated at reflux for 24 hours before cooling to room temperature. 
The mixture was diluted with dichloromethane (500 mL) and the organic layer washed with 
water then brine. After drying over MgSO4 the volatile organics were removed under reduced 
pressure and the residue purified by column chromatography (eluent petroleum ether/ethyl 
acetate, 9/1) to afford the title compound 217 as colourless oil (14.1 g, 47.8 mmol, 93%). 
(217, colourless oil) FTIR (film) νmax 2981, 2891, 1734, 1622, 1367, 1216, 1142, 1053, 909, 
848, 679, 708, 692; 1H NMR (300 MHz, CDCl3) δ 7.70-7.61 (m, 2H, H-Ar), 7.51-7.40 (m, 
3H, H-Ar), 7.39-7.29 (m, 3H, H-Ar), 7.24-7.13 (m, 2H, H-Ar), 4.13 (s, 2H, H-3), 1.47 (s, 9H, 
H-1); 13C NMR (100 MHz, CDCl3) δ 171.7 (C-3/5), 169.9 (C-3/5), 139.5 (C-6/10), 136.3 (C-
6/10), 130.5 (CH-Ar), 128.9 (CH-Ar), 128.7 (CH-Ar), 128.2 (CH-Ar), 127.9 (CH-Ar), 81.2 
(C-2), 56.4 (C-4), 28.2 (C-1); HRMS (ESI) calculated for C19H21NO2 [M+Na]
+ 318.1470 
found 318.1465. 
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Allylated Glycine Imine 218 
 
Protected glycine 217 (14.0 g, 47.5 mmol) and N-(9-anthracenylmethyl)cinchonindinium 
chloride (2.47 mg, 4.75 mmol) were dissolved in toluene and allyl bromide (4.52 mL, 52.3 
mmol) was added. The resulting mixture was treated with an aqueous solution of potassium 
hydroxide (50% w/v, 107 mL, 0.95 mol) and allowed to stir for 24 hours. The layers were 
separated and the aqueous phase extracted with ethyl acetate. The organic layers were 
combined, dried (MgSO4) and concentrated under reduced pressure to afford the title 
compound 218 as a yellow oil (16.3 g, ~47.5 mmol, quant.) that could be used without further 
purification. 
(218, yellow oil) [α]D
22 −10.4 (c 1.00, CHCl3); FTIR (film) νmax 2979, 1731, 1657, 1598, 
1447, 1276, 1150; 1H NMR (300 MHz, CDCl3) δ 7.86-7.78 (m, 1H, H-Ar), 7.69-7.62 (m, 1H, 
H-Ar), 7.55-7.29 (m, 6H, H-Ar), 7.23-7.15 (m, 2H, H-Ar), 5.74 (m, 1H, H-6), 5.18-4.94 (m, 
2H, H-7), 4.03 (dd, J=7.4, 5.5, 1H, H-4), 2.71-2.57 (m, 2H, H-5), 1.46 (s, 9H, H-1); 13C NMR 
(100 MHz, CDCl3) δ 171.0 (C-3/8), 170.2 (C-3/8), 139.9 (C-9/13), 136.8 (C-9/13), 134.9 (C-
6), 130.2 (CH-Ar), 128.9 (CH-Ar), 128.6 (CH-Ar), 128.5 (CH-Ar), 128.4 (CH-Ar), 128.1 
(CH-Ar), 117.4 (C-7), 81.1 (C-2), 66.0 (C-4), 38.3 (C-5), 28.2 (C-1); HRMS (ESI) calculated 
for C22H25NO2 [M+Na]
+ 358.1783 found 358.1792. 
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Allylated Glycine 219 
 
Protected allylglycine 218 (16.3 g ~47.5 mmol) was dissolved in tetrahydrofuran (250 mL) 
and treated with an aqueous solution of citric acid (15% w/v, 125 mL). The resulting mixture 
was allowed to stir at room temperature for 24 hours then concentrated under reduced 
pressure. The residue was partitioned between water (150 mL) and petroleum ether (150 mL) 
and the layers separated. The aqueous phase was adjusted to pH 13 with potassium carbonate 
then extracted with dichloromethane (3 x 150 mL). The combined dichloromethane layers 
were dried over MgSO4 and concentrated under reduced pressure to afford the title amine 219 
as a yellow oil (6.07 g, 27.5 mmol, 58%). 
(219, yellow oil) [α]D
22 +3.6 (c 1.00, CHCl3); FTIR (film) νmax 2979, 1727, 1648, 1535, 1369, 
1154; 1H NMR (300 MHz, CDCl3) δ 5.76 (m, 1H, H-6), 5.25-4.96 (m, 2H, H-7), 3.42 (dd, 
J=6.9, 5.2, 1H, H-4), 2.60-2.17 (m, 2H, H-5), 1.47 (s, 9H, H-1); 13C NMR (100 MHz, CDCl3) 
δ 174.7 (C-3), 133.8 (C-6), 118.5 (C-7), 81.2 (C-2), 54.5 (C-4), 39.5 (C-5), 28.2 (C-1); HRMS 
(ESI) calculated for C9H17NO2 [M+Na]
+ 194.1157 found 194.1155. 
 
N-Boc Propargylated Proline O-Methyl Ester 221 
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Substituted proline 188 (3.21 g, ~15.4 mmol) was dissolved in dichloromethane (45 mL) and 
treated with diisopropylethylamine (5.36 mL, 30.8 mmol). A solution of Boc2O (8.40 g, 38.5 
mmol) in dichloromethane (30 mL) was added and the resulting mixture allowed to stir at 
room temperature for three days. The volatile organics were removed under reduced pressure 
and the residue purified by column chromatography (eluent petroleum ether/ethyl acetate, 9/1 
to 8/2) to afford N-Boc proline 221 as a colourless oil (1.69 g, 6.33 mmol, 41% from 
oxazolidinone 187). 
(221, colourless oil) [α]D
22 +65.2 (c 1.00, CHCl3); FTIR (film) νmax 2976, 1740, 1692, 1387, 
1367, 1245, 1161, 1133; 1H NMR (300 MHz, CDCl3) (major rotamer) δ 3.71 (s, 3H, H-9), 
3.80-3.39 (m, 2H, H-1), 3.07 (dd, J=17.1, 2.7, 1H, H-5), 2.83 (dd, J=17.1, 2.7, 1H, H-5), 2.47-
1.81 (m, 4H, H-2, H-3), 1.96 (t, J=2.7, 1H, H-7), 1.41 (s, 9H, H-12); (minor rotamer) δ 3.70 
(s, 3H, H-9), 3.80-3.39 (m, 2H, H-1), 3.31 (dd, J=17.1, 2.7, 1H, H-5), 2.89-2.76 (m, 1H, H-5), 
2.47-1.81 (m, 4H, H-2, H-3), 1.94 (t, J=2.7, 1H, H-7), 1.44 (s, 9H, H-12); 13C NMR (100 
MHz, CDCl3) (major rotamer) δ 174.2 (C-8), 153.3 (C-10), 80.5 (C-6/11), 80.3 (C-6/11), 
70.7 (C-7), 66.5 (C-4), 52.5 (C-9), 48.7 (C-1), 37.9 (C-3), 28.4 (C-12), 26.4 (C-2), 23.0 (C-5); 
(minor rotamer) δ 174.1 (C-8), 154.1 (C-10), 80.9 (C-6/11), 79.9 (C-6/11), 70.2 (C-7), 67.0 
(C-4), 52.5 (C-9), 48.8 (C-1), 36.5 (C-3), 28.5 (C-12), 25.0 (C-5), 23.5 (C-2); HRMS (ESI) 
calculated for C14H21NO4 [M+Na]
+ 290.1368 found 290.1373. 
 
N-Boc Propargylated Proline 222 
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Protected proline 221 (1.3 g, 4.87 mmol) was dissolved in methanol (30 mL) and treated with 
an aqueous solution of sodium hydroxide (2 N, 30 mL). The resulting mixture was stirred at 
50 °C for 3 hours then cooled to room temperature and concentrated under reduced pressure. 
The residue was partitioned between water (30 mL) and diethyl ether (30 mL) and the layers 
separated. The aqueous phase was cautiously acidified to pH 4 with an aqueous solution of 
citric acid (20% w/v) and extracted with diethyl ether (3 x 50 mL). The combined organic 
phases were dried over MgSO4 and concentrated under reduced pressure to afford the title 
compound 222 as an off-white solid (1.26 g, ~4.87 mmol) that could be used without further 
purification. 
(222, off-white solid) m.p. 93 °C – 96 °C; [α]D
22 +58.0 (c 1.00, MeOH); FTIR (film) νmax 
3323, 2977, 1741, 1631, 1414, 1370, 1226, 1149; 1H NMR (300 MHz, CDCl3) δ 9.80 (s, br, 
1H, OH), 3.81-3.39 (m, 2H, H-1), 3.34 (dd, J=17.0, 2.6, 1H, H-5, major rotamer), 3.11 (dd, 
J=17.2, 2.6, 1H, H-5, minor rotamer), 2.81 (dd, J=17.2, 2.6, 1H, H-5, minor rotamer), 2.78 
(dd, J=17.0, 2.6, 1H, H-5, major rotamer), 2.54-1.82 (m, 4H, H-2, H-3), 1.99 (m, 1H, H-7), 
1.48 (s, 9H, H-11, major rotamer), 1.43 (s, 9H, H-11, minor rotamer); 13C NMR (100 MHz, 
CDCl3) (major rotamer) δ 179.4 (C-8), 156.0 (C-9), 81.6 (C-6/11), 79.6 (C-6/11), 71.0 (C-
7), 68.1 (C-4), 49.5 (C-1), 35.9 (C-3), 28.6 (C-11), 25.0 (C-2), 23.1 (C-5); (minor rotamer); 
δ 176.1 (C-8), 153.4 (C-9), 81.1 (C-6/11), 80.0 (C-6/11), 71.0 (C-7), 66.4 (C-4), 48.8 (C-1), 
38.0 (C-3), 28.4 (C-11), 26.1 (C-5), 23.0 (C-2); HRMS (ESI) calculated for C13H18NO4 
[M−H]− 252.1236 found 252.1245. 
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Proline-Allylglycine Dipeptide 223 
 
General procedure B was followed with allylglycine 219 (1.05 g, 4.74 mmol), N-Boc proline 
222 (1.2 g, 4.74 mmol), HATU (1.98 g, 5.21 mmol) and diisopropylethylamine (1.73 mL, 
9.95 mmol) to afford the title compound 223 as a near-colourless oil (1.71 g, 4.21 mmol, 
89%). 
(223, colourless oil) [α]D
22 +9.2 (c 1.00, CHCl3); FTIR (film) νmax 2978, 1673, 1513, 1366, 
1251, 1154, 1002; 1H NMR (300 MHz, CDCl3) δ 7.46 (d, J=6.5, 1H, N-H, minor rotamer), 
6.74 (d, J=7.1, 1H, N-H, major rotamer), 5.67 (m, 1H, H-11), 5.17-4.98 (m, 2H, H-12), 4.46 
(m, 1H, H-9), 3.79-3.33 (m, 2H, H-1), 3.43 (dd, J=17.1, 2.7, 1H, H-5, minor rotamer), 3.13 
(dd, J=17.3, 2.5, 1H, H-5, major rotamer), 2.88 (m, 1H, H-5, major rotamer), 2.81 (m, 1H, H-
5, minor rotamer), 2.67-2.15 (m, 4H, H-3, H-10), 1.96 (m, 1H, H-7), 2.00-1.63 (m, 2H, H-2), 
1.47 (s, 9H, H-15/18, minor rotamer), 1.46 (s, 9H, H-15/18, major rotamer), 1.45 (s, 9H, H-
15/18, minor rotamer), 1.44 (s, 9H, H-15/18, major rotamer); 13C NMR (100 MHz, CDCl3) 
(major rotamer) δ 173.3 (C-8), 170.4 (C-13), 153.7 (C-17), 132.5 (C-11), 118.9 (C-12), 82.4 
(C-6), 81.1 (C-14/17), 80.4 (C-14/17), 71.1 (C-7), 67.8 (C-4), 51.9 (C-9), 49.4 (C-1), 38.8 (C-
3), 36.7 (C-10), 28.3 (C-15/18), 28.1 (C-15/18), 25.9 (C-2), 22.2 (C-5); (minor rotamer) δ 
172.9 (C-8), 170.6 (C-13), 154.5 (C-17), 132.7 (C-11), 118.7 (C-12), 82.1 (C-6), 80.8 (C-
14/17), 80.4 (C-14/17), 70.5 (C-7), 68.6 (C-4), 52.6 (C-9), 49.7 (C-1), 37.1 (C- 
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3), 36.1 (C-10), 28.5 (C-15/18), 28.1 (C-15/18), 24.8 (C-5), 22.7 (C-2); HRMS (ESI) 
calculated for C22H34N2O5 [M+Na]
+ 429.2365 found 429.2372. 
 
Proline-Allylglycine DKP 225 
 
Dipeptide 223 (893 mg, 2.20 mmol) was dissolved in dichloromethane (14 mL) and treated 
with trifluoroacetic acid (21 mL) followed by water (250 µL). After stirring for 4 hours the 
volatile organics were removed under reduced pressure to afford a sticky oil (1.16 g). A 
portion of this (129 mg, ~0.35 mmol) was dissolved in 1,2-dimethoxyethane (2 mL) at 0 °C 
and treated sequentially with N-methylmorpholine (77 µL, 0.70 mmol) then isobutyl 
chloroformate (92 µL, 0.70 mmol). After stirring for 3 hours at 0 °C the precipitate was 
removed by filtration and washed with 1,2-dimethoxyethane (2 x 2 mL). The filtrate was 
combined, cooled to 0 °C and treated with triethylamine. After stirring at room temperature 
for 20 hours the volatile organics were removed under reduced pressure and the residue 
purified by column chromatography (eluent petroleum ether/ethyl acetate, 1/1 to 100% ethyl 
acetate) to afford the desired DKP 225 as a colourless oil (26 mg, 0.11 mmol, 32%). 
(225, colourless oil) [α]D
22 −15.0 (c 0.50, CHCl3); FTIR (film) νmax 3275, 3236, 1669, 1638, 
1435, 1306, 1142, 990; 1H NMR (300 MHz, CDCl3) δ 5.91 (s, 1H, N-H), 5.76 (m, 1H, H-12), 
5.32-5.19 (m, 2H, H-13), 4.37 (dd, J=9.7, 3.3, 1H, H-9), 3.87 (dt, J=12.4, 8.3, 1H, H-1), 3.56 
(m, 1H, H-1), 3.01 (m, 1H, H-11), 2.79 (dd, J=17.0, 2.7, 1H, H-5), 2.63 (dd, J=17.0, 2.7, 1H, 
H-5), 2.43-1.89 (m, 5H, H-2, H-3, H-11), 2.07 (t, J=2.7, 1H, H-7); 13C NMR (100 MHz, 
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CDCl3) δ 170.3 (C-8/10), 165.3 (C-8/10), 133.3 (C-12), 120.6 (C-13), 78.6 (C-6), 72.4 (C-7), 
67.3 (C-4), 54.1 (C-9), 45.3 (C-1), 36.4 (C-11), 35.0 (C-3), 27.9 (C-5), 20.4 (C-2); HRMS 
(ESI) calculated for C13H16N2O2 [M+Na]
+ 255.1109 found 255.1105. 
 
Tetracyclic Bridged DKP 227 
 
General procedure A was followed with DKP 225 (26 mg, 0.11 mmol), AIBN (0.2 M solution 
in toluene, 1.1 mL, 0.22 mmol), thiophenol (23 µL, 0.22 mmol) and tert-butanol (25 mL) to 
afford the desired bridged compound 227 as a colourless oil (10 mg, 0.03 mmol, 27%). 
(227, colourless oil) [α]D
20 −4.0 (c 1.00, CHCl3); FTIR (film) νmax 2963, 2928, 1685, 1439, 
1402, 1262, 1072; 1H NMR (400 MHz, CDCl3) δ 7.38-7.14 (m, 5H, H-Ar), 6.85 (s, 1H, N-H), 
3.57-3.43 (m, 2H, H-1), 3.26 (dd, J=13.1, 8.7, 1H, H-11), 2.98 (m, 1H, H-6), 2.90 (m, 1H, H-
10), 2.72 (m, 1H, H-3), 2.45 (ddd, J=13.1, 9.7, 6.1, 1H, H-12), 2.17 (dd, J=13.5, 9.7, 1H, H-
5), 2.06-1.93 (m, 2H, H-2), 1.77 (dt, J=13.5, 7.6, 1H, H-3), 1.67 (dd, J=13.4, 6.1, 1H, H-5), 
1.30 (m, 1H, H-10), 1.17 (d, J=7.1, 3H, H-13); 13C NMR (100 MHz, CDCl3) δ 173.6 (C-9), 
168.0 (C-8), 136.5 (C-14), 129.2 (CH-Ar), 128.7 (CH-Ar), 126.1 (CH-Ar), 68.8 (C-4), 66.1 
(C-7), 52.8 (C-11), 51.6 (C-12), 44.0 (C-1), 35.4 (C-6), 35.3 (C-10), 34.7 (C-5), 29.5 (C-3), 
24.8 (C-2), 19.5 (C-13); HRMS (ESI) calculated for C19H22N2O2S [M+Na]
+ 365.1300 found 
365.1308. 
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5.3 Experimental for Chapter 4 
Proline-Aspartic Acid O-Benzyl Ester Dipeptide 241 
 
General procedure B was followed using L-proline O-methyl ester (2.0 g, 12.1 mmol), N-Boc 
aspartic acid β-O-benzyl ester (3.9 g, 12.1 mmol), HATU (5.1 g, 13.3 mmol) and 
diisopropylethylamine (4.4 mL, 25.4 mmol) to afford dipeptide 241 (5.20 g, 11.0 mmol, 91%) 
as a colourless oil. 
(241, colourless oil) [α]D
21 −50.8 (c 1.00, CHCl3); FTIR (film) νmax 2963, 1738, 1646, 1436, 
1257, 1161, 1005; 1H NMR (300 MHz, CDCl3) δ 7.42-7.28 (m, 5H, H-Ar), 5.41 (d, J=9.3, 
1H, N-H), 5.15 (d, J=3.7, 2H, H-11), 4.89 (dt, J=9.3, 6.4, 1H, H-8), 4.50 (dd, J=8.2, 3.3, 1H, 
H-4), 3.69 (s, 3H, H-6), 3.82-3.57 (m, 2H, H-1), 2.82 (dd, J=15.9, 5.7, 1H, H-9), 2.68 (dd, 
J=15.9, 6.9, 1H, H-9), 2.30-1.77 (m, 4H, H-2, H-3), 1.42 (s, 9H, H-18); 13C NMR (100 MHz, 
CDCl3) δ 172.3 (C=O), 170.4 (C=O), 169.7 (C=O), 155.2 (C-16), 135.8 (C-12), 128.6 (CH-
Ar), 128.4 (CH-Ar), 128.4 (CH-Ar), 80.2 (C-17), 66.9 (C-11), 59.1 (C-4), 52.3 (C-6), 49.1 (C-
8), 47.1 (C-1), 37.6 (C-9), 29.1 (C-3), 28.4 (C-18), 25.0 (C-2); HRMS (ESI) calculated for 
C22H30N2O7 [M+Na]
+ 457.1951 found 457.1961. 
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N-Boc Proline-Aspartic Acid O-Benzyl Ester DKP 242 
 
General procedure D was followed with DKP 304 (2.50 g, 8.27 mmol), Boc2O (3.07 g, 14.1 
mmol), 4-DMAP (101 mg, 0.83 mmol) and acetonitrile (75 mL) to afford N-Boc DKP 242 as 
a colourless oil (1.84 g, 4.57 mmol, 55%). 
(242, colourless oil) [α]D
21 +15.2 (c 1.00, CHCl3); FTIR (film) νmax 2979, 1733, 1713, 1668, 
1368, 1248, 1148; 1H NMR (300 MHz, CDCl3) δ 7.44-7.30 (m, 5H, H-Ar), 5.78 (dd, J=9.1, 
5.1, 1H, H-6), 5.15 (app. s, 2H, H-10), 3.88 (m, 1H, H-4), 3.82-3.68 (m, 2H, H-1), 3.28 (dd, 
J=16.1, 9.1, 1H, H-8), 2.68 (dd, J= 16.1, 5.1, 1H, H-8), 2.62-2.47 (m, 2H, H-3), 2.18-1.89 (m, 
2H, H-2), 1.55 (s, 9H, H-17); 13C NMR (100 MHz, CDCl3) δ 194.4 (C=O), 193.5 (C=O), 
184.8 (C=O), 179.9 (C=O), 133.6 (C-11), 128.7 (CH-Ar), 128.3 (CH-Ar), 124.9 (CH-Ar), 
85.3 (C-16), 66.8 (C-10), 53.4 (C-4), 46.1 (C-1), 39.6 (C-6), 34.3 (C-8), 33.4 (C-3), 28.1 (C-
17), 17.8 (C-2); LRMS (LC-MS/ESI) calculated for C21H26N2O6 [M+H]
+ 402.2 found 402.2. 
 
N-Boc Proline-Aspartic Acid DKP 243 
 
A 50 mL round bottomed flask was charged with benzyl ester 242 (1.56 g, 4.0 mmol), 
palladium on carbon (10 wt. %, 43 mg, 0.4 mmol) and ethanol (20 mL). The flask was flushed 
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with nitrogen then hydrogen and stirred under this atmosphere for 20 hours. The catalyst was 
removed by filtration through Celite® and the filtrate concentrated under reduced pressure to 
afford the title compound 243 as a colourless oil (1.04 g, 3.33 mmol, 83%) that was used 
without further purification. 
(243, colourless oil) [α]D
21 −2.8 (c 1.00, MeOH); FTIR (film) νmax 3329, 2977, 1708, 1648, 
1399, 1253, 1160, 1050; 1H NMR (300 MHz, CDCl3) δ 7.06 (br. s, 1H, O-H), 5.70 (dd, J=9.2, 
4.7, 1H, H-6), 4.26 (dd, J=10.2, 6.2, 1H, H-4), 4.06-3.51 (m, 2H, H-1), 3.52-3.00 (m, 2H, H-
8), 2.45-1.76 (m, 4H, H-2, H-3), 1.53 (s, 9H, H-12); 13C NMR (100 MHz, CDCl3) δ 180.7 
(C=O), 174.9 (C=O), 174.7 (C=O), 155.8 (C-10), 69.6 (C-11), 49.9 (C-4), 46.1 (C-1), 36.8 
(C-8), 31.1 (C-6), 29.1 (C-3), 28.2 (C-12), 24.9 (C-2); HRMS (ESI) calculated for 
C14H19N2O6 [M−H]
− 311.1243 found 311.1238. 
 
Proline-Aspartic Acid Dipeptide 253 
 
A 100 mL round bottomed flask was charged with dipeptide 241 (5.0 g, 10.6 mmol), 
palladium on carbon (10 wt. %, 113 mg, 0.11 mmol) and ethanol (50 mL). The flask was 
flushed with nitrogen followed by hydrogen and stirred under this atmosphere for 20 hours. 
The catalyst was removed by filtration through Celite® and the filtrate concentrated under 
reduced pressure to afford the desired compound 253 as a colourless oil (3.42 g, 9.93 mmol, 
94%). 
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(253, colourless oil) [α]D
22 −60.8 (c 1.20, CHCl3); FTIR (film) νmax 2979, 1707, 1515, 1367, 
1158, 1049; 1H NMR (300 MHz, CDCl3) δ 7.88 (s, br, 1H, O-H), 5.73 (d, J=9.1, 1H, N-H), 
4.84 (m, 1H, H-8), 4.49 (m, 1H, H-4), 3.83-3.64 (m, 2H, H-1), 3.69 (s, 3H, H-6), 3.00-2.50 
(m, 2H, H-9), 2.33-1.83 (m, 4H, H-2, H-3), 1.42 (s, 9H, H-13); 13C NMR (100 MHz, CDCl3) 
δ 174.0 (C=O), 172.4 (C=O), 170.4 (C=O), 155.5 (C-11), 80.4 (C-12), 59.3 (C-4), 52.5 (C-6), 
49.0 (C-8), 47.3 (C-1), 37.2 (C-9), 29.1 (C-3), 28.4 (C-13), 24.9 (C-2); HRMS (ESI) 
calculated for C15H24N2O7 [M+Na]
+ 367.1481 found 367.1475. 
 
N-Methylmaleimide Substituted Aspartic Acid O-Benzyl Ester 257 
 
N-Boc Aspartic acid α-O-benzyl ester 255 (5.55 g, 17.2 mmol) was dissolved in THF (150 
mL), cooled to −20 °C, and treated sequentially with N-methyl morpholine (1.89 mL, 17.2 
mmol) then isobutyl chloroformate (2.26 mL, 17.2 mmol). After 5 minutes a solution of 2-
mercaptopyridine N-oxide (2.62 g, 20.6 mmol) and triethylamine (3.1 mL, 22.3 mmol) in 
THF (50 mL) was added. The resulting mixture was stirred with the exclusion of light for 4 
hours. The precipitate was removed by filtration and the filtrate irradiated in the presence of 
N-methylmaleimide (9.55 g, 86.0 mmol) for 1 hour with the temperature maintained below 10 
°C. After removal of the volatile organics under reduced pressure, the residue was partitioned 
between dichloromethane (200 mL) and NaHCO3 (150 mL, saturated aqueous solution). The 
layers were separated and the organic phase washed with HCl (0.5 N, 150 mL) then brine 
(150 mL) and dried over MgSO4. The mixture was concentrated under reduced pressure and 
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the residue purified by column chromatography (eluent petroleum ether/ethyl acetate, 8/2 to 
1/1) to afford a white foam (6.1 g, ~12.2 mmol, 71%). Signals in the 1H NMR spectrum (300 
MHz, CDCl3) at 8.24-8.14, 7.56-7.44, 7.23-7.12 and 7.04-6.89 ppm and mass spectrometry 
(HRMS (ESI) calculated for C25H29N3O6S [M+Na]
+ 522.1675 found 522.1680) indicated that 
the 2-thiopyridyl moiety was present. The white foam was dissolved in chloroform (100 mL), 
cooled to 0 °C and treated with a solution of mCPBA (70-75% in H2O, 2.8 g, ~12.2 mmol) in 
chloroform (100 mL). Further small portions of mCPBA were added until TLC indicated that 
all of the starting material had been consumed. The mixture was diluted with dichloromethane 
(200 mL) and washed with NaHCO3 (saturated aqueous solution, 300 mL), HCl (0.5 N, 300 
mL) and brine (300 mL). After drying over MgSO4, the mixture was concentrated under 
reduced pressure and the resulting white foam dissolved in toluene (200 mL) then heated at 
reflux for 1.5 hours. The solvent was removed under reduced pressure and the residue purified 
by column chromatography (eluent petroleum ether/ethyl acetate, 8/2 to 1/1) to afford the 
desired compound 257 as a colourless oil (3.84 g, 9.88 mmol, 81%). 
(257, colourless oil) [α]D
20 −4.8 (c 1.00, CHCl3); FTIR (film) νmax 3379, 2989, 1752, 1700, 
1682, 1522, 1213, 1156; 1H NMR (300 MHz, CDCl3) δ 7.47-7.17 (m, 5H, H-Ar), 6.30 (s, 1H, 
H-5), 5.36 (d, J=7.7, 1H, N-H), 5.26-5.05 (m, 2H, H-9), 4.62 (dd, J=12.9, 7.3, 1H, H-2), 2.93 
(s, 3H, H-8), 3.09-2.75 (m, 2H, H-3), 1.41 (s, 9H, H-16); 13C NMR (100 MHz, CDCl3) δ 
171.3 (C-1/6/7), 170.8 (C-1/6/7), 170.4 (C-1/6/7), 155.2 (C-14), 144.5 (C-4), 135.0 (C-10), 
129.2 (C-11/12/13), 128.8 (C-11/12/13), 128.7 (C-11/12/13), 125.7 (C-5), 80.5 (C-15), 67.8 
(C-9), 52.1 (C-2), 28.8 (C-3), 28.3 (C-16), 23.9 (C-8); HRMS (ESI) calculated for 
C20H24N2O6 [M+Na]
+ 411.1532 found 411.1533. 
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N-Methylsuccinimide Substituted N-Boc Aspartic Acid 258 
 
A 100 mL round bottomed flask was charged with benzyl ester 257 (1.18 g, 3.04 mmol), 
palladium on carbon (10 wt. %, 32 mg, 0.30 mmol) and ethanol (25 mL). The flask was 
flushed with nitrogen followed by hydrogen and stirred under this atmosphere for 20 hours. 
The catalyst was removed by filtration through Celite® and the filtrate concentrated under 
reduced pressure to afford the desired compound 258 as a colourless oil (859 mg, 2.86 mmol, 
94%) which was used without further purification. 
(258, colourless oil) [α]D
20 +5.5 (c 1.00, CHCl3); FTIR (film) νmax 3322, 2977, 1730, 1681, 
1276, 1159, 1117; 1H NMR (300 MHz, CD3OD) δ 7.52 (s, br, 1H, O-H), 5.36 (d, J=7.8, 1H, 
N-H), 4.46 (m, 1H, H-2), 3.14-2.86 (m, 2H, H-3), 3.00 (s, 3H, H-8), 2.64-2.23 (m, 2H, H-5), 
2.02 (m, 1H, H-4), 1.45 (s, 9H, H-11); 13C NMR (100 MHz, CD3OD) δ 181.7 (C=O), 178.7 
(C=O), 175.3 (C=O), 158.1 (C-9), 80.7 (C-10), 52.8 (C-2), 38.6 (C-4), 35.2 (C-3), 33.9 (C-5), 
28.7 (C-11), 25.0 (C-8); HRMS (ESI) calculated for C13H20N2O6 [M+Na]
+ 323.1219 found 
323.1205. 
 
N-Methylmaleimide Substituted Aspartic Acid 259 
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O-Benzyl ester 257 (693 mg, 1.78 mmol) was dissolved in hydrogen chloride in dioxane (4M, 
7.0 mL) and allowed to stir at room temperature for 20 hours. The volatile organics were 
removed under reduced pressure to afford the title compound 259 as a yellow oil (514 mg, 
1.78 mmol, quant.) which was used without further purification. 
(259, yellow oil) [α]D
20 +5.0 (c 0.50, MeOH); FTIR (film) νmax 2925, 1699, 1447, 1391, 1219, 
1119, 1011; 1H NMR (300 MHz, CD3OD) δ 7.54-7.09 (m, 5H, H-Ar), 6.53 (s, 1H, H-5), 5.26 
(app. q, J=11.9, 2H, H-9), 4.52 (t, J=6.6, 1H, H-2), 3.21-2.90 (m, 2H, H-3), 2.86 (s, 3H, H-8); 
13C NMR (100 MHz, CD3OD) δ 172.4 (C=O), 171.3 (C=O), 169.1 (C=O), 143.4 (C-4),  
136.0 (C-10), 131.8 (C-5), 130.0 (CH-Ar), 129.8 (CH-Ar), 128.0 (CH-Ar), 69.6 (C-9), 52.1 
(C-2), 27.4 (C-3), 23.9 (C-8); HRMS (ESI) calculated for C15H17N2O4 [M+H]
+ 289.1188 
found 289.1181. 
 
N-Boc-Proline-N-Methylmaleimide Substituted Aspartic Acid Dipeptide 261 
 
General procedure B was followed with maleimide 259 (514 mg, 1.78 mmol), N-Boc proline 
(384 mg, 1.78 mmol), HATU (746 mg, 1.96 mmol) and diisopropylethylamine (0.65 mL, 3.74 
mmol) to afford the title compound 261 as a yellow oil (841 mg, 1.73 mmol, 97%). 
(261, yellow oil) [α]D
21 −25.0 (c 1.00, CHCl3); FTIR (film) νmax 2969, 1738, 1714, 1396, 
1261, 1168, 1090, 1020; 1H NMR (300 MHz, CDCl3) δ (rotamers) 7.38-7.32 (m, 5H, H-Ar), 
6.31 (br. s, 1H, H-N), 5.18 (d, J=3.0, 2H, H-14), 4.85 (dd, J=12.7, 6.9, 1H, H-9), 4.37 (m, 1H, 
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H-6), 4.26 (m, 1H, H-4), 3.65-3.29 (m, 2H, H-1), 2.94 (s, 3H, H-12), 3.21-2.76 (m, 2H, H-7), 
2.19-1.73 (m, 4H, H-2, H-3), 1.45 (br. s, 9H, H-21); 13C NMR (100 MHz, CDCl3) δ 177.9 
(C=O), 174.9 (C=O), 171.4 (C=O), 170.3 (C=O), 154.0 (C-19), 144.3 (C-8), 135.0 (C-15), 
129.3 (C-9), 128.9 (CH-Ar), 128.8 (CH-Ar), 128.7 (CH-Ar), 81.4 (C-20), 67.8 (C-14), 59.2 
(C-4), 50.8 (C-6), 47.1 (C-7), 46.4 (C-1), 31.0 (C-3), 28.4 (C-21), 24.4 (C-2), 23.9 (C-12); 
HRMS (ESI) calculated for C25H31N3O7 [M+Na]
+ 508.2060 found 508.2069. 
 
N-Methylmaleimide Substituted Aspartic Acid 267 
 
A pressure tube was charged with protected aspartic acid 257 (1.50 g, 3.86 mmol), 
trimethyltin hydroxide (1.0 g, 5.79 mmol) and 1,2-dichloroethane (15 mL). The tube was 
sealed and heated at 80 °C for 20 hours. After cooling to room temperature the volatile 
organics were removed under reduced pressure and the residue partitioned between ethyl 
acetate and HCl (5% v/v aqueous solution). The layers were separated and the organic phase 
washed with further portions of HCl until 1H NMR indicated no trimethyltin species were 
present. After drying over MgSO4 the mixture was concentrated under reduced pressure to 
afford 267 as a colourless oil (1.34 g, ~3.86 mmol) that could be used without further 
purification. An analytically pure sample was obtained by flash column chromatography 
(eluent petroleum ether/ethyl acetate, 7/3 to 1/1). 
(267, colourless oil) [α]D
21 −19.2 (c 0.50, CHCl3); FTIR (film) νmax 3362, 2980, 1696, 1515, 
1445, 1390, 1158; 1H NMR (300 MHz, CDCl3) δ 6.49 (s, 1H, H-5), 5.69 (s, br, 1H, O-H), 
5.38 (d, J=7.4, 1H, N-H), 4.62 (dd, J=12.4, 7.4, 1H, H-2), 3.02 (s, 3H, H-8), 3.22-2.77 (m, 
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2H, H-3), 1.44 (s, 9H, H-11); 13C NMR (100 MHz, CDCl3) δ 173.9 (C-1/6/7), 173.8 (C-
1/6/7), 170.4 (C-1/6/7), 155.5 (C-9), 144.4 (C-4), 129.4 (C-5), 80.9 (C-10), 51.9 (C-2), 28.4 
(C-3), 28.2 (C-11), 23.9 (C-8); HRMS (ESI) calculated for C13H18N2O6 [M+Na]
+ 321.1063 
found 321.1058. 
 
N-Boc Aspartic Acid O-Fluorenylmethyl Ester 270 
 
Dicyclohexylcarbodiimide (2.13 g, 10.3 mmol) was added in portions to a solution of N-Boc 
aspartic acid 268 (2.29 g, 9.82 mmol) in ethyl acetate (20 mL) at 0 °C. After stirring for one 
hour the mixture was warmed to room temperature and stirred for a further one hour when 
TLC showed consumption of the starting material. The precipitate was removed by filtration 
and the filtrate concentrated under reduced pressure. The residue was dissolved in THF (20 
mL) and treated with 9-fluorenylmethanol (2.12 g, 10.8 mmol) followed by 
diisopropylethylamine (1.41 mL, 11.8 mmol). After stirring at room temperature for 20 hours, 
the volatile organics were removed under reduced pressure. The residue was dissolved in 
ethyl acetate (50 mL) and washed with KHSO4 (0.5 M, 2 x 50 mL) followed by brine (2 x 50 
mL). After drying over MgSO4 the mixture was concentrated under reduced pressure to give 
an off-white solid which was purified further by recrystallisation from ethyl acetate to afford 
the title compound 270 as a white solid (2.0 g, 4.86 mmol, 49%). 
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(270, white solid) m.p. 159 °C – 162 °C; [α]D
20 −12.5 (c 1.00, CHCl3); FTIR (film) νmax 2977, 
1739, 1697, 1500, 1446, 1238, 1207, 1157; 1H NMR (300 MHz, CDCl3) δ 7.82-7.71 (m, 2H, 
H-Ar), 7.62-7.52 (m, 2H, H-Ar), 7.45-7.36 (m, 2H, H-Ar), 7.35-7.28 (m, 2H, H-Ar), 6.44 (s, 
br, 1H, O-H), 5.51 (d, J=8.6, 1H, N-H), 4.65 (dt, J=8.6, 4.2, 1H, H-2), 4.56-4.40 (m, 2H, H-
5), 4.22 (t, J=6.6, 1H, H-6), 2.99 (dd, J=17.6, 4.2, 1H, H-3), 2.83 (dd, J=17.6, 4.2, 1H, H-3), 
1.47 (s, 9H, H-15); 13C NMR (100 MHz, CDCl3) δ 175.3 (C-1/4), 170.9 (C-1/4), 160.8 (C-
13), 143.6 (C-7/12), 141.4 (C-7/12), 128.0 (CH-Ar), 127.3 (CH-Ar), 125.1 (CH-Ar), 120.2 
(CH-Ar), 77.7 (C-14), 67.8 (C-5), 49.9 (C-2), 46.8 (C-6), 36.4 (C-3), 28.5 (C-15); HRMS 
(ESI) calculated for C23H25NO6 [M+Na]
+ 434.1580 found 434.1573. 
 
N-Methylmaleimide Substituted N-Boc Aspartic Acid Fluorenylmethyl Ester 272 
 
Carboxylic acid 270 (1.0 g, 2.43 mmol) was dissolved in THF (20 mL) and treated with N-
methyl morpholine (270 µL, 2.43 mmol) and isobutyl chloroformate (320 µL, 2.43 mmol) at 
−20 °C. After 5 minutes a solution of 2-mercaptopyridine N-oxide (370 mg, 2.92 mmol) and 
triethylamine (440 µL, 3.16 mmol) in THF (10 mL) was added. The resulting mixture was 
stirred in the dark for 4 hours and the resulting white solid removed by filtration. The filtrate 
was irradiated in the presence of N-methylmaleimide (1.36 g, 12.2 mmol) for 1 hour with the 
temperature maintained below 10 °C. The volatile organics were removed under reduced 
pressure and the residue partitioned between dichloromethane (75 mL) and NaHCO3 (sat. aq. 
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soln., 75 mL). The layers were separated and the organic phase washed with water (75 mL), 
HCl (0.5 N, 75 mL), water (75 mL) and brine (75 mL) before drying over MgSO4. After 
removal of the solvent under reduced pressure diethyl ether (75 mL) was added and the 
resulting white preciptate removed by filtration. The filtrate was concentrated under reduced 
pressure and the residue purified by column chromatography (eluent petroleum ether/ethyl 
acetate, 3/2 gradually to 1/1) to afford a white foam (544 mg, 0.93 mmol, 38%). Signals in the 
1H NMR spectrum (300 MHz, CDCl3) at 8.23-8.16, 7.60-7.49, 7.20-7.12 and 7.02-6.92 ppm 
and mass spectrometry (HRMS (ESI) calculated for C32H33N3O6S [M+Na]
+ 610.1988 found 
610.1981) indicated that the 2-thiopyridyl moiety was present. A portion of the white foam 
(349 mg, 0.59 mmol) was dissolved in chloroform (6 mL), cooled to 0 °C and treated with a 
solution of mCPBA (70-75% in H2O, 140 mg, ~0.59 mmol) in chloroform (6 mL). Further 
small portions of mCPBA were added until TLC indicated that all of the starting material had 
been consumed. The mixture was diluted with dichloromethane (20 mL) and washed with 
NaHCO3 (saturated aqueous solution, 20 mL), HCl (0.5 N, 20 mL) and brine (20 mL). After 
drying over MgSO4, the mixture was concentrated under reduced pressure and the resulting 
white foam dissolved in toluene (15 mL) then heated at reflux for 1.5 hours. The solvent was 
removed under reduced pressure and the residue purified by column chromatography (eluent 
petroleum ether/ethyl acetate, 8/2 to 1/1) to afford the desired compound 272 as a colourless 
oil (233 mg, 0.49 mmol, 83%). 
(272, colourless oil) [α]D
22 −9.5 (c 1.00, CHCl3); FTIR (film) νmax 2979, 1700, 1505, 1448, 
1389, 1158, 1006; 1H NMR (300 MHz, CDCl3) δ 7.76 (dd, J=7.4, 2.9, 2H, H-Ar), 7.62-7.55 
(m, 2H, H-Ar), 7.46-7.37 (m, 2H, H-Ar), 7.36-7.28 (m, 2H, H-Ar), 6.30 (s, 1H, H-5), 5.28 (d, 
J=8.5, 1H, N-H), 4.71-4.41 (m, 3H, H-2, H-9), 4.22 (t, J=6.4, 1H, H-10), 2.97 (s, 3H, H-8), 
2.90 (dd, J=15.3, 4.8, 1H, H-3), 2.66 (dd, J=15.3, 7.5, 1H, H-3), 1.42 (s, 9H, H-19); 13C NMR 
Chapter 5    Experimental 
     
 
147 
 
(100 MHz, CDCl3) δ 171.3 (C=O), 170.9 (C=O), 170.4 (C=O), 155.2 (C-17), 144.5 (C-4), 
143.4 (C-11/16), 141.4 (C-11/16), 129.0 (C-5), 128.1 (CH-Ar), 127.3 (CH-Ar), 125.0 (CH-
Ar), 120.2 (CH-Ar), 80.5 (C-18), 67.4 (C-9), 52.0 (C-2), 46.9 (C-10), 28.8 (C-3), 28.3 (C-19), 
23.9 (C-8); HRMS (ESI) calculated for C27H28N2O6 [M+Na]
+ 499.1845 found 499.1868. 
 
N-Fmoc Aspartic Acid Diester 274 
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Fmoc-Aspartic acid β-O-benzyl ester 273 (5.38 g, 12.1 mmol) was dissolved in 
dichloromethane (10 mL) and treated with tert-butanol (1.32 mL, 13.9 mmol) followed by 
dicyclohexylcarbodiimide (1 M in DCM, 14 mL, 14.0 mmol) then 4-dimethylaminopyridine 
(148 mg, 1.21 mmol). After stirring at room temperature for 20 hours, the white precipitate 
was removed by filtration and the filtrate concentrated under reduced pressure. The residue 
was purified by column chromatography (eluent 100% dichloromethane) to afford the desired 
compound 274 as a colourless oil (2.82 g, 5.62 mmol, 46%). 
(274, colourless oil) [α]D
21 +5.6 (c 1.00, CHCl3); FTIR (film) νmax 2979, 1723, 1503, 1450, 
1218, 1150, 1044; 1H NMR (300 MHz, CDCl3) δ 7.78 (d, J=7.5, 2H, H-Ar), 7.61 (d, J=7.5, 
2H, H-Ar), 7.52-7.27 (m, 9H, H-Ar), 5.81 (d, J=8.2, 1H, N-H), 5.17 (q, J=12.2, 2H, H-5), 
4.58 (m, 1H, H-2), 4.50-4.14 (m, 3H, H-13, H-14), 3.06 (dd, J=17.0, 4.6, 1H, H-3), 2.91 (dd, 
J=17.0, 4.6, 1H, H-3), 1.45 (s, 9H, H-11); 13C NMR (100 MHz, CDCl3) δ 170.8 (C-1/4), 
170.0 (C-1/4), 156.1 (C-12), 144.0 (C-15/20), 143.9 (C-15/20), 141.4 (C-6), 128.7 (C-Ar), 
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128.6 (C-Ar), 128.5 (C-Ar), 127.8 (C-Ar), 127.2 (C-Ar), 125.3 (C-Ar), 120.1 (C-Ar), 82.8 (C-
10), 67.3 (C-5/13), 66.9 (C-5/13), 51.1 (C-2), 47.3 (C-14), 37.1 (C-3), 28.0 (C-11); HRMS 
(ESI) calculated for C30H31NO6 [M+Na]
+ 524.2049 found 524.2054. 
 
N-Fmoc Aspartic Acid O-tert-Butyl Ester 275 
 
A round bottomed flask was charged with aspartic acid 274 (2.82 g, 5.62 mmol), palladium 
on carbon (10 wt. %, 119 mg, 0.11 mmol) and ethanol (50 mL). The flask was carefully 
flushed with dry nitrogen followed by hydrogen and then stirred under an atmosphere of 
hydrogen for 20 hours. The catalyst was removed by filtration through Celite® and the filtrate 
concentrated under reduced pressure to afford the desired carboxylic acid 275 as a colourless 
oil (2.22 g, 5.40 mmol, 96%) which was used without further purification. 
(275, colourless oil) [α]D
21 −3.6 (c 1.00, CHCl3); FTIR (film) νmax 3341, 2980, 1713, 1452, 
1369, 1224, 1151, 1046; 1H NMR (300 MHz, CDCl3) δ 7.77 (d, J=7.4, 2H, H-Ar), 7.61 (d, 
J=7.4, 2H, H-Ar), 7.46-7.25 (m, 4H, H-Ar), 6.29 (s, br, 1H, O-H), 5.85 (d, J=8.1, 1H, N-H), 
4.56 (dt, J=8.5, 4.4, 1H, H-2), 4.48-4.15 (m, 3H, H-8, H-9), 3.06 (dd, J=17.2, 4.5, 1H, H-3), 
2.90 (dd, J=17.2, 4.5, 1H, H-3), 1.48 (s, 9H, H-6); 13C NMR (100 MHz, CDCl3) δ 175.6 (C-
1/4), 169.5 (C-1/4), 156.1 (C-7), 143.7 (C-10/15), 141.3 (C-10/15), 127.7 (C-Ar), 127.1 (C-
Ar), 125.1 (C-Ar), 120.0 (C-Ar), 82.9 (C-5), 67.3 (C-8), 50.8 (C-2), 47.1 (C-14), 36.7 (C-3), 
27.8 (C-6); HRMS (ESI) calculated for C23H25NO6 [M+Na]
+ 434.1580 found 434.1597. 
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N-Methylmaleimide Substituted N-Fmoc Aspartic Acid O-tert-Butyl Ester 277 
 
Aspartic acid 275 (2.10 g, 5.11 mmol) was dissolved in THF (60 mL), cooled to −20 °C, and 
treated sequentially with N-methyl morpholine (562 µL, 5.11 mmol) then isobutyl 
chloroformate (671 µL, 5.11 mmol). After 5 minutes a solution of 2-mercaptopyridine N-
oxide (780 mg, 6.13 mmol) and triethylamine (921 µL, 6.64 mmol) in THF (20 mL) was 
added. The resulting mixture was stirred with the exclusion of light for 4 hours. The 
precipitate was removed by filtration and the filtrate irradiated in the presence of N-
methylmaleimide (2.84 g, 25.6 mmol) for 1 hour with the temperature maintained below 10 
°C. After removal of the volatile organics under reduced pressure, the residue was partitioned 
between dichloromethane (50 mL) and NaHCO3 (40 mL, saturated aqueous solution). The 
layers were separated and the organic phase washed with HCl (0.5 N, 40 mL) then brine (40 
mL) and dried over MgSO4. The mixture was concentrated under reduced pressure and the 
residue purified by column chromatography (eluent petroleum ether/ethyl acetate, 3/1 to 1/1) 
to afford a white foam (792 mg, ~1.35 mmol, 26%). Signals in the 1H NMR spectrum (300 
MHz, CDCl3) at 8.27-8.13, 7.68-7.54, 7.24-7.07 and 7.02-6.90 and mass spectrometry 
(HRMS (ESI) calculated for C32H33N3O6S [M+Na]
+ 610.1988 found 620.1980) indicated that 
the 2-thiopyridyl moiety was present. A portion of the white foam (750 mg, 1.28 mmol) was 
dissolved in chloroform (12 mL), cooled to 0 °C and treated with a solution of mCPBA (70-
75% in H2O, 294 mg, ~1.28 mmol) in chloroform (12 mL). Further small portions of mCPBA 
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were added until TLC indicated that all of the starting material had been consumed. The 
mixture was diluted with dichloromethane (40 mL) and washed with NaHCO3 (saturated 
aqueous solution, 30 mL), HCl (0.5 N, 30 mL) and brine (30 mL). After drying over MgSO4, 
the mixture was concentrated under reduced pressure and the resulting white foam dissolved 
in toluene (30 mL) then heated at reflux for 1 hour. The solvent was removed under reduced 
pressure and the residue purified by column chromatography (eluent petroleum ether/ethyl 
acetate, 7/3 to 2/3) to afford the desired compound 277 as a yellow foam (306 mg, 0.64 mmol, 
50%). 
(277, yellow foam) [α]D
21 +5.2 (c 1.00, CHCl3); FTIR (film) νmax 2975, 1704, 1450, 1260, 
1149, 1050, 1007; 1H NMR (300 MHz, CDCl3) δ 7.77 (d, J=7.5, 2H, H-Ar), 7.59 (d, J=7.5, 
2H, H-Ar), 7.49-7.27 (m, 4H, H-Ar), 6.41 (s, 1H, H-5), 5.58 (d, J=7.4, 1H, N-H), 4.55 (dd, 
J=12.9, 7.4, 1H, H-2), 4.41 (m, 2H, H-12), 4.22 (t, J=6.8, 1H, H-13), 3.02 (s, 3H, H-8), 3.15-
2.77 (m, 2H, H-3), 1.47 (s, 9H, H-10); 13C NMR (100 MHz, CDCl3) δ 175.9 (C=O), 175.8 
(C=O), 171.5 (C=O), 171.3 (C=O), 143.9 (C-5/14/19), 143.8 (C-5/14/19), 141.5 (C-5/14/19), 
129.0 (C-Ar), 127.9 (C-Ar), 127.2 (C-Ar), 125.1 (C-Ar), 120.2 (C-4), 83.5 (C-9), 67.3 (C-12), 
52.92 (C-2/13), 52.91 (C-2/13), 28.7 (C-3), 28.1 (C-10), 24.0 (C-8); HRMS (ESI) calculated 
for C27H28N2O6 [M+Na]
+ 499.1845 found 499.1855. 
 
N-Methylmaleimide Substituted N-Fmoc Aspartic Acid 278 
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Aspartic acid 277 (198 mg, 0.42 mmol) was dissolved in neat formic acid (2 mL) and allowed 
to stir for 20 hours at room temperature. The volatile organics were removed under reduced 
pressure to afford the desired compound 278 as a yellow oil (186 mg, ~0.42 mmol) that was 
used without further purification. 
(278, yellow oil) [α]D
20 −18.0 (c 1.00, MeOH); FTIR (film) νmax 2963, 2925, 2855, 1709, 
1642, 1450, 1263, 1122; 1H NMR (300 MHz, CDCl3) δ 8.45 (s, br, 1H, O-H), 7.75 (d, J=7.5, 
2H, H-Ar), 7.57 (d, J=5.0, 2H, H-Ar), 7.47-7.22 (m, 4H, H-Ar), 6.44 (s, 1H, H-5), 5.79 (d, 
J=7.8, 1H, N-H), 4.67 (dd, J=12.7, 7.4, 1H, H-2), 4.41 (dd, J=6.7, 3.0, 2H, H-10), 4.20 (t, 
J=6.5, 1H, H-11), 3.15-2.87 (m, 2H, H-3), 2.99 (s, 3H, H-8); 13C NMR (100 MHz, CDCl3) δ 
173.7 (C-1/6/7), 171.5 (C-1/6/7), 170.3 (C-1/6/7), 156.0 (C-9), 143.6 (C-4/12/17), 143.5 (C-
4/12/17), 141.3 (C-4/12/17), 129.4 (C-Ar), 127.8 (C-Ar), 127.1 (C-Ar), 125.0 (C-Ar), 120.0 
(C-5), 67.3 (C-10), 52.2 (C-2), 47.1 (C-11), 28.1 (C-3), 23.9 (C-8); HRMS (ESI) calculated 
for C23H19N2O6 [M+Na]
+ 419.1243 found 419.1245. 
 
Proline-Maleimide Substituted N-Fmoc Aspartic Acid Dipeptide 279 
 
Aspartic acid 278 (186 mg, 0.42 mmol), L-proline O-methyl ester (73 mg, 0.44 mmol) and 
HATU (184 mg, 0.48 mmol) were dissolved in acetonitrile (10 mL) and treated with 
diisopropylethylamine (161 µL, 0.92 mmol). The resulting mixture was allowed to stir at 
room temperature for 20 hours then concentrated under reduced pressure. The residue was 
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purified by column chromatography (eluent petroleum ether/ethyl acetate, 1/1 to 1/3) to afford 
the desired dipeptide 279 as an orange oil (168 mg, 0.32 mmol, 76% from 277). 
(279, orange oil) [α]D
20 −7.0 (c 0.50, CHCl3); FTIR (film) νmax 2966, 2855, 1707, 1645, 1450, 
1264, 1102, 1024; 1H NMR (300 MHz, CDCl3) δ 7.82-7.73 (m, 2H, H-Ar), 7.61-7.53 (m, 2H, 
H-Ar), 7.45-7.23 (m, 4H, H-Ar), 6.45 (s, 1H, H-11), 5.82 (d, J=8.4, 1H, N-H), 4.88-4.78 (m, 
1H, H-8), 4.55 (m, 1H, H-4), 4.46-4.26 (m, 2H, H-16), 4.18 (m, 1H, H-17), 3.87-3.65 (m, 2H, 
H-1), 3.74 (s, 3H, H-6), 3.03 (s, 3H, H-14), 3.13-2.61 (m, 2H, H-9), 2.37-1.91 (m, 4H, H-2, 
H-3); 13C NMR (100 MHz, CDCl3) δ 172.0 (C=O), 171.9 (C=O), 171.6 (C=O), 171.4 (C=O), 
156.0 (C-15), 143.9 (C-10), 143.7 (C-18/23), 141.3 (C-18/23), 129.5 (C-11), 127.7 (C-Ar), 
127.1 (C-Ar), 125.0 (C-Ar), 120.0 (C-Ar), 67.3 (C-16), 59.0 (C-4), 52.5 (C-6), 50.9 (C-8), 
47.4 (C-1), 47.0 (C-17), 29.1 (C-3/9), 29.0 (C-3/9), 24.9 (C-2), 23.9 (C-14); HRMS (ESI) 
calculated for C29H29N3O7 [M+Na]
+ 554.1903 found 554.1909. 
 
Proline-N-Methylmaleimide Substituted Aspartic Acid Dipeptide 284 
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General procedure B was followed with aspartic acid 267 (1.0 g, 3.35 mmol), proline 188 
(327 mg, 1.61 mmol), HATU (673 mg, 1.77 mmol) and diisopropylethylamine (0.59 mL, 3.38 
mmol) to afford the title compound 284 as a colourless oil (184 mg, 0.41 mmol, 26%). 
(284, colourless oil) [α]D
22 −20.5 (c 1.00, CHCl3); FTIR (film) νmax 2927, 1702, 1643, 1434, 
1390, 1247, 1161; 1H NMR (300 MHz, CDCl3) δ 6.39 (s, 1H, H-14), 5.37 (d, J=9.0, 1H, N-
Chapter 5    Experimental 
     
 
153 
 
H), 4.74 (td, J=9.4, 3.8, 1H, H-11), 4.36 (m, 1H, H-1), 3.76 (m, 1H, H-1), 3.67 (s, 3H, H-9), 
3.40 (dd, J=17.2, 2.7, 1H, H-5), 3.00 (s, 3H, H-17), 2.88 (m, 1H, H-12), 2.74 (m, 1H, H-5), 
2.53 (dd, J=14.5, 9.6, 1H, H-12), 2.44-1.85 (m, 4H, H-2, H-3), 1.94 (t, J=2.7, 1H, H-7), 1.34 
(s, 9H, H-20); 13C NMR (100 MHz, CDCl3) δ 172.6 (C=O), 171.6 (C=O), 170.7 (C=O), 168.9 
(C=O), 155.3 (C-18), 145.1 (C-13), 128.7 (C-14), 80.1 (C-6/14), 80.0 (C-6/14), 70.9 (C-7), 
68.0 (C-4), 52.8 (C-9), 50.7 (C-11), 49.3 (C-1), 36.1 (C-3), 29.7 (C-12), 28.3 (C-20), 24.5 (C-
5), 24.1 (C-2), 23.9 (C-17); HRMS (ESI) calculated for C22H29N3O7 [M+Na]
+ 470.1903 found 
470.1894. 
 
N-Methylmaleimide DKP 285 
 
Dipeptide 284 (280 mg, 0.63 mmol) was dissolved in formic acid (3 mL) and allowed to stir 
at room temperature for 4 hours. The volatile organics were removed under reduced pressure 
and the residue dissolved in toluene. The resulting solution was heated at reflux for 2 hours 
then concentrated under reduced pressure. The residue was purified by column 
chromatography (eluent petroleum ether/ethyl acetate, 1/1 to 100% ethyl acetate) to afford the 
desired DKP 285 (183 mg, 0.58 mmol, 92%) as a colourless oil. 
(285, white solid) m.p. 155 °C (dec.); [α]D
20 −61.5 (c 1.00, CHCl3); FTIR (film) νmax 2962, 
2896, 1704, 1651, 1422, 1388, 1259, 1004; 1H NMR (300 MHz, CDCl3) δ 7.05 (s, 1H, N-H), 
6.48 (t, J=1.4, 1H, H-13), 4.78 (dd, J=6.6, 4.7, 1H, H-9), 3.83 (m, 1H, H-1), 3.57 (m, 1H, H-
1), 3.21 (ddd, J=15.3, 4.7, 1.4, 1H, H-11), 3.00 (s, 3H, H-16), 2.96 (m, 1H, H-11), 2.75 (dd, 
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J=17.0, 2.7, 1H, H-5), 2.61 (dd, J=17.0, 2.7, 1H, H-5), 2.10 (t, J=2.7, 1H, H-7), 2.21-1.91 (m, 
4H, H-2, H-3); 13C NMR (100 MHz, CDCl3) δ 172.0 (C=O), 171.0 (C=O), 170.5 (C=O), 
164.4 (C=O), 144.4 (C-12), 130.4 (C-13), 78.5 (C-6), 72.6 (C-7), 67.4 (C-4), 54.3 (C-9), 45.5 
(C-1), 35.1 (C-3), 27.8 (C-11), 27.3 (C-5), 24.1 (C-16), 20.4 (C-2); HRMS (ESI) calculated 
for C16H17N3O4 [M+Na]
+ 338.1117 found 338.1103. 
 
Asperparaline Core Structure 287 
 
General procedure A was followed with DKP 285 (48 mg, 0.15 mmol), AIBN (0.2 M solution 
in toluene, 1.50 mL, 0.30 mmol), thiophenol (31 µL, 0.30 mmol) and tert-butanol (25 mL) to 
afford the desired bridged compound 287 as a slightly yellow solid (20 mg, 0.05 mmol, 30%). 
(287, yellow solid) m.p. 163 °C – 165 °C; [α]D
20 −32.5 (c 1.00, CHCl3); FTIR (film) νmax 
2920, 1699, 1683, 1437, 1424, 1280, 1002; 1H NMR (500 MHz, C6D6) δ 7.30 (s, 1H, N-H), 
7.19 (dd, J=6.4, 3.0, 2H, H-Ar), 6.87 (m, 3H, H-Ar), 6.30 (s, 1H, N-H), 3.11 (m, 1H, H-1), 
3.05 (br. s, 1H, H-6), 3.04 (m, 1H, H-10), 2.95 (dt, J=11.3, 7.4, 1H, H-1), 2.86 (d, J=18.6, 1H, 
H-13), 2.78 (s, 3H, H-16), 2.58 (m, 1H, H-3), 2.58 (d, J=12.9, 1H, H-12), 2.53 (d, J=18.6, 1H, 
H-13), 2.36 (d, J=12.9, 1H, H-12), 1.75 (dd, J=13.3, 8.6, 1H, H-5), 1.39-1.30 (m, 2H, H-2, H-
5), 1.26-1.11 (m, 2H, H-2, H-3); 13C NMR (100 MHz, C6D6) δ 180.2 (C=O), 174.4 (C=O), 
173.0 (C=O), 167.8 (C=O), 133.8 (C-17), 133.0 (CH-Ar), 129.7 (CH-Ar), 128.5 (CH-Ar), 
68.7 (C-4), 66.1 (C-7), 62.5 (C-10), 55.2 (C-11), 52.7 (C-6), 44.2 (C-1), 43.8 (C-18), 37.2 (C-
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12), 34.3 (C-5), 30.2 (C-3), 24.6 (C-2, C-23); HRMS (ESI) calculated for C22H23N3O4S 
[M+Na]+ 448.1307 found 448.1306. 
 
Proline-Aspartic Acid O-Benzyl Ester DKP 304 
 
General procedure C was followed with dipeptide 241 (4.48 g, 10.3 mmol), formic acid (40 
mL), 2-butanol (75 mL) and toluene (25 mL) to afford the title compound 304 as a colourless 
oil (2.11 g, 6.98 mmol, 68%). 
(304, colourless oil) [α]D
21 −43.0 (c 1.00, CHCl3); FTIR (film) νmax 3221, 1731, 1675, 1636, 
1453, 1319, 1262, 1171, 1007; 1H NMR (300 MHz, CDCl3) δ 7.44-7.30 (m, 5H, H-Ar), 6.77 
(s, 1H, N-H), 5.15 (s, 2H, H-10), 4.51 (d, J=8.8, 1H, H-6), 4.19-3.88 (m, 3H, H-1, H-4), 3.58 
(m, 1H, H-1), 3.17 (dd, J=17.6, 3.1, 1H, H-8), 2.88 (dd, J=17.6, 9.0, 1H, H-8), 2.81–2.68 (m, 
2H, H-3), 2.13-1.76 (m, 2H, H-2); 13C NMR (100 MHz, CDCl3) δ 170.7 (C=O), 161.1 (C=O), 
157.0 (C=O), 135.2 (C-11), 128.8 (CH-Ar), 128.8 (CH-Ar), 128.6 (CH-Ar), 67.5 (C-10), 67.3 
(C-1), 54.3 (C-6), 54.0 (C-4), 45.8 (C-8), 39.0 (C-3), 28.0 (C-2); HRMS (ESI) calculated for 
C16H18N2O4 [M+Na]
+ 325.1164 found 325.1171. 
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1H NMR spectrum of bridged DKPs 193a and 193b (500 MHz, CDCl3) 
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13C NMR spectrum of bridged DKPs 193a and 193b (75 MHz, CDCl3) 
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1H NMR spectrum of bridged DKPs 194a and 194b (500 MHz, CDCl3) 
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13C NMR spectrum of bridged DKPs 194a and 194b (75 MHz, CDCl3) 
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1H NMR spectrum of bridged DKPs 195a and 195b (500 MHz, CDCl3) 
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13C NMR spectrum of bridged DKPs 195a and 195b (75 MHz, CDCl3) 
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1H NMR spectrum of bridged DKP 198 (400 MHz, CDCl3) 
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13C NMR spectrum of bridged DKP 198 (75 MHz, CDCl3) 
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1H NMR spectrum of bridged DKPs 199a and 199b (400 MHz, CDCl3) 
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13C NMR spectrum of bridged DKPs 199a and 199b (75 MHz, CDCl3) 
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1H NMR spectrum of bridged DKPs 208a and 208b (300 MHz, CDCl3) 
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13C NMR spectrum of bridged DKPs 208a and 208b (75 MHz, CDCl3) 
 
 
Appendix 1  Selected NMR Spectra 
    
 
168 
 
1H NMR spectrum of bridged DKPs 209a and 209b (300 MHz, CDCl3) 
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13C NMR spectrum of bridged DKPs 209a and 209b (100 MHz, CDCl3) 
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1H NMR spectrum of bridged DKPs 210a and 210b (300 MHz, CDCl3) 
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13C NMR spectrum of bridged DKPs 210a and 210b (100 MHz, CDCl3) 
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1H NMR spectrum of bridged DKP 227 (300 MHz, CDCl3) 
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13C NMR spectrum of bridged DKP 227 (100 MHz, CDCl3) 
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1H NMR spectrum of bridged DKP 287 (500 MHz, CDCl3) 
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13C NMR spectrum of bridged DKP 287 (100 MHz, CDCl3) 
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Crystal Structure Data for DKP 203 
 
Table 1.  Crystal data and structure refinement for 2009NS1. 
Identification code  2009NS1 
Empirical formula  C21 H23 N3 O2 
Formula weight  349.42 
Temperature  120(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P 2(1) 2(1) 2(1) 
Unit cell dimensions a = 8.0642(4) Å  = 90°. 
 b = 9.4021(5) Å  = 90°. 
 c = 23.4940(12) Å   = 90°. 
Volume 1781.32(16) Å3 
Z 4 
Density (calculated) 1.303 Mg/m3 
Absorption coefficient 0.680 mm-1 
F(000) 744 
Crystal size 0.30 x 0.30 x 0.20 mm3 
Theta range for data collection 6.66 to 70.02°. 
Index ranges -8<=h<=9, -11<=k<=11, -28<=l<=28 
Reflections collected 15134 
Independent reflections 1940 [R(int) = 0.0347] 
Completeness to theta = 70.02° 99.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8759 and 0.8219 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1940 / 0 / 237 
Goodness-of-fit on F2 1.066 
Final R indices [I>2sigma(I)] R1 = 0.0256, wR2 = 0.0642 
R indices (all data) R1 = 0.0262, wR2 = 0.0647 
Absolute structure parameter ? 
Largest diff. peak and hole 0.163 and -0.175 e.Å-3 
 
Notes: 
The hydrogen atoms were fixed as riding models. 
The absolute structure could not be determined from the diffraction data as there are no heavy atoms present. 
However, it can be confirmed that the chirality of atom C(11) is opposite to that of atom C(13). 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 2009NS1.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 4096(2) 5259(2) -119(1) 21(1) 
C(2) 5169(2) 6270(2) -345(1) 24(1) 
C(3) 6749(2) 6337(2) -116(1) 26(1) 
C(4) 7250(2) 5424(2) 324(1) 25(1) 
C(5) 6175(2) 4414(2) 540(1) 23(1) 
C(6) 4569(2) 4307(2) 317(1) 20(1) 
C(7) 3178(2) 3391(2) 425(1) 21(1) 
C(8) 1953(2) 3841(2) 65(1) 22(1) 
C(9) 1529(2) 5625(2) -711(1) 27(1) 
C(10) 3063(2) 2125(2) 811(1) 21(1) 
C(11) 2604(2) 2462(2) 1439(1) 20(1) 
C(12) 4072(2) 3197(2) 1712(1) 21(1) 
C(13) 2356(2) 5368(2) 1855(1) 21(1) 
C(14) 910(2) 4624(2) 1571(1) 20(1) 
C(15) -429(2) 2473(2) 1266(1) 24(1) 
C(16) 2924(2) 6725(2) 1554(1) 29(1) 
C(17) 4694(2) 6949(2) 1778(1) 36(1) 
C(18) 5294(2) 5493(2) 1989(1) 29(1) 
C(19) 1809(2) 5705(2) 2476(1) 21(1) 
C(20) 1479(2) 4407(2) 2797(1) 23(1) 
C(21) 1248(2) 3313(2) 3039(1) 28(1) 
N(1) 2470(2) 4967(1) -259(1) 23(1) 
N(2) 1039(2) 3230(1) 1466(1) 19(1) 
N(3) 3888(2) 4549(1) 1869(1) 22(1) 
O(1) 5396(1) 2549(1) 1745(1) 29(1) 
O(2) -381(1) 5295(1) 1490(1) 28(1) 
________________________________________________________________________________ 
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Crystal Structure Data for TKP 215 
 
Table 1.  Crystal data and structure refinement for 2008NS3. 
Identification code  2008NS3 
Empirical formula  C11 H12 N2 O3 
Formula weight  220.23 
Temperature  120(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P 2(1) 
Unit cell dimensions a = 7.7088(1) Å  = 90°. 
 b = 8.0240(1) Å  = 105.641(1)°. 
 c = 8.5966(1) Å   = 90°. 
Volume 512.055(11) Å3 
Z 2 
Density (calculated) 1.428 Mg/m3 
Absorption coefficient 0.881 mm-1 
F(000) 232 
Crystal size 0.12 x 0.04 x 0.04 mm3 
Theta range for data collection 6.85 to 70.04°. 
Index ranges -9<=h<=9, -9<=k<=8, -10<=l<=10 
Reflections collected 4297 
Independent reflections 1685 [R(int) = 0.0168] 
Completeness to theta = 70.04° 98.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9656 and 0.9017 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1685 / 1 / 146 
Goodness-of-fit on F2 1.059 
Final R indices [I>2sigma(I)] R1 = 0.0261, wR2 = 0.0697 
R indices (all data) R1 = 0.0263, wR2 = 0.0700 
Absolute structure parameter 0.06(16) 
Largest diff. peak and hole 0.157 and -0.193 e.Å-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 2008NS3.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 8282(2) 5695(2) 2143(2) 16(1) 
C(2) 7269(2) 6237(2) 3349(2) 15(1) 
C(3) 4835(2) 7322(2) 1077(2) 19(1) 
C(4) 6206(2) 7347(2) 69(2) 19(1) 
C(5) 8952(2) 6211(2) -452(2) 25(1) 
C(6) 8369(2) 7710(2) 4333(1) 17(1) 
C(7) 8230(2) 9251(2) 3400(1) 18(1) 
C(8) 8037(2) 10493(2) 2608(2) 21(1) 
C(9) 7035(2) 4857(2) 4495(2) 17(1) 
C(10) 5387(2) 5449(2) 5030(2) 21(1) 
C(11) 4142(2) 6193(2) 3492(2) 19(1) 
N(1) 7775(1) 6438(2) 625(1) 18(1) 
N(2) 5410(1) 6725(1) 2573(1) 16(1) 
O(1) 9576(1) 4784(1) 2542(1) 23(1) 
O(2) 3280(1) 7759(1) 447(1) 25(1) 
O(3) 5822(1) 8034(2) -1233(1) 30(1) 
________________________________________________________________________________ 
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